UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 30, 2018

OPHTHOTECH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

One Penn Plaza, 35th Floor

New York, NY 10119

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (212) 845-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Item 1.01. Entry into a Material Definitive Agreement.

Merger Agreement

On October 30, 2018, Ophthotech Corporation (“Ophthotech”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Ophthotech, Orion Ophthalmology Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Ophthotech (“Merger Sub I”), Orion Ophthalmology LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Ophthotech (“Merger Sub II”), Inception 4, Inc., a Delaware corporation (“Inception 4”), and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Inception 4, Fortis Advisors LLC, a Delaware limited liability company.  Pursuant to the Merger Agreement, on October 30, 2018, Ophthotech acquired Inception 4 through the merger of Merger Sub I with and into Inception 4, with Inception 4 surviving as a direct, wholly owned subsidiary of Ophthotech (the “First Merger”), and as part of the same overall transaction, the merger of Inception 4 with and into Merger Sub II, with Merger Sub II surviving as a direct, wholly owned subsidiary of Ophthotech (the “Second Merger” and, collectively with the First Merger, the “Merger”).  Prior to the Merger, Inception 4 was a privately held biotechnology company focused on research and development of small molecule inhibitors of High temperature requirement A serine peptidase 1 protein (“HtrA1”) for age-related retinal diseases in humans. As part of the Merger, Ophthotech also acquired approximately $6.1 million in cash held by Inception 4.

In connection with the closing of the Merger on October 30, 2018, Ophthotech issued 5,044,201 shares of its common stock to the former equityholders of Inception 4 (the “Aggregate Closing Consideration”), which together with the 130,526 Holdback Shares (as defined below) constitute approximately 14.3% of the voting power of Ophthotech as of immediately prior to the issuance of such shares of Ophthotech common stock. Subject to the terms of the Merger Agreement, Ophthotech withheld 130,526 shares (the “Holdback Shares”) at closing as partial security for obligations of the former Inception 4 equityholders relating to any post-closing purchase price adjustments.  Ophthotech is entitled to recover from the Holdback Shares any final purchase price adjustment, provided that such final purchase price adjustment exceeds $25,000 (in which case Ophthotech may recover the full amount). Any remaining Holdback Shares will be distributed to the former Inception 4 equityholders following the determination of the final adjustments to the Aggregate Closing Consideration.

In addition, pursuant to the Merger Agreement, the former equityholders of Inception 4 will be entitled to receive contingent future payments from Ophthotech based on the achievement of certain clinical and regulatory milestones of up to an aggregate maximum amount of $105 million (the “Contingent Consideration”). Ophthotech is required pursuant to the Merger Agreement to pay such Contingent Consideration in shares of its common stock, unless and until the issuance of any such shares would, together with all other shares of Ophthotech’s common stock issued in connection with the Merger, exceed an overall maximum limit of approximately 7.2 million shares, which is equal to 19.9% of the issued and outstanding shares of Ophthotech’s common stock as of the close of business on the business day prior to the closing date (the “Share Cap”). Ophthotech will be required to pay any Contingent Consideration in excess of the Share Cap in cash.

Ophthotech has agreed to use commercially reasonable efforts to perform the activities described in a development plan outlining certain activities for developing at least one HtrA1 inhibitor for the treatment of geographic atrophy. Ophthotech’s maximum aggregate liability for any and all breaches of its obligation under the Merger Agreement to use commercially reasonable efforts to develop an HtrA1 inhibitor is limited to $5 million.

The Merger Agreement contains customary representations, warranties and covenants of Inception 4 and Ophthotech. The representations and warranties generally will survive until the first anniversary of the closing date, with certain specified representations and warranties surviving to 30 months after the closing date and other specified representations and warranties surviving to the expiration of the applicable statute of limitations. The Merger Agreement also contains customary indemnification provisions whereby the former equityholders of Inception 4 will indemnify Ophthotech and certain affiliated parties for any losses arising out of breaches of the representations, warranties and covenants of Inception 4 under the Merger Agreement; pre-closing tax matters; appraisal claims of former Inception 4 stockholders; any pre-closing indebtedness or expenses not previously adjusted for at the closing; fraud with respect to representations and warranties of Inception 4; and certain other matters.

2

As of October 30, 2018, immediately prior to the closing of the Merger, there were 36,222,470 shares of Ophthotech common stock outstanding. As of immediately after the closing of the Merger, the former equityholders of Inception 4 beneficially owned approximately 12.5% of the outstanding shares of common stock of Ophthotech. All of the shares of Ophthotech common stock issued at closing were issued to Versant Venture Capital IV, L.P. (“Versant Fund IV”) and Versant Side Fund IV, L.P. (collectively with Versant Fund IV, the “Versant Funds”), which are affiliated funds of Versant Ventures. The Versant Funds have also separately agreed not to sell or transfer any of the shares of Ophthotech common stock issued as part of the Aggregate Closing Consideration, until (i) with respect to 50% of such shares, on or after the six-month anniversary of the closing or (ii) with respect to all remaining such shares, on or after the one-year anniversary of the closing. The Aggregate Closing Consideration was, and the Holdback Shares and any other shares of Ophthotech’s common stock that may become issuable in the future under the Merger Agreement will be, issued in reliance on the exemption from registration provided under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Regulation S or Regulation D thereunder.

The foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the terms of the Merger Agreement, filed as Exhibit 2.1 hereto and incorporated herein by reference.

The Merger Agreement has been filed as an exhibit to this Current Report on Form 8-K in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) to provide investors with information regarding its terms. It is not intended to provide any other factual information about Ophthotech or Inception 4. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of the Merger Agreement as of the specific dates therein, were solely for the benefit of the parties to the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in Ophthotech’s public disclosures.

Stockholder Agreement

In connection with the Merger Agreement, on October 30, 2018, Ophthotech entered into a Stockholder Agreement (the “Stockholder Agreement”) by and among Ophthotech, the Versant Funds and Versant Venture Management, LLC (“Versant LLC”).  Pursuant to the Stockholder Agreement, Ophthotech has agreed to use commercially reasonable efforts to file with the SEC, on or before March 31, 2019, a registration statement on Form S-3 covering the resale of the shares of common stock issued by Ophthotech to the Versant Funds pursuant to the Merger Agreement, and to keep such registration statement effective until the two-year anniversary of the effective date of such registration, or such earlier time as the shares covered by such registration statement have been sold or may be sold without manner of sale or volume restrictions pursuant to Rule 144 under the Securities Act. Ophthotech has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Versant Funds’ shares for resale. Ophthotech has granted to the Versant Funds, and the Versant Funds have granted to Ophthotech, customary indemnification rights in connection with the registration statement.

Under the Stockholder Agreement, the Versant Funds agreed to certain customary standstill provisions, effective as of the date of the Stockholder Agreement until the date on which the Versant Funds no longer beneficially own 5% or more of the then issued and outstanding shares of Ophthotech’s common stock, including provisions prohibiting the Versant Funds from, either alone or in concert with others and subject to certain customary exceptions: acquiring additional securities or assets of Ophthotech, supporting or engaging in certain transactions involving Ophthotech or seeking to control or influence management, the Board of Directors or policies of Ophthotech with respect to such matters.

In addition, during the period beginning on the date of the Stockholder Agreement and ending on December 31, 2021, Versant LLC has agreed to use commercially reasonable efforts to propose to Ophthotech at least three bona

3

fide opportunities to acquire or license the rights to an asset intended to treat at least one back-of-the-eye indication in humans, subject to certain conditions and limitations.

The foregoing description of the Stockholder Agreement does not purport to be complete and is qualified in its entirety by reference to the Stockholder Agreement, which is filed as Exhibit 10.1 hereto, and is incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities.

The description of the common stock consideration under the terms of the Merger Agreement, including the Aggregate Closing Consideration, Contingent Consideration and Holdback Shares, set forth in Item 1.01 is incorporated herein by reference.  In connection with the Merger, on October 30, 2018, Ophthotech issued to the Inception 4 equityholders the Aggregate Closing Consideration pursuant to an exemption from registration afforded by Section 4(a)(2) of the Securities Act and/or Regulation S or Regulation D promulgated thereunder.

Item 7.01.    Regulation FD Disclosure.

On October 31, 2018, Ophthotech issued a press release in which it announced that it entered into the Merger Agreement. A copy of the press release is attached to this Report as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

In addition, on October 31, 2018, Ophthotech issued a press release in which it announced that it entered into an exclusive option agreement with the University of Pennsylvania (“Penn”) and the University of Florida Research Foundation (“UFRF”), under which Penn and UFRF granted Ophthotech an exclusive option to acquire an exclusive, global license to develop and commercialize novel adeno-associated virus gene therapy candidates for the treatment of Best vitelliform macular dystrophy, an inherited retinal disease also known as Best disease. A copy of the press release is attached to this Report as Exhibit 99.2 and is incorporated by reference into this Item 7.01.

The information set forth in or incorporated by reference into this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01.    Other Information.

Ophthotech is providing the below description of the acquired Inception 4 business.

Description of Inception 4 Acquired Business

The HtrA1 gene codes an enzyme that can affect cellular structure, function and homeostasis, which is the dynamic equilibrium maintained in cells and tissue required for normal physiology.  Genetic linkage studies, including a study published in Molecular Vision in 2017, show a correlation between the expression of HtrA1 and a certain set of genes conferring risk for age-related macular degeneration (“AMD”).  A study of post-mortem eyes from subjects with AMD published in EBioMedicine in 2018 found evidence of overexpression of HtrA1 in retinal pigment epithelium (“RPE”) cells as compared to the eyes of non-AMD subjects.  Additionally, the overexpression of HtrA1 was found in an in vitro experiment published in the same article to lead to alterations and disruptions in normal function in RPE cells and possibly photoreceptor cells in the retina.  Photoreceptor cells are responsible for sensing light within the retina and are dependent on RPE cells for their survival.  Ophthotech believes that these findings suggest that HtrA1 overexpression may play a role in AMD and that molecules involved in the regulation and inhibition of HtrA1 may be attractive targets for therapeutic intervention in the treatment of dry AMD, including geographic atrophy (“GA”), which is the late-stage form of dry AMD, as well as potentially other age-related retinal diseases.

The Inception 4 HtrA1 inhibitor program includes multiple lead small molecule compounds that have shown high affinity and specificity for HtrA1 when tested in vitro and target engagement when tested in multiple animal models as well as a number of backup compounds.

4

Ophthotech plans to initiate and conduct formulation studies on multiple compounds with the goal of identifying a lead compound and formulation for intravitreal application in the eye. If Ophthotech is successful in identifying and formulating a lead compound, Ophthotech plans to initiate IND-enabling activities for the selected product candidate.  Ophthotech believes the approximately $6.1 million in cash it received in connection with its acquisition of Inception 4 will be sufficient to fund the substantial majority of anticipated development costs associated with this program through the IND submission stage.

Based on current timelines and subject to successful completion of preclinical development, Ophthotech is currently targeting submission of an investigational new drug application to the U.S. Food and Drug Administration for a product candidate from this program for the treatment of geographic atrophy secondary to dry AMD by late 2020.

Ophthotech believes the Inception 4 HtrA1 program is supported by a strong scientific rationale, has the potential to address a high unmet medical need and complements its existing research and development pipeline, including Zimura® (avacincaptad pegol), Ophthotech’s complement c5 inhibitor that is in development for the treatment of multiple age-related retinal diseases as well as autosomal recessive Stargardt disease, an orphan inherited retinal disease.

Inception 4 currently owns three families of patent applications related to its HtrA1 inhibitor program. Ophthotech expects that the patent terms of any patents resulting from these patent applications, if granted, will expire in 2037, subject to any applicable patent term adjustments or extensions that may be available on a jurisdictional basis.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits:

* Confidential treatment has been requested as to certain portions, which portions have been omitted and separately filed with the U.S. Securities and Exchange Commission. In addition, schedules have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the U.S. Securities and Exchange Commission upon request; provided, however, that the registrant may request confidential treatment for any document so furnished.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Any statements in this Current Report on Form 8-K about the Merger and the other transactions contemplated in the Merger Agreement, and any other statements about Ophthotech’s future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about Ophthotech’s strategy, future operations and future expectations and plans and prospects for Ophthotech, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this Current Report on Form 8-K, Ophthotech’s forward-looking statements include statements about Ophthotech’s expectations with respect to the financial impact and benefits to Ophthotech of the Merger; Ophthotech’s expectations with respect to contingent payments to the Inception 4 equityholders based on the achievement of milestones; the future expectations, plans and prospects for Ophthotech; Ophthotech’s strategy, future operations, future financial position, future revenues or projected costs; the integration of Inception 4’s operations; and the objectives of management. Such forward-looking statements involve substantial risks and uncertainties that could cause Ophthotech’s

5

preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to Ophthotech’s ability to realize the anticipated benefits of the Merger, including the possibility that the expected benefits from the Merger will not be realized or will not be realized within the expected time-period; negative effects of the announcement of the Merger Agreement on the market price of Ophthotech’s common stock; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the Merger; other business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the sufficiency of Ophthotech’s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; the integration of Inception 4’s operations; and the factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that Ophthotech files with the SEC.  Any forward-looking statements represent Ophthotech’s views only as of the date of this Current Report on Form 8-K. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

6

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

7

Exhibit 2.1

Execution Copy

Confidential Materials omitted and filed separately with
the Securities and Exchange Commission.

AGREEMENT AND PLAN OF MERGER

by and among

OPHTHOTECH CORPORATION,

ORION OPHTHALMOLOGY MERGER SUB, INC.,

ORION OPHTHALMOLOGY LLC,

INCEPTION 4, INC.,

and,

SOLELY IN ITS CAPACITY AS COMPANY EQUITYHOLDER REPRESENTATIVE,

FORTIS ADVISORS LLC

Dated as of October 30, 2018

TABLE OF CONTENTS

i

Table of Contents

(continued)

ii

Table of Contents

(continued)

iii

Company Disclosure Schedule

Buyer Disclosure Schedule

iv

AGREEMENT AND PLAN OF MERGER

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of October 30, 2018, by and among: Ophthotech Corporation, a Delaware corporation (the “Buyer”); Orion Ophthalmology Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Buyer (the “Merger Subsidiary I”); Orion Ophthalmology LLC, a Delaware limited liability company and a direct wholly owned subsidiary of the Buyer (“Merger Subsidiary II”, and together with Merger Subsidiary I, the “Merger Subsidiaries”); Inception 4, Inc., a Delaware corporation (the “Company”); and, solely for purposes of being bound by Section 2.4, Section 2.6, Section 2.7, Section 2.8, Article V, Article VI, Article VII, and Article VIII, Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the Company Equityholder Representative, (the “Company Equityholder Representative”).

RECITALS

WHEREAS, the Boards of Directors of the Buyer and the Company deem it advisable and in the best interests of each corporation and their respective stockholders that the Buyer acquire the Company, in accordance with and on the terms contemplated by this Agreement, in order to advance the long-term business interests of the Buyer and the Company;

WHEREAS, on October 30, 2018, Versant Ventures invested aggregate net cash proceeds, in the form of equity capital, into the Company of Five Million Dollars ($5,000,000) (the “Versant Investment”);

WHEREAS, the Buyer, the Merger Subsidiaries and the Company intend to effect a reorganization in which, as steps in a single, integrated transaction, (a) the First Merger (as defined below) will be consummated, and (b) following the First Merger, as part of the same overall transaction, the Company will merge with and into Merger Subsidiary II, the Company will cease to exist, and Merger Subsidiary II will survive as a direct wholly owned subsidiary of Buyer (the “Second Merger” and, collectively or in seriatim with the First Merger, as appropriate, the “Merger”);

WHEREAS, the parties intend that the First Merger and the Second Merger will be treated as integrated steps in a single transaction and will qualify as a “reorganization” within the meaning of Section 368(a) of the Code, and that this Agreement shall constitute a “plan of reorganization” for purposes of Sections 354 and 361 of the Code and within the meaning of Sections 1.368-2(g) and 1.368-3 of the Treasury Regulations;

WHEREAS, concurrently with the execution of this Agreement, and as a condition of the willingness of the Buyer to enter into this Agreement, 90% of the Company Stockholders are entering into Support and Joinder Agreements; and

WHEREAS, prior to the execution of this Agreement, and as a condition to the willingness of the Buyer to enter into this Agreement, the Company has obtained and delivered to the Buyer a true, correct and complete copy of an irrevocable written consent of 90% of the Company Stockholders evidencing the Company Stockholder Approval, which written consent is conditioned upon, and shall become effective immediately following, the execution of this Agreement;

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Buyer, the Merger Subsidiaries, the Company, and (solely for purposes of being bound by Section 2.4, Section 2.6, Section 2.7, Section 2.8, Article V, Article VI, Article VII and Article VIII and solely in its capacity as the Company Equityholder Representative) the Company Equityholder Representative agree as follows:

ARTICLE I

THE MERGER

1.1                               First Merger and Second Merger; Effective Time of the Merger.

(a)                                 First Merger and Second Merger;

(i)                                     Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the applicable provisions of the DGCL, the Buyer, Merger Subsidiary I and the Company (Merger Subsidiary I and the Company sometimes being referred to herein as the “First Merger Constituent Corporations”) shall cause Merger Subsidiary I to be merged with and into the Company effective as of the Effective Time, with the Company being the surviving corporation (the “First Merger”).  The First Merger shall be consummated at the Effective Time in accordance with this Agreement and evidenced by a certificate of merger relating to the First Merger in substantially the form of Exhibit A-1 (the “First Certificate of Merger”).

(ii)                                  Upon consummation of the First Merger, the separate corporate existence of Merger Subsidiary I shall cease and the Company, as the surviving corporation of the First Merger (hereinafter referred to for the periods at and after the Effective Time as the “First Step Surviving Entity”), shall continue its corporate existence under the DGCL as a direct wholly owned subsidiary of the Buyer.

(iii)                               Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the applicable provisions of the DGCL, the Buyer, Merger Subsidiary II and the First Step Surviving Entity (Merger Subsidiary II and the First Step Surviving Entity sometimes being referred to herein as the “Second Merger Constituent Corporations”) shall cause the Second Merger to be consummated.  The Second Merger shall be consummated at the Second Effective Time in accordance with this Agreement and evidenced by a certificate of merger relating to the Second Merger in substantially the form of Exhibit A-2 (the “Second Certificate of Merger”).

(iv)                              Upon consummation of the Second Merger, the separate corporate existence of the First Step Surviving Entity shall cease and Merger Subsidiary II, as the surviving entity of the Second Merger (hereinafter referred to for the periods at and after the Second Effective Time as the “Surviving Entity”), shall continue its corporate existence under the DGCL as a direct wholly owned subsidiary of Buyer.

2

(b)                                 Effective Time of the Merger.

(i)                                     Subject to the provisions of this Agreement, the Buyer, Merger Subsidiary I and the Company shall cause the First Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware.  The First Merger shall become effective at the time when the First Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed by Buyer and the Company in writing and specified in the First Certificate of Merger (the “Effective Time”).  Subject to the provisions of this Agreement, promptly following the Effective Time, the Buyer, Merger Subsidiary II and the Company shall cause the Second Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware.  The Second Merger shall become effective at the time when the Second Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed by Buyer and the Company in writing and specified in the Second Certificate of Merger (the “Second Effective Time”).

1.2                               Closing; Actions at the Closing.

(a)                                 The Closing shall take place remotely, via electronic exchange of documents, simultaneous with the execution and delivery of this Agreement, unless another date, place or time is agreed to in writing by the Buyer and the Company.

(b)                                 At the Closing:

(i)                           the Company shall deliver to the Buyer and the Merger Subsidiaries the following certificates, instruments and documents:

(A)                     copies of Written Consents evidencing that this Agreement and the Merger have received the Company Stockholder Approval;

(B)                     copies of the resignations, effective as of the Closing and in the form set forth on Schedule 1.2(b)(i)(B) to the Buyer, of each director and officer of the Company (other than any such resignations which the Buyer designates, by written notice to the Company, as unnecessary) from their officer and director positions;

(C)                     executed Forfeiture Agreements from holders of Company Options set forth on Schedule 1.2(b)(i)(C);

(D)                     that certain Transition Agreement, in form and substance reasonably acceptable to the Company and the Buyer, executed and delivered by each of Inception Sciences, Inc. and Inception Sciences Canada, Inc.;

(E)                      executed Support and Joinder Agreements from 90% of the Company Stockholders;

(F)                       each of the items contemplated to be delivered by the Company in accordance with Section 2.1(d)(i);

3

(G)                     evidence, in form and substance reasonably satisfactory to Buyer, that (i) the Company has submitted to a stockholder vote, in a manner that satisfies the stockholder approval requirements under Section 280G(b)(5)(B) of the Code and the Treasury Regulations promulgated thereunder, the right of any “disqualified individual” (as defined in Section 280G(c) of the Code) to receive any and all payments (or other benefits) contingent on the consummation of the transactions contemplated by this Agreement (within the meaning of Section 280G(b)(2)(A)(i) of the Code) to the extent necessary so that no payment received by such “disqualified individual” shall be a “parachute payment” under Section 280G(b) of the Code (determined without regard to Section 280G(b)(4) of the Code), which such vote shall establish the disqualified individual’s right to the payment or other compensation if approved by the Company Stockholders, (ii) Company has obtained from the disqualified individual prior to the vote a waiver of such payments if the requisite vote under Section 280G(b)(5)(B) is not obtained and (iii) the Company has provided adequate disclosure to Company Stockholders that hold voting Company Stock of all material facts concerning all payments to any disqualified individual that, but for such vote, could be deemed “parachute payments” under Section 280G of the Code in a manner that satisfies Section 280G(b)(5)(B)(ii) of the Code and the regulations promulgated thereunder;

(H)                    a certificate, in form and substance required under Treasury Regulations Section 1.1445-2(c)(3), stating that the Company is not and has not been a “United States real property holding corporation” (as defined in Section 897(c)(2) of the Code) during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, and a copy of the notice of such certification to be sent to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2), together with written authorization for the Buyer to deliver such notice to the IRS on behalf of the Company following the Closing;

(I)                         evidence that the Versant Investment has been completed and fully funded on terms reasonably acceptable to the Buyer, such evidence consisting of (i) the executed purchase agreement and any other related documents or agreements executed in connection therewith, (ii) the as-filed amendment to the Company’s charter (if required in connection with the Versant Investment) and (iii) documentation reasonably acceptable to the Buyer evidencing receipt of the Versant Investment funded amount;

(J)                         an executed counterpart of the Stockholder Agreement executed by the applicable Company Equityholders;

(K)                     the Company Required Information; and

(L)                      such other certificates and instruments (including certificates of good standing of the Company in Delaware, certified charter documents and certificates as to the incumbency of officers and the adoption of authorizing resolutions) as the Buyer shall reasonably request in connection with the Closing;

(ii)                        the number of Company Equityholders who have not executed Support and Joinder Agreements and/or Optionholder Agreements certifying that such Company Stockholder (a) is not a “U.S. Person” within the meaning of Rule 902 of Regulation S of the

4

Securities Act or (b) is an “accredited investor” pursuant to Regulation D under the Securities Act, is less than 35;

(iii)                     the Buyer, the Company, Merger Subsidiary I and Merger Subsidiary II shall take, or cause to be taken, the actions set forth in Section 1.1(a) and Section 1.1(b);

(iv)                    the Buyer shall have delivered such other certificates and instruments (including certificates of good standing of the Buyer and certificates as to the incumbency of officers and the adoption of authorizing resolutions) as the Company shall reasonably request in connection with the Closing; and

(v)                       the Buyer shall make the payments contemplated by Section 2.1(d)(ii).

1.3                               Effects of the Merger.

(a)                                 At and after the Effective Time, (i) the effect of the First Merger shall be as provided in this Agreement and the applicable provisions of the DGCL and (ii) the Company Certificate of Incorporation shall be amended and restated in its entirety to read as set forth on Exhibit B-1. Without limiting the foregoing, the First Step Surviving Entity shall thereupon and thereafter possess all of the rights, property, privileges, powers and franchises, of a public as well as a private nature, of the First Merger Constituent Corporations, and shall become subject to all the restrictions, disabilities and duties of each of the First Merger Constituent Corporations.  In addition, the Buyer shall cause the by-laws of the First Step Surviving Entity to be amended and restated in their entirety so that, immediately following the Effective Time, they are identical to the by-laws of Merger Subsidiary I as in effect immediately prior to the Effective Time, except that all references to the name of Merger Subsidiary I therein shall be changed to refer to the name of the Company.

(b)                                 At and after the Second Effective Time, (i) the effect of the Second Merger shall be as provided in this Agreement and the applicable provisions of the DGCL, (ii) the Surviving Entity’s Certificate of Formation shall be amended and restated in its entirety to read as set forth in the Second Certificate of Merger, and (iii) the Surviving Entity’s limited liability company agreement shall be amended and restated in its entirety to read as set forth on Exhibit B-2. Without limiting the foregoing, the Surviving Entity shall thereupon and thereafter possess all of the rights, property, privileges, powers and franchises, of a public as well as a private nature, of the Second Merger Constituent Corporations, and shall become subject to all the restrictions, disabilities and duties of each of the Second Merger Constituent Corporations.

1.4                               Directors and Officers.

(a)                                 The directors of Merger Subsidiary I immediately prior to the Effective Time shall be the initial directors of the First Step Surviving Entity immediately after the Effective Time, each to hold office in accordance with the certificate of incorporation and by-laws of the First Step Surviving Entity.

5

(b)                                 The officers of Merger Subsidiary I immediately prior to the Effective Time shall be the initial officers of the First Step Surviving Entity, each to hold office in accordance with the certificate of incorporation and by-laws of the First Step Surviving Entity.

(c)                                  The managers of Merger Subsidiary II immediately prior to the Second Effective Time shall be the sole managers of the Surviving Entity immediately after the Second Effective Time, each to hold office in accordance with the limited liability company agreement of the Surviving Entity.

(d)                                 The officers of Merger Subsidiary II immediately prior to the Second Effective Time shall be the initial officers of the Surviving Entity, each to hold office in accordance with the limited liability company agreement of the Surviving Entity.

1.5                               Additional Action.  The Surviving Entity may, at any time from and after the Second Effective Time, take any action, including executing and delivering any document, in the name and on behalf of either the Company or the Merger Subsidiaries in order to consummate and give effect to the transactions contemplated by this Agreement.

ARTICLE II

CONVERSION OF SECURITIES

2.1                               Conversion of Capital Stock.

(a)                                 Capital Stock of the Merger Subsidiaries.

(i)                                     At the Effective Time, by virtue of the First Merger and without any action on the part of Buyer or Merger Subsidiary I, each share of common stock, par value $0.001 per share, of Merger Subsidiary I issued and outstanding immediately prior to the Effective Time shall be cancelled and, in exchange for the cancellation of such shares of Merger Subsidiary I common stock and the funding of the Aggregate Closing Consideration by the Buyer, the First Step Surviving Entity shall issue an equivalent number of shares of common stock, par value $0.001 per share, all of which shares shall be held by the Buyer, and which shall constitute the only outstanding shares of common stock of the First Step Surviving Entity immediately following the Effective Time.

(ii)                                  At the Second Effective Time, by virtue of the Second Merger and without any action on the part of the Buyer or Merger Subsidiary II, each share of common stock, par value $0.001 per share, of the First Step Surviving Entity issued and outstanding immediately prior to the Second Effective Time shall be cancelled and, in exchange for the cancellation of such shares of First Step Surviving Entity common stock, the Surviving Entity shall issue an equivalent number of units, all of which units shall be held by the Buyer, and which shall constitute the only outstanding units of the Surviving Entity immediately following the Second Effective Time.

(b)                                 Cancellation of Treasury Stock and Buyer-Owned Stock.  At the Effective Time, by virtue of the First Merger and without any action on the part of the Buyer, the Company, any holder of Company Stock or any other Person, each share of Company Stock that

6

is owned by the Company as treasury stock and each share of Company Stock that is owned by the Buyer, any Merger Subsidiary or any other wholly-owned direct or indirect subsidiary of the Buyer as of immediately prior to the Effective Time shall be cancelled and shall cease to exist and no payment or consideration shall be delivered in exchange therefor.

(c)                                  Conversion of Company Stock.  At the Effective Time, by virtue of the First Merger and without any action on the part of the Buyer, the Company, any holder of Company Stock or any other Person:

(i)                                     Subject to Section 2.2(b), each share of Company Preferred Stock that is issued and outstanding as of immediately prior to the Effective Time (other than (A) shares of Company Preferred Stock referenced in Section 2.1(b) and (B) Dissenting Shares) shall be converted into the right of the holder thereof to receive:  (1) the Series A Preference Consideration (to the extent available out of the Aggregate Consideration), plus (2) such share’s Pro Rata Share of the Aggregate Residual Closing Consideration, plus (3) such share’s Pro Rata Share of the portion of all Future Payments that become payable pursuant to the terms of this Agreement.

(ii)                                  Subject to Section 2.2(b), each share of Company Common Stock that is issued and outstanding as of immediately prior to the Effective Time (other than (A) shares of Company Common Stock referenced in Section 2.1(b) and (B) Dissenting Shares) shall be converted into the right of the holder thereof to receive:  (1) such share’s Pro Rata Share of the Aggregate Residual Closing Consideration, plus (2) such share’s Pro Rata Share of the portion of all Future Payments that become payable pursuant to the terms of this Agreement.

(d)                                 Payment Certificate; Closing Date Payments.

(i)                                     The Company has delivered, prior to the date hereof:  (A) the Payment Certificate; (B) a pay-off letter in form and substance reasonably satisfactory to the Buyer duly executed by each Person to whom any Indebtedness is (or at the Closing will be) owed by the Company or the Surviving Entity, which shall include a release of the Company and the Surviving Entity from all Liens, liabilities and other obligations with respect to such Indebtedness, effective upon the discharge of such Indebtedness at the Closing; and (C) final invoices submitted by each Person to whom any Company Transaction Expenses are (or at the Closing will be) owed, which shall state that the amount invoiced thereby represents all Company Transaction Expenses payable to such Person with respect to the period through the Closing.

(ii)                                  At the Closing, the Buyer shall make the following payments, in each case in the respective amounts set forth in the Payment Certificate:

(A)                               to the Company Equityholder Representative, by wire transfer of immediately available funds, the Company Equityholder Representative Expense Amount;

(B)                               to each Person specified in the Payment Certificate as a recipient of payments in respect of the Closing Indebtedness, by wire transfer of immediately available funds, the amount payable to such Person as specified in the Payment Certificate;

7

(C)                               to each Person specified in the Payment Certificate as a recipient of payments in respect of Company Transaction Expenses that remain unpaid as of immediately prior to the Effective Time, by wire transfer of immediately available funds, the amount payable to such Person as specified in the Payment Certificate; and

(D)                               to the Exchange and Paying Agent, the Aggregate Closing Consideration by shares of Buyer Common Stock issued in book entry.

(e)                                  Closing Adjustment Holdback.

(i)                                     At the Closing, the Buyer shall withhold from the Aggregate Closing Consideration the Holdback Shares. Any Holdback Shares shall be issued by the Buyer pursuant to this Agreement in accordance with, and on the date(s) specified by, this Section 2.1(e).

(ii)                                  Within five (5) Business Days after the date of the final determination of the Final Closing Adjustment pursuant to Section 2.6 hereof, the shares of Buyer Common Stock constituting the Holdback Fund (if any) shall be issued to the Company Equityholders in accordance with this Agreement.  The Company Equityholder Representative shall, prior to any issuance of Holdback Shares pursuant to this Section 2.1(e), deliver to the Buyer a Post-Closing Disbursement Certificate in respect of such issuance.

(f)                                   Certain Adjustments to Per Share Amounts.  All per share amounts payable to the Company Equityholders pursuant to this Article II shall be adjusted, as applicable and appropriate, to reflect fully the effect of any reclassification, stock split, reverse split, stock dividend (including any dividend or distribution of securities convertible into Company Stock), reorganization, recapitalization or other like change with respect to Company Stock occurring after the date of this Agreement and prior to the Effective Time.

(g)                                  No Fractional Shares.  Notwithstanding any other provision of this Agreement, no fractional shares of Buyer Common Stock shall be issued in exchange for any Company Stock or Company Equity Awards, and no holder of any of the foregoing shall be entitled to receive a fractional share of Buyer Common Stock.  Any fraction of a share of Buyer Common Stock that actually becomes due and issuable by the Buyer to any Company Equityholder (or which the Buyer becomes entitled to withhold, set off, or offset) pursuant to this Agreement shall, after aggregating all such shares, be rounded up to the nearest whole number.

2.2                               Payment Fund.  The procedures for exchanging outstanding shares of Company Stock (including Restricted Stock Awards converted pursuant to Section 2.5(b)) for the consideration to be paid to the holders of such Company Stock in connection with the Merger are as follows:

(a)                                 Exchange and Paying Agent.  The Exchange and Paying Agent shall, pursuant to instructions from the Buyer in accordance with the Exchange and Paying Agent Agreement and the Allocation Schedule, deliver the Aggregate Closing Consideration to the Company Stockholders (including, if applicable, holders of Company Restricted Stock Awards).  The Payment Fund shall not be used for any purpose other than as specified in this Section 2.2(a).

8

(b)                                 Exchange Procedures.  Promptly after the Effective Time (but in no event later than three (3) Business Days), the Buyer shall cause the Exchange and Paying Agent to mail to each holder of record of Company Stock that was issued and outstanding as of immediately prior to the Effective Time (i) a Letter of Transmittal and (ii) instructions for effecting the surrender of such Certificate in exchange for the applicable Aggregate Consideration that is or may become payable with respect thereto pursuant to the terms of this Agreement.  Upon (A) proper surrender of a Certificate for cancellation to the Exchange and Paying Agent and (B) delivery of a duly completed and executed Letter of Transmittal, the holder of such Certificate shall be entitled to receive in exchange therefor the number of shares of Buyer Common Stock as determined in accordance with Section 2.1 and reflected on the Allocation Schedule attached to the Payment Certificate.  If payment in respect of any Certificate is to be made to a Person other than the Person in whose name such Certificate is registered, it shall be a condition of payment that the Certificate so surrendered shall be transferable and be properly endorsed or shall otherwise be in proper form for transfer, that the signatures on such Certificate or any related stock power shall be properly guaranteed and that the Person requesting such payment shall have established to the reasonable satisfaction of the Buyer and the Exchange and Paying Agent that any transfer and other Taxes required by reason of such payment to a Person other than the registered holder of such Certificate have been paid or are not applicable. Until surrendered as contemplated by this Section 2.2(b), each Certificate shall be deemed at all times after the Effective Time to represent only the right to receive upon such surrender the applicable Aggregate Consideration that becomes payable in respect of such Certificate pursuant to this Agreement.  Holders of Certificates shall not be entitled to receive any portion of the Aggregate Consideration to which they would otherwise be entitled until such Certificates are properly surrendered.

(c)                                  No Further Ownership Rights in Company Stock.  All consideration paid following the surrender for exchange of Certificates evidencing shares of Company Stock (including any Future Payments payable with respect thereto) in accordance with the terms hereof shall be deemed to have been paid in satisfaction of all rights pertaining to such shares of Company Stock, and from and after the Effective Time there shall be no further registration of transfers on the stock transfer books of the Surviving Entity of the shares of Company Stock which were outstanding as of immediately prior to the Effective Time.  If, after the Effective Time, Certificates are presented to the Surviving Entity or the Exchange and Paying Agent for any reason, they shall be cancelled and exchanged as provided in this Article II, subject to Section 2.2(e).

(d)                                 Termination of Payment Fund.  Any portion of the Payment Fund deposited with the Exchange and Paying Agent (including shares of Buyer Common Stock issued to a Buyer reserve account) that remains undistributed to the holders of Company Stock as of one (1) year after the Effective Time shall be delivered to the Buyer (subject to abandoned property, escheat or similar Law), upon demand, and any holder of Company Stock who is entitled to such amount under this Section 2.2 shall (subject to Section 2.2(e)) be entitled to seek payment of such amount from the Buyer only as a general creditor thereof.

(e)                                  No Liability.  To the extent permitted by applicable Law, none of the Buyer, the Merger Subsidiaries, the Company, the Surviving Entity or the Exchange and Paying Agent shall be liable to any Company Equityholder for any amount delivered to a public official

9

pursuant to any applicable abandoned property, escheat or similar Law.

(f)                                   Lost Certificates.  If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact and a customary indemnification of the Company and the Buyer in a form reasonably satisfactory to the Buyer by the Person claiming such Certificate to be lost, stolen or destroyed, the Exchange and Paying Agent shall pay in exchange for such lost, stolen or destroyed Certificate the Aggregate Consideration payable in respect thereof pursuant to this Agreement.  The Exchange and Paying Agent or the Buyer may, in its discretion and as a condition precedent to the payment thereof, require the owner of such lost, stolen or destroyed Certificate to give the Exchange and Paying Agent and/or the Buyer a bond in such sum as it may reasonably direct as an indemnity against any claim that may be made against the Exchange and Paying Agent or the Buyer with respect to the Certificate alleged to have been lost, stolen or destroyed.

2.3                               Dissenting Shares.

(a)                                 Notwithstanding anything to the contrary contained in this Agreement, Dissenting Shares shall not be converted into or represent the right to receive any portion of the Aggregate Consideration in accordance with Section 2.1, but shall be entitled only to such rights as are granted by the DGCL to a holder of Dissenting Shares.

(b)                                 If any Dissenting Shares shall lose their status as such (through failure to perfect or otherwise), then, as of the later of the Effective Time or the date of loss of such status, such shares shall automatically be converted into and shall represent only the right to receive any portion of the Aggregate Consideration otherwise payable in respect thereof pursuant to this Agreement, without interest thereon, upon surrender of the Certificate formerly representing such shares.

(c)                                  The Company shall give the Buyer (i) prompt notice of any written demand for appraisal received by the Company prior to the Effective Time pursuant to the DGCL, any withdrawal of any such demand and any other demand, notice or instrument delivered to the Company prior to the Effective Time pursuant to the DGCL that relates to such demand and (ii) the opportunity to direct all negotiations and proceedings with respect to any such demand, notice or instrument.  The Company shall not settle or make any payment or settlement offer prior to the Effective Time with respect to any such demand, notice or instrument unless the Buyer shall have given its written consent to such settlement, payment or settlement offer.

2.4                               Company Equityholder Representative.

(a)                                 By their execution of this Agreement or the Letter of Transmittal, approval of the Merger and adoption of this Agreement and/or their acceptance of any consideration pursuant to this Agreement, the Company Equityholders hereby irrevocably (subject only to Section 2.4(e)) appoint the Company Equityholder Representative as the representative, attorney-in-fact and agent of the Company Equityholders in connection with the transactions contemplated by this Agreement, the Exchange and Paying Agent Agreement, the Company Equityholder Representative Engagement Agreement or any other agreement contemplated

10

hereby or thereby, and in any litigation or arbitration involving this Agreement or the Exchange and Paying Agent Agreement, or any other agreement contemplated hereby or thereby.  In connection therewith, the Company Equityholder Representative is authorized to do or refrain from doing all further acts and things, and to execute all such documents as the Company Equityholder Representative shall deem necessary or appropriate, and shall have the power and authority to:

(i)                                     act for some or all of the Company Equityholders with regard to all matters pertaining to this Agreement, the Exchange and Paying Agent Agreement, the Company Equityholder Representative Engagement Agreement or any other agreement contemplated hereby or thereby;

(ii)                                  act for the Company Equityholders to transact matters of litigation;

(iii)                               execute and deliver all amendments, waivers, ancillary agreements, certificates and documents that the Company Equityholder Representative deems necessary or appropriate in connection with the consummation of the transactions contemplated by this Agreement, the Exchange and Paying Agent Agreement, or any other agreement contemplated hereby or thereby including delivering any update to or correction, amendment or modification of the Allocation Schedule permitted by Section 2.7(a);

(iv)                              receive funds, make payments of funds, and give receipts for funds;

(v)                                 do or refrain from doing, on behalf of the Company Equityholders, any further act or deed that the Company Equityholder Representative deems necessary or appropriate in the Company Equityholder Representative’s discretion relating to the subject matter of this Agreement, the Exchange and Paying Agent Agreement, the Company Equityholder Representative Engagement Agreement or any other agreement contemplated hereby or thereby, in each case as fully and completely as the Company Equityholders could do if personally present;

(vi)                              give and receive all notices required to be given or received by the Company Equityholders under this Agreement, the Exchange and Paying Agent Agreement, or any other agreement contemplated hereby or thereby;

(vii)                           give any written direction to the Exchange and Paying Agent on behalf of the Company Equityholders;

(viii)                        agree to, negotiate and/or comply with the determination of the Final Closing Adjustment Statement, the Final Closing Adjustment Items and the Final Closing Adjustment pursuant to Section 2.6, and to agree to, negotiate, comply with and/or enter into any modification or amendment of (subject only to the requirements of the DGCL), or any settlement and compromises regarding any Contingent Consideration or the Buyer or the Surviving Entity’s obligations pursuant to, Section 2.8;

11

(ix)                              agree to, negotiate, enter into settlements and compromises and/or comply with arbitration awards and court orders with respect to claims for indemnification made by the Buyer under Article V;

(x)                                 receive service of process in connection with any claims under this Agreement, the Exchange and Paying Agent Agreement, or any other agreement contemplated hereby or thereby; and

(xi)                              engage attorneys, accountants, financial and other advisors, paying agents and other Persons necessary or appropriate in the judgment of the Company Equityholder Representative for the accomplishment of the foregoing, in each case solely at the expense of the Company Equityholder Representative (on behalf of the Company Equityholders and paid from the Company Equityholder Representative Expense Amount).

(b)                                 All decisions and actions of the Company Equityholder Representative on behalf of the Company Equityholders shall be deemed to be facts ascertainable outside of this Agreement and shall be binding upon all Company Equityholders and their respective successors, and no Company Equityholder shall have the right to object, dissent, protest or otherwise contest the same. The Company Equityholder Representative shall be entitled to: (i) rely upon the Allocation Schedule, (ii) rely upon any signature believed by it to be genuine, and (iii) reasonably assume that a signatory has proper authorization to sign on behalf of the applicable Company Equityholder or other party.

(c)                                  At the Effective Time, the Buyer shall pay the Company Equityholder Representative Expense Amount to the Company Equityholder Representative, which Company Equityholder Representative Expense Amount shall be maintained by the Company Equityholder Representative in a segregated account.  The Company Equityholder Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Company Equityholder Expense Amount other than as a result of its gross negligence or willful misconduct.  The Company Equityholder Representative is not acting as a withholding agent or in any similar capacity in connection with the Company Equityholder Expense Amount, and has no tax reporting or income distribution obligations.  The Company Equityholders will not receive any interest on the Company Equityholder Expense Amount and assign to the Company Equityholder Representative any such interest.  Subject to Advisory Group approval, the Company Equityholder Representative may contribute funds to the Company Equityholder Expense Amount from any consideration otherwise distributable to the Company Equityholders.  The Company Equityholder Representative shall be reimbursed for any Company Equityholder Representative Expenses or any other reasonable out-of-pocket expenses incurred in the performance of the Company Equityholder Representative’s duties (including the reasonable fees and expenses of counsel) under this Agreement and under the Company Equityholder Representative Engagement Agreement from the Company Equityholder Representative Expense Amount and, if the remaining Company Equityholder Representative Expense Amount is insufficient to pay such expenses, from the first proceeds from any Future Payments otherwise available for distribution to the Company Equityholders or directly from the Company Equityholders.  In no event shall the Buyer or the Surviving Entity (or any of their respective Affiliates) be obligated to reimburse the Company Equityholder Representative for any such

12

expenses.  Upon the determination of the Company Equityholder Representative that retaining any portion of the Company Equityholder Representative Expense Amount is no longer necessary, the Company Equityholder Representative shall deliver any then remaining portion of the Company Equityholder Representative Expense Amount (the “Company Equityholder Representative Account Payment”) to the Buyer, which will promptly pay (i) a portion thereof equal to the Pro Rata Share that is represented by each share of Company Stock converted pursuant to Section 2.1(c) to the Exchange and Paying Agent for payment to the holder thereof and (ii) a portion thereof equal to the Pro Rata Share that is represented by each Company Equity Award to the Surviving Entity for payment to the holder thereof (which amount shall be paid by the Surviving Entity or the Exchange and Paying Agent to such holder, subject to any applicable withholding as provided in Section 2.9).  The Company Equityholder Representative shall prior to any disbursement of funds for the benefit of Company Equityholders pursuant to this Section 2.4(c), deliver to the Buyer a Post-Closing Disbursement Certificate in respect of such disbursement.  The Company Equityholder Representative shall hold, invest, reinvest and disburse the Company Equityholder Representative Expense Amount in trust for all of the Company Equityholders, and the Company Equityholder Representative Expense Amount shall not be used for any other purpose and shall not be available to the Buyer to satisfy any claims hereunder.

(d)                                 The Company Equityholder Representative shall act for the Company Equityholders on all of the matters set forth in this Agreement, the Exchange and Paying Agent Agreement, the Company Equityholder Representative Engagement Agreement, or any other agreement contemplated hereby or thereby in the manner the Company Equityholder Representative believes to be in the best interest of the Company Equityholders.  The Company Equityholder Representative is authorized to act on behalf of the Company Equityholders notwithstanding any dispute or disagreement among the Company Equityholders.  The Company Equityholder Representative may, in all questions arising hereunder, rely on the advice of counsel, and the Company Equityholder Representative shall not be liable to any Company Equityholder for anything done, omitted or suffered in good faith by the Company Equityholder Representative based on such advice.  The Company Equityholder Representative undertakes to perform such duties and only such duties as are specifically set forth in this Agreement and no implied covenants or obligations shall be read into this Agreement against the Company Equityholder Representative.  The Company Equityholder Representative shall not have any liability to any of the Company Equityholders for any act done or omitted hereunder or under the Company Equityholder Representative Engagement Agreement as Company Equityholder Representative while acting in good faith unless such act done or omitted was in willful violation of Law or resulted from its gross negligence, fraud or bad faith in the performance of such duties under this Agreement.  The Company Equityholder Representative Group (as defined below) shall be indemnified by the Company Equityholders from and against any loss, liability, claim, damage, fee, fine, cost, judgment, amounts paid in settlement or expense incurred in good faith on the part of the Company Equityholder Representative and arising out of or in connection with the acceptance or administration of the Company Equityholder Representative’s duties hereunder and under the Company Equityholder Representative Engagement Agreement (collectively, the “Company Equityholder Representative Expenses”).  Any such claim for indemnification shall be satisfied first from any then available portion of the remaining Company Equityholder Representative Expense Amount and, if such amount is insufficient to satisfy any such Company Equityholder Representative Expense, from the first proceeds from any Future Payments

13

otherwise available for distribution to the Company Equityholders or by a claim against the Company Equityholders (with each Company Equityholder liable for the Pro Rata Fraction of any such claim that is represented by such Company Equityholder’s Company Stock and Company Equity Awards). In no event shall the Buyer or the Surviving Entity (or any of their respective Affiliates) be responsible for any fees, costs or expenses of the Company Equityholder Representative. Notwithstanding the foregoing, no Company Equityholder shall be liable to the Company Equityholder Representative for any amount in excess of the aggregate amount of Aggregate Consideration such Company Equityholder has received in connection with the Closing (less any amounts actually paid by such Company Equityholder for any other claim for indemnification under this Agreement). In the event the Company Equityholder Representative becomes unable to perform the Company Equityholder Representative’s responsibilities hereunder or resigns from such position, the Company Equityholders (acting by a written instrument signed by holders of Company Stock who held, as of immediately prior to the Effective Time, a majority (by voting power) of the then outstanding shares of Company Stock) shall select another representative to fill the vacancy of the Company Equityholder Representative, and such substituted representative shall be deemed to be the Company Equityholder Representative for all purposes of this Agreement, or any other agreement contemplated hereby. The Company Equityholder Representative may be removed only upon delivery of written notice to the Buyer signed by the Advisory Group; provided, that no such removal shall be effective until such time as a successor Company Equityholder Representative shall have been validly appointed hereunder.  The Company Equityholder Representative shall provide the Buyer prompt written notice of any replacement of the Company Equityholder Representative, including the identity and address of the new Company Equityholder Representative.  The immunities and rights to indemnification shall survive the resignation or removal of the Company Equityholder Representative or any member of the Advisory Group and the Closing and/or any termination of this Agreement.

(e)                                  The Company Equityholder Representative agrees not to, directly or indirectly, disclose the existence or terms of this Agreement or any other agreement contemplated hereby or any other information regarding this Agreement, the Merger or any of the other matters contemplated hereby, including information provided to the Company Equityholder Representative pursuant to the terms of this Agreement, except, in each case (i) to the extent such information is or becomes generally known to the public (other than as a result of a disclosure by the Company Equityholder Representative in breach of its obligations under this Section 2.4), (ii) if and to the extent required by applicable Law, (iii) to employees, advisors, agents or consultants of the Company Equityholder Representative and to the Company Equityholders, in each case who have a need to know such information, and further provided that such Persons are subject to confidentiality obligations with respect thereto, or (iv) in connection with, and only to the extent required for, enforcement of rights or defense of claims (including, in each case, on behalf of the Company Equityholders) under this Agreement and the transactions contemplated hereby.

(f)                                   Advisory Group.  Certain Company Equityholders have entered into an engagement agreement (the “Company Equityholder Representative Engagement Agreement”) with the Company Equityholder Representative to provide direction to the Company Equityholder Representative in connection with its services under this Agreement and the Company Equityholder Representative Engagement Agreement (such Company Equityholders,

14

including their individual representatives, collectively hereinafter referred to as the “Advisory Group”). As solely between the Company Equityholders and the Company Equityholder Representative, neither the Company Equityholder Representative nor its members, managers, directors, officers, contractors, agents and employees nor any member of the Advisory Group (collectively, the “Company Equityholder Representative Group”) shall be liable for any act done or omitted hereunder or under the Company Equityholder Representative Engagement Agreement as Company Equityholder Representative while acting in good faith, and any act done or omitted to be done pursuant to the advice of counsel shall be conclusive evidence of such good faith.

(g)                                  For all purposes of this Agreement:

(i)                                     the Buyer shall be entitled to rely conclusively on the instructions and decisions of the Company Equityholder Representative as to the settlement of any disputes or claims under this Agreement or any agreements ancillary hereto, including, the Exchange and Paying Agent Agreement, or any other agreement contemplated hereby or thereby, or any other actions required or permitted to be taken by the Company Equityholder Representative hereunder or thereunder, and no party hereunder or any Company Equityholder shall have any claim, cause of action, objection or complaint against the Buyer for any action taken by the Buyer in reliance upon the instructions or decisions of the Company Equityholder Representative;

(ii)                                  except as specifically set forth herein, no Company Equityholder shall have any right to bring any claim, cause of action, objection or complaint except through the Company Equityholder Representative, and the Company Equityholder Representative shall have the sole authority to act for, and to enforce the rights of, all Company Equityholders in connection with this Agreement and the transactions contemplated hereby;

(iii)                               the provisions of this Section 2.4 and the powers, immunities and rights to indemnification granted to the Company Equityholder Representative Group hereunder: (A) are independent and severable, are irrevocable (subject only to Section 2.4(d)) and coupled with an interest and shall be enforceable notwithstanding any rights or remedies that any Company Equityholder may have in connection with the transactions contemplated by this Agreement and (B) shall survive the delivery of an assignment by any Company Equityholder of the whole or any fraction of his, her or its interest in the Future Payments; and

(iv)                              the provisions of this Section 2.4 shall be binding upon the executors, heirs, legal representatives, personal representatives, successor trustees and successors of each Company Equityholder, and any references in this Agreement to a Company Equityholder shall mean and include the successors to the rights of each applicable Company Equityholder hereunder, whether pursuant to testamentary disposition, the Laws of descent and distribution or otherwise.

2.5                               Treatment of Company Equity Awards.

(a)                                 As of immediately prior to the Effective Time, each Company Option that is then outstanding (whether such Company Option is vested or unvested, but not to the extent it has theretofore been exercised) shall vest in full (if unvested in whole or in part) and shall be

15

converted, in settlement and cancellation thereof, into the right to receive an amount equal to (i) (A) such Company Option’s Pro Rata Share of the Aggregate Residual Closing Consideration, if any, plus (B) such Company Option’s Pro Rata Share of the portion of all Future Payments that become payable pursuant to the terms of this Agreement, less (ii) the aggregate exercise price of such Company Option, in each case subject to withholding as provided in Section 2.9; provided, however, that notwithstanding anything to the contrary herein, no portion of the Aggregate Consideration shall be payable to any holder of any such Company Option unless and until such holder shall have executed and delivered to the Buyer an executed Optionholder Agreement.

(b)                                 As of immediately prior to the Effective Time, each Company Restricted Stock Award that is unvested in whole or in part shall vest in full (and all outstanding shares of Company Common Stock issued in connection with such Company Restricted Stock Award shall be (A) converted pursuant to Section 2.1(c)(ii)), and (B) subject to the procedures set forth in Section 2.2).

(c)                                  Upon the conversion and cancellation of any Company Equity Award pursuant to this Section 2.5, such Company Equity Award shall no longer represent the right to acquire any shares of Company Stock or other Equity Interests, but shall entitle the holder thereof to receive only the consideration payable in respect thereof pursuant to this Section 2.5.

(d)                                 Prior to or on the date hereof, each holder of Restricted Stock Awards shall have executed and delivered a Support and Joinder Agreement.

(e)                                  The Buyer shall cause the Surviving Entity or, with respect to the holders of Company Options set forth on Schedule 2.5(e), the applicable Exchange and Paying Agent, to pay to each holder of Company Options any amounts payable with respect to each Future Payment (subject to any applicable withholding as provided in Section 2.9) in accordance with Section 2.7 hereof.

(f)                                   The Company has, prior to the date hereof, taken all actions necessary or desirable in connection with the treatment of Company Equity Awards contemplated by this Section 2.5, including obtaining the consent from each holder of any Company Equity Award (unless such consent is not required under the terms of the applicable agreement, instrument or plan).

2.6                               Adjustment Before and After the Closing.  The Estimated Closing Adjustment and the Final Closing Adjustment shall be determined as set forth below in this Section 2.6:

(a)                                 At least 48 hours prior to the execution of this Agreement, the Company delivered to the Buyer a statement (the “Estimated Closing Adjustment Statement”), in the form attached as Schedule 2.6(a)(i) hereto, setting forth the Estimated Closing Adjustment, including an estimated balance sheet of the Company as of the Effective Time (other than with respect to the Closing Net Working Capital, which shall be as of the time specified in such definition).  The Estimated Closing Adjustment Statement and such balance sheet were prepared in accordance with GAAP applied on a basis consistent with the application thereof to the most recent audited financial statements included in the Company Financial Statements (to the extent consistent with GAAP).  Schedule 2.6(a)(ii) attached hereto reflects the Closing Adjustment Items included in

16

the Estimated Closing Adjustment Statement, including estimated amounts in respect thereof as of the date of this Agreement.  During such 48-hour period, the Company provided the Buyer and its accountants with access to the Company and its accountants and with complete and accurate copies of, and reasonable access to, the work papers and supporting records of the Company and its accountants so as to allow the Buyer and its accountants to verify the accuracy of the Estimated Closing Adjustment Statement.

(b)                                 Not later than sixty (60) calendar days after the Closing Date, the Buyer shall deliver to the Company Equityholder Representative the Closing Adjustment Statement, including a balance sheet of the Company as of the Effective Time (other than with respect to the Closing Net Working Capital, which shall be as of the time specified in such definition).  The Closing Adjustment Statement and such balance sheet shall be prepared in accordance with GAAP applied on a basis consistent with the application thereof to the most recent audited financial statements included in the Company Financial Statements (to the extent consistent with GAAP).  The Closing Adjustment Statement delivered pursuant to this Section 2.6(b) shall be accompanied by a statement setting forth the amount, if any, by which the total of the Closing Adjustment Items is greater than, or less than, the Estimated Closing Adjustment.  The Closing Adjustment Statement, as proposed by Buyer pursuant to this Section 2.6(b), shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Statement,” the Closing Adjustment Items reflected thereon shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Items” and each shall be final and binding on all parties to this Agreement and on all Company Equityholders, unless the Company Equityholder Representative timely delivers to the Buyer an Objection Notice in accordance with Section 2.6(c).

(c)                                  In the event that the Company Equityholder Representative disputes the Closing Adjustment Statement or the amount of the Closing Adjustment Items, the Company Equityholder Representative shall notify the Buyer in writing (the “Objection Notice”) of the amount, nature and basis of such dispute, within forty-five (45) calendar days after delivery of the Closing Adjustment Statement pursuant to Section 2.6(b).  Any such Objection Notice shall specify those items or amounts as to which the Company Equityholder Representative disagrees, and the Company Equityholder Representative shall be deemed to have agreed with all other items and amounts contained in the Closing Adjustment Statement and the amount of the Closing Adjustment Items delivered pursuant to Section 2.6(b).  In the event of such a dispute, the Buyer and the Company Equityholder Representative shall first negotiate in good faith to reach agreement on the disputed items or amounts in order to determine the amount of the Closing Adjustment Items, which amount shall not be more than the Buyer’s calculation delivered pursuant to Section 2.6(b) nor less than the Company Equityholder Representative’s calculation delivered pursuant to this Section 2.6(c).  If the Buyer and the Company Equityholder Representative reach a final resolution on the Closing Adjustment Statement within forty-five (45) calendar days after the Buyer’s receipt of the Objection Notice (or within any additional period as mutually agreed to between the Buyer and the Company Equityholder Representative), then the Closing Adjustment Statement agreed upon by the Buyer and the Company Equityholder Representative shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Statement,” the Closing Adjustment Items reflected thereon shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Items” and each shall be final and binding on all parties to this Agreement and on all Company Equityholders.

17

(d)                                 If the Buyer and the Company Equityholder Representative are unable to resolve the dispute within forty-five (45) calendar days after delivery of the Objection Notice, then any remaining items in dispute shall be submitted to the Neutral Accountant.  All determinations and calculations pursuant to this Section 2.6(d) shall consider only those Closing Adjustment Items that are set forth in the Objection Notice and remain in dispute, shall be a value that is not more than the Buyer’s calculation delivered pursuant to Section 2.6(b) nor less than the Company Equityholder Representative’s calculation delivered pursuant to Section 2.6(c), shall be in writing and shall be delivered to the Buyer and the Company Equityholder Representative as promptly as practicable.  Absent fraud or manifest error, the Closing Adjustment Statement as finally determined by the Neutral Accountant shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Statement,” the Closing Adjustment Items reflected thereon shall be deemed for purposes of this Section 2.6 to be the “Final Closing Adjustment Items” and each shall be final and binding on all parties to this Agreement and on all Company Equityholders.  In determining the Closing Adjustment Statement and the Closing Adjustment Items, the Neutral Accountant shall act as an expert and not as arbitrator.  A judgment on the determination made by the Neutral Accountant pursuant to this Section 2.6 may be entered in and enforced by any court having jurisdiction thereover.

(e)                                  The fees and expenses of the Neutral Accountant in connection with the resolution of disputes pursuant to Section 2.6(d) shall be borne by the Company Equityholders, on the one hand, and the Buyer, on the other hand, in proportion to the amounts by which the proposals of the Buyer and the Company Equityholder Representative differed from the Neutral Accountant’s final determination.

(f)                                   The “Final Closing Adjustment” shall be a number of shares of Buyer Common Stock equal to (i) the amount of the Final Closing Adjustment Items minus the Estimated Closing Adjustment, divided by (ii) the Buyer Closing Stock Price. For the avoidance of doubt, the Final Closing Adjustment may be a positive or negative number.  If the Final Closing Adjustment is a positive number, then the Buyer shall be entitled to seek recovery of the Final Closing Adjustment from the Holdback Shares and Holdback Fund in accordance with Section 2.1(e); provided, that if the aggregate amount of the Final Closing Adjustment is less than $25,000, the Buyer will not be entitled to seek recovery from the Holdback Shares and Holdback Fund pursuant to Section 2.1(e) or this Section 2.6(f).

(g)                                  From the delivery of the Closing Adjustment Statement until such time as the calculation of the Final Closing Adjustment has been finally determined pursuant to this Section 2.6, the Company Equityholder Representative and its accountants (at the Company Equityholder Representative’s expense on behalf of the Company Equityholders) shall, upon reasonable notice and during normal business hours, be permitted to discuss with the Buyer and its accountants the Closing Adjustment Statement and shall be provided complete and accurate copies of, and have reasonable access, upon reasonable notice at reasonable times during normal business hours, to the work papers and supporting records of the Buyer and its accountants so as to allow the Company Equityholder Representative and its accountants to verify the accuracy of the Closing Adjustment Statement.

(h)                                 The parties agree that the procedures set forth in this Section 2.6 and, subject to Section 5.1(d), recourse against the Holdback Shares shall be the sole and exclusive

18

method for resolving any disputes with respect to the determination of the Final Closing Adjustment Statement, the Final Closing Adjustment Items and the Final Closing Adjustment; provided, that this provision shall not prohibit the Buyer or the Company Equityholder Representative from instituting litigation to enforce the determination of the Neutral Accountant and shall not limit any remedy of any party under Article V.

2.7                               Allocation Schedule; Payments of Future Payments.

(a)                                 The Allocation Schedule sets forth a true, correct and complete summary of the allocation of the Aggregate Closing Consideration payable to the Company Equityholders pursuant to this Agreement.  From time to time after the Effective Time, the Company Equityholder Representative may, with the written agreement of the Buyer, update, correct or otherwise amend or modify the Allocation Schedule in any manner that is consistent with the express provisions of this Article II, including by delivering a Post-Closing Disbursement Certificate that supersedes such Allocation Schedule.  The Buyer shall be entitled to rely conclusively on the Allocation Schedule as in effect from time to time and/or any Post-Closing Disbursement Certificate, as applicable, and, as between the Company Equityholders, on the one hand, and the Buyer and the Surviving Entity, on the other hand, any amounts delivered by the Buyer to any Company Equityholder (or delivered by the Buyer to the Exchange and Paying Agent for delivery) in accordance with the Allocation Schedule and/or Post-Closing Disbursement Certificate, as applicable, in effect from time to time shall be deemed for all purposes to have been delivered to the applicable Company Equityholder in full satisfaction of the obligations of the Buyer and the Surviving Entity under this Article II.

(b)                                 The Exchange and Paying Agent shall pay the portion of the Aggregate Closing Consideration payable to the applicable Company Stockholders in accordance with the Allocation Schedule and the Letters of Transmittal, and the Buyer, the Surviving Entity or the Exchange and Paying Agent as applicable, shall pay the portion of the Aggregate Closing Consideration payable to the holders of Company Options pursuant to Section 2.5 to such holders in accordance with the Allocation Schedule (subject to any applicable withholding as provided in Section 2.9).

(c)                                  The portion of any Future Payment payable in respect of Company Stock shall be paid by the Buyer to the Exchange and Paying Agent for the benefit of the holders thereof, and the portion of any Future Payment payable in respect of Company Options shall be paid (subject to any applicable withholding as provided in Section 2.9) by the Surviving Entity or the Exchange and Paying Agent, as applicable, to such holders, in each case in accordance with the Post-Closing Disbursement Certificate.  The Company Equityholder Representative shall, prior to any disbursement of funds for the benefit of Company Equityholders pursuant to this Section 2.7(c), deliver to the Buyer a Post-Closing Disbursement Certificate in respect of such disbursement.

(d)                                 The parties understand and agree that (i) the Company Equityholders have no rights as a security holder of the Surviving Entity or the Buyer as a result of their right to receive the Future Payments, (ii) without limiting the generality of Section 8.4, no right to receive any Future Payment may be assigned or otherwise transferred without the prior written consent of the Buyer and any purported assignment or transfer in the absence of such consent

19

shall be null and void ab initio, and (iii) no interest is payable as additional consideration with respect to any of the Future Payments.

2.8                               Contingent Payments.  Subject to Section 5.3(f), the Company Equityholders shall be entitled to certain one-time (regardless of the number of times the corresponding milestones are achieved or the number of products with which they are achieved) contingent payments determined as set forth below (each, a “Milestone Payment” and, collectively, the “Contingent Consideration”) based on the achievement of the corresponding events set forth below (each, a “Milestone Event”) by Buyer or the Surviving Entity or any of its or their Affiliates or licensees:

(a)                                 Milestone Payments.

(b)                                 Procedures; Limitations.

(i)                                     Within ten (10) calendar days following the first achievement of a Milestone Event, the Buyer shall notify the Company Equityholder Representative that such Milestone Event has been achieved, and no later than thirty (30) calendar days following the date of the first achievement of such Milestone Event (the date of each such first achievement, each a “Milestone Achievement Date”) the Buyer (or its designee) shall (A) deliver, in accordance with Section 2.7, for the benefit of the Company Equityholders, a number of shares of Buyer Common Stock equal to the applicable Milestone Amount divided by the Buyer Post-Closing

20

Stock Price, or (B) if the issuance of such shares of Buyer Common Stock pursuant to this Section 2.8, together with all other issuances of Buyer Common Stock pursuant to this Agreement issued prior to such date, would cause the Share Cap to be exceeded, pay any such excess Contingent Consideration in cash to the Exchange and Paying Agent, in each case, for prompt distribution to the Company Equityholders in accordance with Section 2.7 and the applicable Post-Closing Disbursement Certificate; provided, that the “determination date” for purposes of determining the Buyer Post-Closing Stock Price under this Section 2.8(b)(i) shall be the Milestone Achievement Date for such Milestone Event.

(ii)                                  Each of the Milestone Payments shall only be payable once, upon the first occurrence of the corresponding Milestone Event, and no additional payment will be due in the event of any repeated occurrence of any such Milestone Event.  No Milestone Payment shall be payable with respect to any Milestone Event that is first achieved after the end of the Payment Term.

(iii)                               If, during the Payment Term, there occurs a Milestone Successor Event in which the Buyer is not the surviving parent entity, then the Successor Entity shall pay any Milestone Payment that becomes due and payable in cash.

(c)                                  Buyer shall, collectively with the Surviving Entity and its or their applicable assignees and delegates, and any applicable Affiliates and licensees of any of the foregoing, keep reasonable documentation relating to the Milestone Products.  For each calendar year during the Payment Term beginning with the calendar year ending on December 31, 2018, Buyer shall provide the Company Equityholder Representative with an annual development report within forty-five (45) calendar days after the end of such calendar year summarizing in reasonable detail (i) the status of efforts of Buyer or the Surviving Entity or any of its or their assignees or delegates, or any Affiliates or licensees of any of the foregoing, during such calendar year, to develop, to the extent required under Section 2.8(d), at least one Lead Diligence Product through the dosing of a first patient in the first Phase II Clinical Trial (or, if no such Phase II Clinical Trial is earlier commenced, dosing of a first patient in the first Phase III Clinical Trial) of such Lead Diligence Product for the treatment of Geographic Atrophy and any modifications to the Development Plan during the prior calendar year and (ii) the progress, if any, during such calendar year to achieve other Milestone Events.  Buyer shall respond to reasonable follow-up questions from the Company Equityholder Representative regarding such reports and, if the Company Equityholder Representative requests meeting(s) with representatives of Buyer to discuss such annual report(s), up to three (3) representatives of each of Buyer and the Company Equityholders shall meet to discuss such questions in person or via teleconference, not more often than once in any calendar year, with such representatives of Buyer including at least one executive of the Buyer having primary operating responsibility with respect to the development of the Milestone Products by the Buyer or the Surviving Entity or any of its or their assignees or delegates, or any Affiliates or licensees of any of the foregoing, as applicable.  Following each such meeting relating to a report described in clause (i) above, upon the reasonable request of the Company Equityholder Representative, Buyer shall provide copies of and access to material data and final reports of the activities conducted under the Development Plan and relied upon for the preparation of the annual report or portion thereof that relates to the efforts described in clause (i) above for inspection and copying for the purpose of

21

determining the status and progress of the development of the Milestone Product described in clause (i) above.

(d)                                 Each of the Company Equityholders, by his, her or its execution of a Support and Joinder Agreement, a Written Consent, an Optionholder Agreement, a Letter of Transmittal and/or receipt of Aggregate Consideration hereunder, acknowledges and agrees that: (i) nothing herein shall constitute a guarantee by the Buyer of the achievement of any or all of the Milestone Events; and (ii) subject only to the immediately succeeding sentence, (A) Buyer shall have the sole decision-making authority over the development of the Milestone Products; (B) Buyer is entitled to conduct the business of the Surviving Entity and with respect to any Milestone Products in a manner that is in the best interests of Buyer and its shareholders (without taking into account its obligations to Company Equityholders under this Section 2.8), and shall have the absolute right and sole and absolute discretion to operate and otherwise make decisions with respect to the conduct of the business of the Surviving Entity with respect to the development of the Milestone Products or the achievement of any Milestone Events and to take or refrain from taking any action with respect to the development of any Milestone Products or the achievement of any Milestone Events; and (C) Buyer or an Affiliate of Buyer currently or may in the future offer or develop products or services that compete, either directly or indirectly, with the Milestone Products and may make decisions with respect to such products and services that may adversely affect the development of the Milestone Products or the achievement of any Milestone Event.  Notwithstanding anything set forth in the immediately foregoing sentence, during the Payment Term, the Buyer shall, collectively with the Surviving Entity and its or their applicable assignees and delegates, and any applicable Affiliates and licensees of any of the foregoing, use Commercially Reasonable Efforts to perform the activities specified in the Development Plan with respect to the development of a Lead Diligence Product through the dosing of a first patient in the first Phase II Clinical Trial (or, if no such Phase II Clinical Trial is earlier commenced, dosing of a first patient in the first Phase III Clinical Trial) of such Lead Diligence Product for the treatment of Geographic Atrophy.  The Buyer’s maximum aggregate liability for any and all breaches by the Buyer of its obligations under this Section 2.8 shall be limited to the unpaid portion, if any, of the Milestone Payment for the Milestone Event set forth in Section 2.8(a)(vi) and all documented and reasonable legal fees and other documented and reasonable out-of-pocket costs and expenses incurred by the Company Equityholder Representative and the Company Equityholders for the successful assertion of any claim of non-payment under this Section 2.8, and neither the Buyer nor any of its Affiliates shall have any other liability hereunder to any Company Equityholder or any other Person for any claim, loss or damage of any nature, including claims, losses or damages that arise out of or relate in any way to any decisions or actions affecting whether or not or the extent to which the Contingent Consideration becomes payable in accordance with this Section 2.8; provided, that, for the avoidance of doubt, nothing in this Section 2.8(d) shall modify Buyer’s obligation pursuant to Section 2.8(a) to make any Milestone Payment following the first achievement during the Payment Term of the applicable Milestone Event.

(e)                                  The right of any Company Equityholder to receive any amounts with respect to Contingent Consideration (i) shall not be evidenced by a certificate or other instrument, (ii) shall not be assignable or otherwise transferable by such Company Equityholder, except by will, upon death or by operation of Law and (iii) does not represent any right other than the right to receive the consideration set forth in this Section 2.8.  Any attempted transfer of

22

the right to any amounts with respect to Contingent Consideration by any holder thereof (other than as specifically permitted by the immediately preceding sentence) shall be null and void.

(f)                                   Notwithstanding anything else contained in this Agreement, the Buyer may, without the consent of any other party hereto, effect a Milestone Successor Event; provided, that in the event that a Milestone Successor Event occurs during the Payment Term, (i) the Buyer shall require the relevant transferee, assignee, delegatee or other successor of the Buyer (the “Successor Entity”) pursuant to such Milestone Successor Event, to assume and expressly agree in writing to perform the obligations of the Buyer under and be bound by this Section 2.8 as if such Successor Entity were the original Buyer named in Section 2.8 of this Agreement and (ii) the Company Equityholder Representative (on behalf of the Company Equityholders) is made an express third party beneficiary of such written agreement, and (iii) the Buyer shall provide the Company Equityholder Representative prompt written notice of such Milestone Successor Event.

(g)                                  Notwithstanding any other provision in this Agreement, the Buyer’s obligations to pay any Contingent Consideration hereunder is subject to (i) Section 5.3(f) and (ii) receipt by Buyer of a Post-Closing Disbursement Certificate pursuant to, and in accordance with, Section 2.7(c).

(h)                                 Certain Definitions. As used in this Agreement, the following terms shall have the meanings ascribed to them below:

(i)                                     “Commercially Reasonable Efforts” shall mean with respect to research, development and commercialization of a Lead Diligence Product, use of those efforts and resources, consistent with the exercise of reasonable scientific and business judgment, as are applied by biopharmaceutical companies of comparable size and resources as those of Buyer to a product, resulting from its own research efforts or otherwise owned by such company or to which it has rights, of similar value, stage of development, life cycle and commercial potential, without taking into account the obligation to make any Milestone Payments hereunder or internal programs that compete with the same indication of any Lead Diligence Product.

(ii)                                  “Development Plan” shall mean Buyer’s plan outlining the development activities for developing at least one Lead Diligence Product through the dosing of a first patient in the first Phase II Clinical Trial (or, if no such Phase II Clinical Trial is earlier commenced, dosing of a first patient in the first Phase III Clinical Trial) of such Lead Diligence Product for the treatment of Geographic Atrophy, which is attached as Schedule 2.8(h)(ii) hereto and which Buyer may modify from time to time in its reasonable discretion, provided that Buyer shall not modify such plan or any activities set forth therein in a manner that would reasonably be expected to adversely affect the achievement of the dosing of a first patient in the first Phase II Clinical Trial (or, if no such Phase II Clinical Trial is earlier commenced, dosing of a first patient in the first Phase III Clinical Trial) of such Lead Diligence Product for the treatment of Geographic Atrophy.

(iii)                               “EU” shall mean the economic, scientific and political organization of the European Union as it may be constituted from time to time.

23

(iv)          “Geographic Atrophy” shall mean the ophthalmic disease geographic atrophy, including early forms (i.e. dry age-related macular degeneration) and late forms.  For the avoidance of doubt, Geographic Atrophy and Wet AMD are distinct diseases and neither is a form of the other.

(v)           “Lead Compounds” shall mean each of the proprietary compounds of the Company known as NXT-3683 and NXT-5834, compounds specifically claimed in any Patent Rights within the Company Registrations as of the Closing Date, in each case as listed on Schedule 2.8(h)(v), or any salts, esters, polymorphs, isomers or metabolites thereof, in any form or formulation.

(vi)          “Lead Diligence Product” shall mean a product containing NXT-3683 or NXT-5834, or any salts, esters, polymorphs, isomers or metabolites thereof, in any form or formulation, as an active pharmaceutical ingredient provided that, once the formulation activities set forth in the “Formulation Development” section of the Development Plan are completed and such a product is selected by the Buyer or the Surviving Entity for further development under the Development Plan, the Lead Diligence Product shall thereafter be limited to the selected product.  For the avoidance of doubt, the selection of the Lead Diligence Product pursuant to the proviso in the immediately preceding sentence does not affect the Company Equityholders’ rights to receive the applicable one-time Milestone Payment contemplated by Section 2.8(a) following the first achievement of the corresponding Milestone Event with a Milestone Product, regardless of whether such Milestone Product is the Lead Diligence Product.

(vii)         “MHLW” shall mean the Japanese Ministry of Health, Labour and Welfare or any successor agency thereto.

(viii)        “Milestone Product” shall mean a product containing a Lead Compound as an active pharmaceutical ingredient.

(ix)          “Milestone Successor Event” means any of the following events: (1) a sale, conveyance, assignment or other disposition of all or substantially all of the assets of Buyer and its Subsidiaries on a consolidated basis (other than to the Buyer or any Subsidiary of the Buyer), (2) a merger or consolidation in which Buyer is not the ultimate parent entity and in which the stockholders of Buyer immediately prior to such consolidation or merger own less than fifty percent (50%) of the ultimate parent entity’s voting power as of immediately after the transaction and (3) the sale or transfer by Buyer and/or its Subsidiaries of all or substantially all of its assets related to the Lead Compounds and Milestone Products.

(x)           “New Drug Application” shall mean a New Drug Application (as defined in Title 21, Section 314.50 et seq. of the U.S. Code of Federal Regulations or any successor regulations), including any amendment or supplement thereto, or any comparable application filed in or for jurisdictions outside the US.

(xi)          “Payment Term” shall mean the period of seventeen (17) years immediately following the Closing Date.

(xii)         “Phase II Clinical Trial” shall mean a randomized, controlled human clinical trial that satisfies the requirements of 21 C.F.R. 321.21(b), as the same may be

24

amended from time to time, or its successor regulation or comparable regulation in any jurisdiction outside the US, the principal purpose of which is a preliminary determination of clinical safety and efficacy in a target patient population following an earlier dose-finding human clinical trial.  A Phase II Clinical Trial shall exclude all portions that are phase I clinical trials (i.e., human clinical trials that satisfy the requirements of 21 C.F.R. 321.21(a), as the same may be amended from time to time, or its successor regulation or comparable regulation in any jurisdiction outside the US), but shall include any portion of a phase I/II or a phase II/III clinical trial that satisfies the definition of Phase II Clinical Trial.  For purposes of clarity, a “controlled” clinical trial is one that includes at least one arm of the trial where patients receive as study treatment (a) either sham treatment or standard-of-care treatment and (b) do not receive the applicable Milestone Product being investigated in the trial.

(xiii)        “Phase III Clinical Trial” shall mean a randomized, controlled human clinical trial that satisfies the requirements of 21 C.F.R. 321.21(c) and is intended to establish that a product is safe and efficacious for its intended use and support regulatory approval thereof, or a similar clinical study prescribed by an applicable regulatory authority outside the US. For purposes of clarity, a “controlled” clinical trial is one that includes at least one arm of the trial where patients receive as study treatment (a) either sham treatment or standard-of-care treatment and (b) do not receive the applicable Milestone Compound being investigated in the trial.

(xiv)        “US” shall mean the United States of America and its territories and possessions.

(xv)         “Wet AMD” shall mean the ophthalmic disease wet age-related macular degeneration.

(i)            To the extent that Contingent Consideration payable to Company Equityholders in respect of shares of Company Stock is treated as composed of a principal component and an interest component, as contemplated in 6.2(f)(ii)(A), and such Contingent Consideration is payable in shares of Buyer Common Stock, shares of Buyer Common Stock representing the principal component (with a value equal to the principal component) and shares of Buyer Common Stock representing the interest component (with a value equal to the interest component) shall be represented by separate share certificates or book entry accounts, as the case may be.

2.9          Withholding Rights.  The Buyer, the Company, the Surviving Entity and the Exchange and Paying Agent will be entitled to deduct and withhold from the amounts otherwise payable by it pursuant to this Agreement to any Person, such amounts as it reasonably determines that it is required to deduct and withhold with respect to the making of such payment under the Code, or any provision of state, local or foreign Tax Law, and shall request any necessary Tax forms, including Forms W-8 or W-9, as applicable, or any similar information, from Company Stockholders and any other recipients of payments hereunder to minimize such withholding.  In the event that any amount is so deducted and withheld, and properly remitted to the appropriate Governmental Entity in accordance with applicable Law, such amount will be treated for all purposes of this Agreement as having been paid to the Person to whom the payment from which such amount was withheld was made.

25

2.10        Share Issuance.

(a)           All shares of Closing Buyer Common Stock issued pursuant to this Agreement shall bear a legend (and Buyer will make a notation on its transfer books to such effect) prominently stamped or printed thereon or the substance of which will otherwise be reflected on the books and records of the transfer agent for Buyer Common Stock with respect to book-entry shares, in each case reading substantially as follows:

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO RESALE IN CONNECTION WITH A DISTRIBUTION AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT.”

Notwithstanding the foregoing, if the recipient of such Buyer Common Stock is a “non-U.S. person”, a legend in substantially the following form may also be used:

“THESE SECURITIES MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION.  HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

(b)           Notwithstanding anything else herein, the Buyer shall not be required to issue shares of Buyer Common Stock pursuant to this Agreement in excess of the Share Cap.

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company represents and warrants to the Buyer that, except as set forth in the Company Disclosure Schedule, the statements contained in this Article III are true and correct as of the date of this Agreement, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date).  The Company Disclosure Schedule, as given the effects set forth herein, the “Company Disclosure Modifications”, shall be arranged in sections and paragraphs corresponding to the numbered and lettered sections and paragraphs contained in this Article III; provided, however, that the disclosures in any section or paragraph of the Company Disclosure Schedule shall qualify (a) the corresponding section or paragraph in this Article III and (b) such other sections or paragraphs in this Article III (whether or not there is a specific cross reference) to the extent that it is reasonably apparent on the face of the disclosure that such disclosure also qualifies or applies to such other section or paragraph.

26

3.1          Organization, Standing and Corporate Power.  The Company is a corporation duly organized, validly existing and in corporate good standing under the Laws of the State of Delaware.  The Company is duly qualified to conduct business and is in corporate and Tax good standing under the Laws of each jurisdiction listed in Section 3.1 of the Company Disclosure Schedule, which jurisdictions constitute the only jurisdictions in which the nature of the Company’s businesses or the ownership or leasing of its properties requires such qualification.  The Company has all requisite power and authority (corporate and other) to carry on the businesses in which it is engaged and to own and use the properties owned and used by it, except where the failure to have such power and authority would not, individually or in the aggregate, result in the loss of a material benefit or the incurrence of a material liability.  The Company has made available to the Buyer complete and accurate copies of its Organizational Documents.  The Company is not in default under or in violation of any provision of its Organizational Documents.

3.2          Capitalization.

(a)           The authorized capital stock of the Company consists of 30,400,000 shares of Company Common Stock and 10,000,000 shares of Company Preferred Stock, all of which are designated as Series A Preferred Stock.  As of the date of this Agreement, there are (i) 3,107,882 shares of Company Common Stock outstanding, and 10,000,000 shares of Company Preferred Stock outstanding and (ii) no shares of Company Stock held in treasury.

(b)           Section 3.2(b) of the Company Disclosure Schedule sets forth a complete and accurate list, as of the date of the Agreement, of the holders of capital stock of the Company, showing the number of shares of capital stock, and the class or series of such shares, held by each stockholder and (for shares other than shares of Company Common Stock) the number of shares of Company Common Stock (if any) into which such shares are convertible.  Section 3.2(b) of the Company Disclosure Schedule also indicates all outstanding shares of Company Stock that constitute restricted stock or that are otherwise subject to a repurchase or redemption right, indicating the name of the applicable stockholder, the vesting schedule (including any acceleration provisions with respect thereto), and the repurchase price payable by the Company.  All of the issued and outstanding shares of capital stock of the Company have been duly authorized, validly issued, fully paid, nonassessable and free of all preemptive rights.  All of the issued and outstanding shares of capital stock of the Company have been offered, issued and sold by the Company in compliance with all applicable federal and state securities Laws.

(c)           Section 3.2(c) of the Company Disclosure Schedule sets forth a complete and accurate list, as of the date of this Agreement, of: (i) all Company Stock Plans, indicating for each Company Stock Plan the number of shares of Company Stock issued to date under such Company Stock Plan, the number of shares of Company Stock subject to outstanding options under such Company Stock Plan and the number of shares of Company Stock reserved for future issuance under such Company Stock Plan, (ii) all holders of outstanding Company Options, indicating with respect to each Company Option, the Company Stock Plan under which it was granted, the number of shares of Company Stock subject to such Company Option, the exercise price, the date of grant, and the vesting schedule (including any acceleration provisions with respect thereto), and (iii) all other outstanding Company Equity Awards, indicating with respect to each such award the name of the holder thereof, the Company Stock Plan under which it was

27

granted, the number and class or series of shares of Company Stock subject to such award, the date of grant, and the vesting schedule, including whether (and to what extent) the vesting will be accelerated in any way in connection with the Merger or any of the other transactions contemplated by this Agreement or upon related, concurrent or subsequent employment termination, or in combination with any other event.  Elections under Section 83(b) of the Code have been timely filed by all individuals who have purchased shares of Company Common Stock subject to vesting and repurchase rights.  The Company has made available to the Buyer complete and accurate copies of all Company Stock Plans, forms of all stock option agreements evidencing Company Options.  All of the shares of capital stock of the Company subject to Company Options will be, upon issuance pursuant to the exercise of such instruments, duly authorized, validly issued, fully paid, nonassessable and free of all preemptive rights.

(d)           With respect to each Company Option (whether outstanding or previously exercised), (i) each such Company Option is, and has at all times been, a nonstatutory stock option, (ii) each grant of a Company Option was duly authorized no later than the date on which the grant of such Company Option was by its terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the Company’s Board of Directors (or a duly constituted and authorized committee thereof), or a duly authorized delegate thereof, and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the applicable Company Stock Plan, the Securities Act, the Exchange Act, and all other applicable Laws and are not and have not been the subject of any internal investigation, review or inquiry, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company.

(e)           Except as set forth in Section 3.2(b) or Section 3.2(c) of the Company Disclosure Schedule, (i) there are no Equity Interests of any class of the Company, or any security exchangeable into or exercisable for such Equity Interests, issued, reserved for issuance or outstanding, (ii) there are no options, warrants, equity securities, calls, rights, commitments or agreements to which the Company is a party or by which the Company is bound obligating the Company to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other Equity Interests of the Company or any security or rights convertible into or exchangeable or exercisable for any such shares or other Equity Interests, or obligating the Company to grant, extend, otherwise modify or amend or enter into any such option, warrant, Equity Interest, call, right, commitment or agreement, (iii) the Company has no obligation (contingent or otherwise) to issue any subscription, warrant, option, convertible security or other such right, or to issue or distribute to holders of any Equity Interests of the Company any assets of the Company, including evidences of Indebtedness, and (iv) the Company has no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any Equity Interests or to pay any dividend or to make any other distribution in respect thereof.  Except as set forth in this Section 3.2, as of the date of this Agreement, the Company does not have any outstanding equity compensation or equity-based compensation. The Company has made available to the Buyer complete and accurate copies of agreements evidencing all Company Equity Awards, including all Restricted Stock Award agreements.

28

(f)            There is no agreement, written or oral, between the Company and any holder of its securities, or, to the Company’s Knowledge, among any holders of its securities, relating to the sale or transfer (including agreements relating to rights of first refusal, co-sale rights or “drag along” rights), registration under the Securities Act or the securities Laws of any other jurisdiction, or voting, of the capital stock of the Company.

(g)           The Allocation Schedule sets forth a true, correct and complete summary of the allocation of the amounts payable to the Company Equityholders pursuant to this Agreement.  The allocation of payments set forth on the Allocation Schedule complies with the terms of the Company’s Organizational Documents, the Company Stock, the Company Equity Awards and the Company Stock Plans.

3.3          Subsidiaries.  The Company does not have, and has never had, any Subsidiaries.  The Company does not own or control directly or indirectly or have any direct or indirect equity participation or similar interest in, or any obligation to providing funding to, any corporation, partnership, limited liability company, joint venture, trust or other business association or entity.

3.4          Authority; No Conflict; Required Filings and Consents.

(a)           The Company has all requisite power and authority to execute and deliver this Agreement and the other agreements contemplated hereby and to perform its obligations hereunder and thereunder.  The execution and delivery by the Company of this Agreement and the other agreements contemplated hereby and, subject to obtaining the Company Stockholder Approval, which is the only approval required from the Company Stockholders, the performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate and other action on the part of the Company.  Without limiting the generality of the foregoing, the Board of Directors of the Company, at a meeting duly called and held, by the unanimous vote of all directors (i) determined that the Merger is advisable, fair and in the best interests of the Company and its stockholders, (ii) approved this Agreement in accordance with the provisions of the DGCL, and (iii) directed that this Agreement and the Merger be submitted to the stockholders of the Company for their adoption and approval and resolved to recommend that the stockholders of the Company vote in favor of the adoption of this Agreement and the approval of the Merger.  This Agreement and all other agreements contemplated hereby have been duly and validly executed and delivered by the Company and constitute or will constitute valid and binding obligations of the Company, enforceable against it in accordance with their terms, subject to (A) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (B) rules of Law governing specific performance, injunctive relief and other equitable remedies (such Laws in clauses (A) and (B) are hereinafter collectively referred to as the “Applicable Bankruptcy Laws”).

(b)           Subject to the filing of the First Certificate of Merger and the Second Certificate of Merger as required by the DGCL, neither the execution and delivery by the Company of this Agreement or any other agreement contemplated hereby, nor the performance by the Company of its obligations hereunder or thereunder, nor the consummation by the Company of the transactions contemplated hereby or thereby, will (i) conflict with or violate any provision of the Organizational Documents of the Company, each as amended or restated to date,

29

(ii) require on the part of the Company or any Company Stockholder any notice to or filing with, or any permit, authorization, consent or approval of, any Governmental Entity, (iii) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in any party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under any Contract, (iv) result in the imposition of any Lien upon any assets of the Company or (v) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the Company or its properties or assets.

(c)           No consent, approval, license, permit, order or authorization of, or registration, declaration, notice or filing with, any Governmental Entity is required by or with respect to the Company in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions contemplated by this Agreement, except for the filing of the First Certificate of Merger and the Second Certificate of Merger with the Delaware Secretary of State and appropriate corresponding documents with the appropriate authorities of other states in which the Company is qualified as a foreign corporation to transact business.

3.5          Financial Statements.

(a)           The Company has made available to the Buyer the Company Financial Statements.  Except as expressly set forth therein or in the notes thereto, the Company Financial Statements (i) comply as to form with all applicable accounting requirements and (ii) were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered thereby; provided, however, that the Company Financial Statements referred to in clause (b) of the definition of such term are subject to normal recurring year-end adjustments (which, individually and in the aggregate, will not be material) and do not include footnotes.

(b)           Each of the Company Financial Statements fairly presents, in all material respects, the assets, liabilities, business, financial condition, results of operations and cash flows of the Company as of the date thereof and for the period referred to therein, and is consistent with the books and records of the Company.

(c)           The Company maintains accurate books and records reflecting its assets and liabilities. The Company has in place customary systems and processes which provide reasonable assurance that (i) transactions are executed with management’s authorization, (ii) the Company Financial Statements are accurate and reliable and (iii) the types of information that would be required to be disclosed in the Company Financial Statements are accumulated, recorded and communicated to the Company’s principal executive officer and principal financial officer in a timely manner.

(d)           The Company does not engage in securitization transactions and has no “off-balance sheet arrangements” (as defined in Item 303(a)(4) of Regulation S-K of the SEC).

(e)           The Company has not extended or maintained credit, arranged for the extension of credit, modified or renewed an extension of credit, in the form of a personal loan or otherwise, to or for any director or executive officer of the Company.  Section 3.5(e) of the

30

Company Disclosure Schedule identifies any loan or extension of credit maintained by the Company to which the second sentence of Section 13(k)(1) of the Exchange Act would apply.

(f)            BDO USA LLP, the Company’s auditors since 2015, is and has been at all times since its engagement by the Company (x) “independent” with respect to the Company within the meaning of Regulation S-X and (y) in compliance with subsections (g) through (l) of Section 10A of the Exchange Act (to the extent applicable) and the related rules of the SEC and the Public Company Accounting Oversight Board.

3.6          Absence of Certain Changes.  Since December 31, 2017, (a) there has occurred no event or development which, individually or in the aggregate, has had, or could reasonably be expected to have in the future, a Company Material Adverse Effect, (b) the Company has conducted its business in the Ordinary Course of Business and (c) the Company has not taken any of the following actions:

(a)           issued or sold any stock or other securities of the Company or any options, warrants or rights to acquire any such stock or other securities (except pursuant to the exercise or conversion of shares of Company Preferred Stock or Company Options outstanding on the date hereof, in each case solely to the extent reflected on the Allocation Schedule), or amended any of the terms of (including the vesting of) any Company Options or Company Restricted Stock Award agreements, or repurchased or redeemed any stock or other securities of the Company (except from former employees, directors or consultants in accordance with agreements in place on the date of this Agreement and providing for the repurchase of shares at their original issuance price in connection with any termination of employment with or services to the Company);

(b)           split, combined or reclassified any shares of its capital stock; or declared, set aside or paid any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock;

(c)           created, incurred or assumed any Indebtedness in excess of $25,000; assumed, guaranteed, endorsed or otherwise became liable or responsible (whether directly, contingently or otherwise) for the obligations of any other Person in excess of $25,000; or made any loans, advances or capital contributions to, or investments in, any other Person;

(d)           hired any new officers or any new employees or consultants;

(e)           except as required to comply with applicable Law, (i) adopted, entered into, terminated or amended any employment or severance plan, agreement or arrangement, any Company Plan or any collective bargaining agreement, (ii) increased the compensation or fringe benefits of, or paid any bonus to, any director, officer, employee or consultant, (iii) amended or accelerated the payment, right to payment or vesting of any compensation or benefits, including any outstanding Company Equity Awards, (iv) paid any benefit not provided for as of the date of this Agreement under any Company Plan, or granted any awards under any bonus, incentive, performance or other compensation plan or arrangement or benefit plan, including the grant of equity or equity-based compensation, or the removal of existing restrictions in any benefit plans or agreements or awards made thereunder, or (v) taken any action to fund or in any other way

31

secure the payment of compensation or benefits under any employee plan, agreement, contract or arrangement or benefit plan, other than the payment of premiums due or contributions owed in the Ordinary Course of Business;

(f)            acquired, sold, leased, licensed or disposed of any assets or property (including any shares or other equity interests in or securities of any other corporation, partnership, association or other business organization or division thereof);

(g)           mortgaged or pledged any of its property or assets or subjected any such property or assets to any Lien, other than pursuant to the terms of any definitive agreement disclosed in the Company Disclosure Schedule pursuant to which any non-exclusive license or other grant of non-exclusive rights in or to any Intellectual Property is made by the Company;

(h)           discharged or satisfied any Lien or paid any obligation or liability other than in the Ordinary Course of Business;

(i)            amended its Organizational Documents;

(j)            sold, assigned, transferred, licensed or sublicensed any Company Intellectual Property;

(k)           changed its accounting methods, principles or practices, except to the extent required by a generally applicable change in GAAP;

(l)            entered into, amended or terminated any contract or agreement of a nature required to be listed (or which would have been required to be listed) in Section 3.11(b), Section 3.12 or Section 3.13 of the Company Disclosure Schedule;

(m)          made or committed to make any capital expenditure in excess of $10,000 per item or $25,000 in the aggregate;

(n)           instituted or settled any Legal Proceeding; or

(o)           agreed in writing or otherwise to take any of the foregoing actions.

3.7          Undisclosed Liabilities.  The Company does not have any material liability (whether known or unknown, whether absolute or contingent, whether liquidated or unliquidated and whether due or to become due), except for (a) liabilities shown on the Most Recent Balance Sheet, a copy of which is attached to Section 3.7 of the Company Disclosure Schedule, (b) liabilities that have arisen since the Most Recent Balance Sheet Date in the Ordinary Course of Business and (c) contractual and other liabilities incurred in the Ordinary Course of Business that are not required by GAAP to be reflected on a balance sheet or liabilities that can be computed from the terms and conditions expressly set forth on the face of a Contract or other contract that has been made available to the Buyer (in each case, none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach of warranty, tort, infringement or violation of Law).

32

3.8          Books and Records.  The minute books and other similar records of the Company contain complete and accurate records of all actions taken at any meetings of the Company’s stockholders, Board of Directors or any committee thereof and of all written consents executed in lieu of the holding of any such meeting.  Section 3.8 of the Company Disclosure Schedule contains a list of all bank accounts and safe deposit boxes of the Company and the names of persons having signature authority with respect thereto or access thereto.

3.9          Tax Matters.

(a)           The Company has properly filed on a timely basis (taking into account extensions) all income and other material Tax Returns that it was required to file, and all such Tax Returns are true, correct and complete in all material respects and were prepared in substantial compliance with all applicable Laws.  The Company has paid all Taxes, whether or not shown on any Tax Return, that were due and payable.  The unpaid Taxes of the Company as of the Most Recent Balance Sheet Date do not exceed the accruals and reserves for Taxes (excluding accruals and reserves for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the Most Recent Balance Sheet.  All unpaid Taxes of the Company for all Tax periods (or portions thereof) commencing after the Most Recent Balance Sheet Date arose in the Ordinary Course of Business (other than Taxes incurred in connection with this Agreement).

(b)           All Taxes that the Company is or was required by Law to withhold or collect have been duly withheld or collected and, to the extent required, have been properly paid to the appropriate Governmental Entity, and the Company has complied with all information reporting and backup withholding requirements, including the maintenance of required records with respect thereto, in connection with amounts paid to any Company Employee, independent contractor, creditor, or other third party.

(c)           The Company is not and has never been a member of an affiliated group with which it has filed (or been required to file) consolidated, combined, unitary or similar Tax Returns, other than a group of which the common parent is the Company.  The Company (i) does not have any liability under Treasury Regulation Section 1.1502-6 (or any comparable or similar provision of federal, state, local or foreign Law), as a transferee or successor, or otherwise pursuant to Law for any Taxes of any Person other than the Company, and (ii) is not a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement (excluding any customary commercial agreements entered into in the Ordinary Course of Business and not primarily related to Taxes).

(d)           The Company made available to the Buyer (i) complete and correct copies of all income and other material Tax Returns of the Company relating to Taxes for all taxable periods ending on or after December 31, 2014, (ii) complete and correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by, or agreed to by or on behalf of the Company relating to Taxes for all taxable periods ending on or after December 31, 2014, and (iii) complete and correct copies of all material agreements, rulings or settlements

33

relating to Tax incentives of the Company that were granted by a Tax authority and are not generally available to Persons without specific application therefor.

(e)           The Company has not received written notice of, and to the Knowledge of the Company there is not, any examination or audit or other action of or relating to any Tax Return of the Company by any Governmental Entity that is currently in progress, threatened or contemplated. The Company has not received written notice of, and to the Knowledge of the Company there is not, any deficiency for Taxes of the Company that has been claimed, proposed or assessed by any Governmental Entity. The Company has not received any written notice, or to the Knowledge of the Company, other notice from a Governmental Entity in any jurisdiction in which the Company does not file a Tax Return that the Governmental Entity believes that the Company was required to file any Tax Return that was not filed or is subject to Tax in such jurisdiction. The Company has not (i) waived any statute of limitations with respect to Taxes or agreed to extend the period for assessment or collection of any Taxes, which waiver or extension is still in effect or (ii) requested any extension of time within which to file any Tax Return, which Tax Return has not yet been filed, other than pursuant to extensions of time to file a Tax Return obtained in the Ordinary Course of Business.  The Company has not executed or filed any power of attorney with any Tax authority which is still in effect.

(f)            The Company has not made any payment, is not obligated to make any payment, and is not a party to any agreement, contract, arrangement or plan that would reasonably be expected to obligate it to make any payment that would be treated as an “excess parachute payment” under Section 280G of the Code (without regard to Sections 280G(b)(4) and 280G(b)(5) of the Code).

(g)           The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any period (or portion thereof) ending after the Closing Date as a result of (i) any change in method of accounting for a taxable period ending on or prior to the Closing Date resulting in adjustments under Section 481 of the Code (or any similar adjustments under any provision of the Code or the corresponding foreign, state or local Tax Law), (ii) deferred intercompany gain or any excess loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding provision of state, local or foreign Tax Law) existing, in each case, on or prior to the Closing Date, (iii) closing agreement as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign Tax Law) executed on or prior to the Closing Date, (iv) installment sale or open transaction disposition made on or prior to the Closing Date, (v) prepaid amount received on or prior to the Closing Date, or (vi) any election made pursuant to Section 108(i) of the Code on or prior to the Closing Date.

(h)           The Company has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(l)(A)(ii) of the Code.

(i)            The Company has not distributed to its shareholders or security holders stock or securities of a controlled corporation, nor has stock or securities of the Company been distributed, in a transaction to which Section 355 of the Code applies (i) in the two (2) years prior to the date of this Agreement or (ii) in a distribution that could otherwise constitute part of

34

a “plan” or “series of related transactions” (within the meaning of Section 355(e) of the Code) that includes the transactions contemplated by this Agreement.

(j)            There are no Liens with respect to Taxes upon any of the assets of the Company, other than with respect to Taxes not yet due and delinquent.

(k)           The Company (i) is not a party to any joint venture, partnership, or other arrangement that is treated as a partnership for federal income tax purposes and (ii) has not made an entity classification (“check-the-box”) election under Section 7701.

(l)            The Company is not subject to tax in any country other than its country of incorporation, organization or formation by virtue of having employees, a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise having an office or other fixed place of business in that country.

(m)          The Company (i) is not a stockholder of a “specified foreign corporation” as defined in Section 965(e) of the Code (or any similar provision of state, local or foreign Law), and (ii) is not a stockholder in a “passive foreign investment company” as defined in Section 1297 of the Code.

(n)           All related party transactions involving the Company have been conducted at arm’s length in substantial compliance with Section 482 of the Code and the Treasury Regulations promulgated thereunder and any comparable provisions of any other Tax Law.

(o)           The Company has not engaged in a “reportable transaction” as set forth in Treasury Regulation section 1.6011-4(b) or a “listed transaction” as set forth in Treasury Regulation section 301.6111-2(b)(2) or any analogous provision of state or local Law.  The Company has disclosed on its federal income Tax Returns all positions taken therein that could give rise to a substantial understatement of federal income Tax within the meaning of Section 6662 of the Code.

(p)           This Section 3.9 and Section 3.17 (to the extent such section relates to Taxes) constitute the exclusive representations and warranties of the Company with respect to Taxes and any claim for breach of representation with respect to Taxes shall be based solely on the representations made in such sections and shall not be based on the representations set forth in any other provision of this Agreement.  Nothing in this Section 3.9 or otherwise in this Agreement shall be construed as a representation or warranty with respect to the amount or availability of any net operating loss, capital loss, Tax credits, Tax basis or other Tax asset or attribute of the Company in any taxable period (or portion thereof) beginning after the Closing Date.  With the exception of Sections 3.9 (c), (f), (g), and (i), no representation or warranty contained in this Section 3.9 shall apply to Taxes with respect to any taxable period (or portion thereof) beginning after the Closing Date.

3.10        Assets.  The Company does not currently own or lease, and has never owned or leased, any tangible assets.

3.11        Owned and Leased Real Property.  The Company does not own, and has never owned, any real property. The Company does not lease, and has never leased, any real property.

35

3.12        Intellectual Property.

(a)           Section 3.12(a) of the Company Disclosure Schedule lists all Company Registrations, in each case enumerating specifically the applicable filing or registration number, title, jurisdiction in which filing was made or from which registration issued, date of filing and issuance, names of all current applicant(s) and registered owners(s), as applicable.  All assignments of Company Registrations to the Company have been properly executed and recorded.  To the Knowledge of the Company, all Company Registrations are valid and enforceable and all issuance, renewal, maintenance and other payments that are or have become due with respect thereto have been timely paid by or on behalf of the Company, and there are no Liens on any of the Company Registrations, other than pursuant to the terms of any definitive agreement disclosed on the Company Disclosure Schedules pursuant to which any non-exclusive license or other grant of non-exclusive rights in or to any Intellectual Property is made by the Company.

(b)           There are no inventorship challenges, opposition or nullity proceedings or interferences declared or commenced, or to the Knowledge of the Company, threatened, with respect to any Patent Rights within the Company Registrations. The Company has complied with its duty of candor and disclosure to the United States Patent and Trademark Office and any relevant foreign patent office with respect to all patent and trademark applications filed by or on behalf of the Company and has made no misrepresentation in such applications.  The Company has no Knowledge of any information that would preclude the Company from having clear title (subject to Applicable Bankruptcy Laws) to the Company Registrations or affecting the patentability of any Patent Rights within the Company Registrations, or in the case of an issued Patent Right, validity or enforceability of any such issued Patent Right within the Company Registrations.  There has been no public disclosure by the Company, or the Knowledge of the Company, by any other Person, of any Company Owned Intellectual Property, including in trade publications or at trade shows, prior to the filing of the first Company Registrations with respect thereto.

(c)           Each item of Company Intellectual Property will be owned or available for use by the Buyer or a subsidiary of the Buyer immediately following the Closing on the same terms and conditions as it was immediately prior to the Closing.  The Company is the sole and exclusive owner of all Company Owned Intellectual Property, free and clear of any Liens, other than pursuant to the terms of any definitive agreement disclosed on the Company Disclosure Schedules pursuant to which any non-exclusive license or other grant of non-exclusive rights in or to any Intellectual Property is made by the Company.  A true and complete list of all Product Offerings, including their chemical structures, is set forth in Section 3.12(c)(i) of the Company Disclosure Schedule, and all Internal Systems that are material to the business of the Company are listed and described in Section 3.12(c)(ii) of the Company Disclosure Schedule.

(d)           The Company has taken all reasonably necessary measures to protect the proprietary nature of each item of Company Intellectual Property, and to maintain in confidence all trade secrets and confidential information comprising a part thereof.  The Company has complied in all material respects with all applicable contractual and legal requirements pertaining to information privacy and security.  No complaint relating to an improper use or disclosure of, or a breach in the security of, any such information has been made or, to the Knowledge of the

36

Company, threatened against the Company.  To the Knowledge of the Company, there has been no: (i) unauthorized disclosure of any third party proprietary or confidential information in the possession, custody or control of the Company, or (ii) breach of the Company’s security procedures resulting in unauthorized disclosure of confidential information to a third Person.

(e)           To the Knowledge of the Company, none of the Product Offerings, or the Exploitation thereof by the Company or by any user thereof, or any other activity of the Company, infringes or violates, or constitutes a misappropriation of, or in the past has infringed or violated, or constituted a misappropriation of, any Intellectual Property rights of any third party.  Section 3.12(e) of the Company Disclosure Schedule lists any written, or to the Knowledge of the Company, oral or other form of complaint, claim or notice, or threat of any of the foregoing (including any notification that a license under any patent is or may be required by the Company), received by the Company alleging any such infringement, violation or misappropriation and any request or demand for indemnification or defense received by the Company from any reseller, distributor, customer, user or any other third party; and the Company has made available to the Buyer copies of all such complaints, claims, notices, requests, demands or threats, as well as any legal opinions, studies, market surveys and analyses received by the Company or any of its Affiliates relating to any alleged or potential infringement, violation or misappropriation of any Intellectual Property rights of any third party.  The Contracts listed in Section 3.12(e)(i) of the Company Disclosure Schedule were terminated as of February 6, 2017, without any further force and effect, and neither the Company nor the counterparty to such agreement has, or could have, any rights, remedies, obligations or liabilities under such Contracts or any related agreement or arrangement, except as set forth in Section 3.12(e)(ii) of the Company Disclosure Schedule.

(f)            To the Knowledge of the Company, no Person (including any Company Employee or current or former consultant of the Company) is infringing, violating or misappropriating any of the Company Owned Intellectual Property or any of the Company Licensed Intellectual Property that is exclusively licensed to the Company.  The Company has made available to the Buyer copies of all correspondence, analyses, legal opinions, complaints, claims, notices or threats to the extent received by the Company or any of its Affiliates in writing and concerning the infringement, violation or misappropriation of any Company Owned Intellectual Property.

(g)           Section 3.12(g) of the Company Disclosure Schedule identifies each license, covenant or other agreement pursuant to which the Company has assigned, transferred, licensed or otherwise granted any right to receive an assignment, transfer or license to any Person, or covenanted not to assert any right, with respect to any Company Intellectual Property (excluding materials transfer agreements and confidentiality agreements entered into in the Ordinary Course of Business).  Except as described in Section 3.12(g) of the Company Disclosure Schedule, the Company has not agreed to indemnify any third party against any infringement or misappropriation of any Intellectual Property rights with respect to any Product Offerings or any third party Intellectual Property rights (excluding indemnities contained in agreements for the purchase, sale or license of products or services entered into in the Ordinary Course of Business).  The Company is not a member of or party to any patent pool, industry standards body, trade association or other organization pursuant to the rules of which it is obligated to license any existing or future Intellectual Property to any Person.

37

(h)           Section 3.12(h) of the Company Disclosure Schedule identifies (i) each item of Company Licensed Intellectual Property and the license or agreement pursuant to which the Company licenses or Exploits it (excluding off-the-shelf Software programs that are part of the Internal Systems and are licensed by the Company pursuant to “shrink wrap” licenses, the total fees associated with which are less than $25,000 per year) and (ii) each agreement, contract, assignment or other instrument pursuant to which the Company has obtained any joint or sole ownership interest in or to each item of Company Owned Intellectual Property.

(i)            Each current or former independent contractor of the Company has executed a valid, binding and enforceable (subject to Applicable Bankruptcy Laws) written agreement expressly assigning to the Company all right, title and interest in any inventions and works of authorship, whether or not patentable, invented, created, developed, conceived and/or reduced to practice during the term of and within the scope of such independent contractor’s work for the Company, and all Intellectual Property rights therein, and has waived all moral rights therein to the extent legally permissible.

(j)            The Company has not sought, applied for nor received any support, funding, resources or assistance from any federal, state, local or foreign governmental or quasi-governmental agency or funding source in connection with the Exploitation of the Product Offerings, the Internal Systems or any facilities or equipment used in connection therewith.  No university or Governmental Entity has sponsored any research or development conducted by the Company, or has any claim of right or ownership of or Lien on any Company Owned Intellectual Property or any Company Licensed Intellectual Property that is, or is purported to be, exclusively licensed to Company.

(k)           Neither the negotiation, execution or delivery of this Agreement, nor the consummation of the Merger, will result in (i) a material breach of or default under any agreement governing any Company Intellectual Property, (ii) a material impairment of the rights of the Company in or to any Company Intellectual Property or portion thereof, (iii) the grant or transfer to any third party, any modification or any loss of any material right with respect to, or the creation of any Lien on, any Company Intellectual Property, or (iv) the Company, the Buyer or any of their respective Affiliates being obligated to pay any penalty or new or increased royalty or fee to any Person under any agreement to which the Company is a party governing any Company Intellectual Property.

3.13        Contracts.

(a)           Section 3.13(a) of the Company Disclosure Schedule lists the following agreements under which the Company has any remaining rights or obligations and to which the Company is, as of the date of this Agreement (other than (x) non-disclosure agreements, (y) purchase orders and (z) and materials supply and materials transfer agreements, in each case entered into in the Ordinary Course of Business), a party (each a “Contract”):

(i)            any agreement (or group of related agreements) for the lease of personal property from or to third parties;

38

(ii)           any agreement (or group of related agreements) for the purchase or sale of products or for the furnishing or receipt of services (A) which calls for performance over a period of more than one (1) year, (B) which involves more than the sum of $25,000, or (C) in which the Company has granted manufacturing rights, “most favored nation” pricing provisions or marketing or distribution rights relating to any services, products or territory or has agreed to purchase a minimum quantity of goods or services or has agreed to purchase goods or services exclusively from a certain party;

(iii)          any agreement providing for any royalty, milestone or similar payments by the Company;

(iv)          any agreement concerning the establishment or operation of a partnership, joint venture or limited liability company;

(v)           any agreement (or group of related agreements) under which the Company has created, incurred, assumed or guaranteed (or may create, incur, assume or guarantee) Indebtedness (including capitalized lease obligations) or under which it has imposed a Lien on any of its assets, tangible or intangible, other than pursuant to the terms of any definitive agreement disclosed on the Company Disclosure Schedules pursuant to which any non-exclusive license or other grant of non-exclusive rights in or to any Intellectual Property is made by the Company;

(vi)          any agreement for the disposition of any assets or business of the Company or any agreement for the acquisition of the assets or business of any other Person (other than purchases of inventory or components in the Ordinary Course of Business);

(vii)         any agreement concerning noncompetition, exclusivity or non-solicitation;

(viii)        any employment agreement or consulting agreement;

(ix)          any agreement providing for severance, retention, change in control payments, or transaction-based bonuses or incentives;

(x)           any settlement agreement or settlement-related agreement (including any agreement in connection with which any employment- or individual services-related claim is settled);

(xi)          any agreement entered into by the Company since inception (whether or not in effect as of the date of this Agreement) with any Affiliate of the Company or with any current or former officer, director or stockholder of the Company or any Affiliate thereof;

(xii)         any agreement the primary purpose of which is to indemnify any other party (excluding indemnities contained in agreements for the purchase, sale or license of products, materials or services entered into in the Ordinary Course of Business);

39

(xiii)        any agreement that would entitle any third party to receive a license or any other right to (or would otherwise bind or purport to bind) Intellectual Property of the Buyer or any of the Buyer’s Affiliates (excluding the Company and the Surviving Entity) following the Closing;

(xiv)        any agreement relating to grants, funding or other forms of assistance received by the Company from any Governmental Entity;

(xv)         any agreement relating the research, development, clinical trial, manufacturing, distribution, supply, marketing or co-promotion of any products, product candidates or devices in development by or which has been or which is being researched, developed, marketed, distributed, supported, sold or licensed out, in each case by or on behalf of the Company; and

(xvi)        any other agreement (or group of related agreements) either involving more than $75,000 or not entered into in the Ordinary Course of Business.

(b)           The Company has made available to the Buyer a complete and accurate copy of (A) each Contract (as amended to date), (B) each materials supply agreement and materials transfer agreement to which the Company is or was a party entered into since the inception of the Company and (C) each agreement which contains any provisions requiring the Company to indemnify any party (excluding indemnities contained in agreements for the purchase, sale or license of products, materials or services entered into in the Ordinary Course of Business).  With respect to each Contract: (i) the Contract is legal, valid, binding and enforceable and in full force and effect against the Company and, to the Company’s Knowledge, against each other party thereto (subject to Applicable Bankruptcy Laws); and (ii) neither the Company nor, to the Knowledge of the Company, any other party, is in breach or violation of, or default under, any such Contract, and no event has occurred, is pending or, to the Knowledge of the Company, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would constitute any such breach or default by the Company or, to the Knowledge of the Company, any other party under such Contract.

(c)           The Company is not a party to any oral contract, agreement or other arrangement which, if reduced to written form, would be required to be listed in Section 3.13(a) of the Company Disclosure Schedule under the terms of Section 3.13(a).

3.14        Litigation.  There is no Legal Proceeding pending or, to the Knowledge of the Company, threatened with respect to, against or affecting the Company or any current or former officer, director, employee, consultant, agent or stockholder of the Company in its, his or her capacity as such or with respect to the Company, or seeking to prevent or delay the transactions contemplated hereby, and no notice of any Legal Proceeding involving or relating to the Company, whether pending or threatened, has been received by the Company.  There are no judgments, orders, injunctions, decrees, stipulations or awards (whether rendered by a court, administrative agency or other Governmental Entity, by arbitration or otherwise) against or involving the Company.  There is no Legal Proceeding by the Company pending, or which the Company has commenced preparations to initiate, against any other Person.

40

3.15        Environmental Matters.

(a)           The Company has complied in all material respects with applicable Environmental Laws.  There is no pending or, to the Knowledge of the Company, threatened Legal Proceeding relating to any Environmental Law involving the Company.

(b)           The Company does not have any material liabilities or obligations arising from the release or threatened release of any Materials of Environmental Concern into the environment.

(c)           The Company is not a party to or bound by any court order, administrative order, consent order or other agreement between the Company and any Governmental Entity entered into in connection with any legal obligation or liability arising under any Environmental Law.

3.16        Labor and Employment.

(a)           The Company has never engaged any individual as an employee.  The Company has not breached or violated any (i) applicable Law respecting employment and employment practices, terms and conditions of employment and wages and hours, including any such Law respecting employment discrimination, employee classification, workers’ compensation, the Immigration Reform and Control Act and occupational safety and health requirements, or (ii) employment or other individual service provider agreements, in each case, in any material respect.  No claims, controversies, investigations, audits or other Legal Proceedings are pending or, to the Knowledge of the Company, threatened, with respect to such Laws or agreements with respect to individual service providers to the Company, either by private Persons or by Governmental Entities.

(b)           Section 3.16(b) of the Company Disclosure Schedule contains a list of all consultants and independent contractors directly engaged since inception (and indicating those currently so engaged) by or for the benefit of the Company, along with the position, date of retention and rate of remuneration for each such Person and whether such Person should be treated as an employee of the Company pursuant to Treasury Regulation Section 31.3401(c)-1(f).  Each consultant and individual independent contractor engaged by or for the benefit of the Company is, or was while so engaged, a party to a written agreement or contract with the Company or an Affiliate.  Neither the Company nor any Affiliate with respect to services related to the Company has incurred, and no circumstances exist under which the Company or any such Affiliate could incur, any liability arising from the misclassification of employees as consultants or independent contractors, or from the misclassification of consultants or independent contractors as employees.  Each such consultant and individual independent contractor has entered into the Company’s or such Affiliate’s standard form of confidentiality, non-competition and assignment of inventions agreement with the Company or such Affiliate, a copy of which has previously been made available to the Buyer.  No Individual Contractor Amounts remain outstanding or unpaid.

41

3.17        Employee Benefit Plans.

(a)           The Company has never maintained any Employee Benefit Plan other than the Company Stock Plan and has no actual or potential liability with respect to any Employee Benefit Plan maintained by any ERISA Affiliate of the Company.  Neither the Company nor any ERISA Affiliate has ever maintained or contributed to or had any actual or potential liability with respect to an Employee Benefit Plan that was ever subject to Section 412 of the Code or Title IV of ERISA.  At no time has the Company or any ERISA Affiliate been obligated to contribute to or had any actual or potential liability with respect to any “multiemployer plan” (as defined in Section 4001(a)(3) of ERISA).  No act or omission has occurred and no condition exists with respect to any Employee Benefit Plan that, with respect to the Company, would subject the Buyer or the Company to (i) any fine, penalty, Tax or liability of any kind imposed under ERISA, the Code or any other applicable Law or (ii) any contractual indemnification or contribution obligation protecting any fiduciary, insurer or service provider with respect to any Employee Benefit Plan, nor will the transactions contemplated by this Agreement give rise to any such liability.  There are no loans or extensions of credit from the Company to any independent contractor to the Company (other than advances of business expenses in the Ordinary Course of Business).

(b)           No Employee Benefit Plan or other contract, agreement, plan or arrangement covering any one or more individuals contains any provision or is subject to any applicable Law that, in connection with the Merger or any of the other transactions contemplated by this Agreement or upon related, concurrent or subsequent termination of services, or in combination with any other event, would (i) increase, accelerate or vest any compensation or benefit, (ii) require termination or retention payments, (iii) provide any term of services or compensation guaranty, (iv) forgive any Indebtedness, (v) require or provide any payment or compensation subject to Section 280G of the Code (and no such payment or compensation has previously been made), (vi) promise or provide any Tax gross ups or indemnification, whether under Sections 409A or 4999 of the Code or otherwise or (vii) measure any values of benefits on the basis of any of the transactions contemplated hereby.  No stockholder, employee, officer or director of the Company has been promised or paid any bonus or incentive compensation by the Company or any of its Affiliates (including Versant Ventures and any of its Affiliates) related to the transactions contemplated hereby.  The Company has made available to the Buyer the information necessary to accurately calculate any excise tax due under Section 4999 of the Code as a result of the Merger or any of the other transactions contemplated by this Agreement for which the Company, the Surviving Entity or the Buyer is or may become directly or indirectly liable and the amount of deductions that may be disallowed under Section 280G of the Code in connection with the Merger or any of the other transactions contemplated by this Agreement.

(c)           Each Company Equity Award and any other arrangement that is or may be a “nonqualified deferred compensation plan” (as defined in Code Section 409A(d)(1)) has been since the later of January 1, 2005 or its inception in compliance with Code Section 409A and IRS Notice 2005-1 and has been in documentary compliance since January 1, 2009.  No corrections of violations of Code Section 409A have occurred.  No stock option or equity unit option granted under any Company Plan has an exercise price that has been less than the fair market value of the underlying stock or equity units (as the case may be) as of the date such option was granted or has any feature for the deferral of compensation other than the deferral of recognition of income until the later of exercise or disposition of such option.  The Company has made available to the Buyer all valuation or similar reports pertaining to the valuation of the Company Stock.

42

3.18        Compliance with Laws.  The Company has conducted, and is conducting, its business and operations in compliance in all material respects with all applicable Laws.  The Company has not received any notice from any Governmental Entity or other Person alleging any noncompliance with any applicable Law.  The Company does not have any material liability for failure to comply with any Law and, to the knowledge of the Company, there is no act, omission, event or circumstance that would reasonably be expected to give rise to any such liability.  The Company has not conducted any internal investigation with respect to any actual, potential or alleged violation of any Law by any manager, member or other equity holder, officer or Company Employee or concerning any actual or alleged fraud.

3.19        Unlawful Payments.  The Company is and has been in compliance with the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq., the Organization for Economic Cooperation and Development Convention Against Bribery of Foreign Public Officials in International Business Transactions and legislation implementing such convention, all other international anti-bribery conventions and all applicable anti-corruption or bribery Laws in any jurisdiction in which the Company has conducted its business (collectively, “Anti-Bribery Laws”).  The Company has not received any written communication from any Governmental Entity that alleges that the Company, or any current or former Representatives thereof, is or may be in violation of, or has, or may have, any liability under, any Anti-Bribery Laws, and no such potential violation of Anti-Bribery Laws has been discovered by or brought to the attention of the Company since inception. The Company has not made and does not anticipate making any disclosures to any Governmental Entity for potential violations of Anti-Bribery Laws.  None of the Company or any of its Representatives is currently an officer, agent or employee of a Governmental Entity.

3.20        Permits and Regulatory Matters.

(a)           Section 3.20 of the Company Disclosure Schedule sets forth a list of all Permits issued to or held by the Company, including all governmental authorizations from the FDA, EMA or any other Regulatory Authority.  Such listed Permits are the only Permits that are required for the Company to conduct its business as presently conducted or as proposed to be conducted.  Each such Permit is in full force and effect; the Company is in compliance with the terms of each such Permit; and, to the Knowledge of the Company, no suspension or cancellation of such Permit is threatened and there is no basis for believing that such Permit will not be renewable upon expiration.  Each such Permit will continue in full force and effect immediately following the Closing. The Company has made available to the Buyer all such Permits.

(b)           All manufacturing, processing, distribution, labeling, storage, testing, specifications and sampling of products performed by or on behalf of the Company are in material compliance with all applicable Laws administered or issued by the FDA, the EMA or any other Governmental Entity exercising comparable authority.  The Company has not received any written notices or correspondence from the FDA, the EMA or any other Governmental Entity exercising comparable authority, and there is no action or proceeding pending or threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in each case alleging that the Company is not currently in compliance with any and all applicable Laws implemented by the FDA, the EMA or any other Governmental Entity exercising

43

comparable authority.  The Company has never made any filing or submission, or had any correspondence, with the FDA, EMA or any other comparable Regulatory Authority.

(c)           The nonclinical and preclinical studies conducted by or on behalf of the Company were and, if still pending, are being conducted in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, including Good Laboratory Practices (GLPs); the Company has not received any written notices or correspondence from the Regulatory Authorities requiring the termination, suspension or modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company. The Company has made available to the Buyer all written formal communications submitted by or on behalf of the Company to any Regulatory Authority, and each such communication, including all supplements and amendments thereto, was true, complete and correct as of the applicable date thereof. The Company has never conducted any clinical trials.

(d)           The Company has made available to the Buyer all of the raw preclinical, nonclinical and other data associated with the Company’s Product Offerings. All summaries of preclinical, nonclinical and other data and studies provided by the Company to the Buyer are consistent with the raw preclinical, nonclinical and other data associated with the Company’s Product Offerings and are true, complete and accurate descriptions of the subject matter thereof.

3.21        Insurance.  Section 3.21 of the Company Disclosure Schedule lists each insurance policy (including fire, theft, casualty, comprehensive general liability, workers compensation, business interruption, environmental, director and officer liability, product liability and automobile insurance policies and bond and surety arrangements) to which the Company is a party, a named insured or otherwise the beneficiary of coverage, all of which are in full force and effect.  Such insurance policies are of the type and in amounts customarily carried by organizations conducting businesses or owning assets similar to those of the Company.  There is no claim pending under any such policy as to which coverage has been questioned, denied or disputed by the underwriter of such policy.  All premiums due and payable under all such policies have been paid, the Company is not liable for retroactive premiums or similar payments, and the Company is otherwise in compliance with the terms of such policies in all material respects.  The Company has no Knowledge of any threatened termination of, or premium increase with respect to, any such policy. Each such policy will continue to be enforceable and in full force and effect immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing. Section 3.21 of the Company Disclosure Schedule identifies all claims asserted by the Company pursuant to any insurance policy since the inception of the Company and describes the nature and status of each such claim.

3.22        Suppliers.  Section 3.22 of the Company Disclosure Schedule sets forth a list of the top ten (10) suppliers by volume for the Company’s current fiscal year and the prior fiscal year that supply products or services to the Company.  No such supplier has indicated in writing or, to the Knowledge of the Company, orally or otherwise within the past year that it will stop, or decrease the rate of, supplying materials, products or services, as applicable, to the Company.  No purchase order or commitment of the Company is in excess of normal requirements, nor are prices provided therein in excess of current market prices for the products or services to be provided thereunder.

44

3.23        Certain Business Relationships With Affiliates.  No Affiliate of the Company, directly or indirectly, (a) owns any property or right, tangible or intangible, which is used in the business of the Company, (b) has any claim or cause of action against the Company, (c) owes any money to, or is owed any money by, the Company, or (d) is a party to any contract or other arrangement (written or oral) with the Company.  Section 3.23 of the Company Disclosure Schedule describes any transactions or relationships between the Company and any Affiliate thereof that occurred or have existed since the beginning of the time period covered by the Company Financial Statements.

3.24        Investor Questionnaires.  The Company has no actual knowledge of any untrue statement of a material fact or omission of material fact required to be stated in the certifications of the Company Equityholders set forth in Annex A to the Support and Joinder Agreements and in Annex B to the executed Optionholder Agreements, in each case to the extent executed and delivered to the Buyer on the date hereof.

3.25        Brokers; Schedule of Fees and Expenses.  The Company does not have any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions contemplated by this Agreement.

3.26        Powers of Attorney.  There are no outstanding powers of attorney executed on behalf of the Company.

3.27        No Other Representations or Warranties.  The Company is not relying and has not relied on any representations or warranties whatsoever regarding the Buyer, express or implied, except for the representations and warranties in Article IV (including the related portions of the Buyer Disclosure Schedule).  Such representations and warranties by the Buyer constitute the sole and exclusive representations and warranties of the Buyer in connection with the Merger and the Company understands, acknowledges and agrees that all other representations and warranties of any kind or nature as to the Buyer, whether express, implied or statutory, are specifically disclaimed by the Buyer. In connection with the due diligence investigation of the Buyer and the Merger Subsidiaries by the Company, the Company and its Affiliates, directors, officers, employees, agents, representatives and advisors have received and may continue to receive after the date hereof from the Buyer and its Affiliates, directors, officers, employees, consultants, agents, representatives and advisors certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding the Buyer and its business and operations.  The Company hereby acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and that the Company will have no claim against the Buyer, or any of its Affiliates, directors, officers, employees, consultants, agents, representatives or advisors, or any other Person with respect thereto unless any such information is expressly addressed or included in a representation or warranty contained in this Agreement.  Accordingly, the Company hereby acknowledges and agrees that neither the Buyer nor any of its Affiliates, directors, officers, employees, consultants, agents, representatives or advisors, nor any other Person, has made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans unless any such information is expressly addressed or included in a representation or warranty made by the Buyer or the Merger Subsidiaries contained in this Agreement.

45

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE BUYER AND THE MERGER SUBSIDIARIES

Each of the Buyer and each Merger Subsidiary represents and warrants to the Company that, except (a) as set forth in the Buyer Disclosure Schedule or (b) as disclosed in the Buyer SEC Reports filed or furnished at least two (2) Business Days prior to the date of this Agreement (excluding, except with respect to the representations and warranties contained in Section 4.6, any disclosures set forth in any section entitled “Risk Factors” or “Forward-Looking Statements” or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), the statements contained in this Article IV are true and correct as of the date of this Agreement, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date). The Buyer Disclosure Schedule, as given the effects set forth herein and including, for the avoidance of doubt, incorporation of the Buyer SEC Reports as applicable pursuant to clause (b) above, the “Buyer Disclosure Modifications”, shall be arranged in sections and paragraphs corresponding to the numbered and lettered sections and paragraphs contained in this Article IV; provided, however, that the disclosures in any section or paragraph of the Buyer Disclosure Schedule shall qualify (a) the corresponding section or paragraph in this Article IV and (b) such other sections or paragraphs in this Article IV (whether or not there is a specific cross reference) to the extent that it is reasonably apparent on the face of the disclosure that such disclosure also qualifies or applies to such other section or paragraph.

4.1          Organization, Standing and Power.  Each of the Buyer and Merger Subsidiary I is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware.  The Buyer is duly qualified to conduct business and is in corporate good standing under the Laws of each jurisdiction listed in Section 4.1 of the Buyer Disclosure Schedule, which jurisdictions constitute the only jurisdictions in which the nature of the Buyer’s businesses or the ownership or leasing of its properties requires such qualification.  The Buyer has all requisite power and authority (corporate and other) to carry on the businesses in which it is engaged and to own and use the properties owned and used by it, except where the failure to have such power and authority would not, individually or in the aggregate, result in the loss of a material benefit or the incurrence of a material liability.  The Buyer is not in default under or in violation of any provision of its Organizational Documents.  Merger Subsidiary II (a) is a limited liability company duly organized, validly existing and in good standing under the Laws of the state of Delaware, (b) is a disregarded entity for federal income Tax purposes and (c) will continue to be treated as a disregarded entity for federal income Tax purposes following the Closing and the Second Effective Time.

4.2          Authority; No Conflict; Required Filings and Consents.

(a)           Each of the Buyer and each Merger Subsidiary has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder and thereunder.  The execution and delivery by the Buyer and each Merger Subsidiary of this Agreement and the consummation by the Buyer and each Merger Subsidiary of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary

46

corporate action on the part of the Buyer and the Merger Subsidiaries, respectively.  This Agreement has been duly and validly executed and delivered by the Buyer and the Merger Subsidiaries and constitutes a valid and binding obligation of the Buyer and the Merger Subsidiaries, enforceable against them in accordance with its terms.

(b)           Subject to the filing of the First Certificate of Merger and the Second Certificate of Merger as required by the DGCL, neither the execution and delivery by the Buyer or the Merger Subsidiaries of this Agreement, nor the performance by the Buyer or the Merger Subsidiaries of their respective obligations hereunder or thereunder, nor the consummation by the Buyer or the Merger Subsidiaries of the transactions contemplated hereby or thereby, will (i) conflict with or violate any provision of the charter or by-laws of the Buyer or the Merger Subsidiaries, (ii) require on the part of the Buyer or the Merger Subsidiaries any filing with, or permit, authorization, consent or approval of, any Governmental Entity, (iii) conflict with, result in breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in any party any right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of Indebtedness, Lien or other agreement to which the Buyer or any Merger Subsidiary is a party or by which any of them are bound or to which any of their assets are subject or (iv) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the Buyer or the Merger Subsidiaries or any of their properties or assets.

(c)           No consent, approval, license, permit, order or authorization of, or registration, declaration, notice or filing with, any Governmental Entity is required by or with respect to the Buyer or the Merger Subsidiaries in connection with the execution and delivery of this Agreement by the Buyer or the Merger Subsidiaries or the consummation by the Buyer or the Merger Subsidiaries of the transactions contemplated by this Agreement, except for the filing of the First Certificate of Merger and the Second Certificate of Merger with the Delaware Secretary of State and appropriate corresponding documents with the appropriate authorities of other states in which the Company is qualified as a foreign corporation to transact business.

4.3          Operations of Merger Subsidiaries.  Each Merger Subsidiary is a direct wholly owned subsidiary of Buyer and has not engaged in any business activities or conducted any operations of any kind, entered into any agreement or arrangement with any Person, or incurred, directly or indirectly, any liabilities, in each case except in connection with its incorporation and the negotiation of this Agreement.

4.4          Capitalization.

(a)           The authorized capital stock of the Buyer consists of 200,000,000 shares of Buyer Common Stock and 5,000,000 shares of Buyer Preferred Stock, $0.001 par value per share (“Buyer Preferred Stock”). As of the close of business on the Business Day prior to the date of this Agreement, there were (i) 36,222,470 shares of Buyer Common Stock outstanding (the “Closing Buyer Outstanding Shares”), (ii) no shares of Buyer Preferred Stock outstanding, (iii) no shares of Buyer Common Stock held in treasury, (iv) 4,852,218 shares of Buyer Common Stock were subject to outstanding options to purchase Buyer Common Stock, (v) 179,698 shares of Buyer Common Stock were underlying Buyer RSUs, and (vi) 2,389,226 shares of Buyer

47

Common Stock (excluding the shares of Buyer Common Stock described in the foregoing clauses (iv) and (v)) were reserved for issuance pursuant to the Buyer Stock Plans.

(b)           Schedule 4.4(b) sets forth a complete and accurate list, as of the date of this Agreement, of all Buyer Stock Plans.  The number of shares of Buyer Common Stock issued to date under the Buyer Stock Plans, the number of shares of Buyer Common Stock subject to outstanding options under the Buyer Stock Plans and the number of shares of Buyer Common Stock reserved for future issuance under the Buyer Stock Plans are accurately reflected in Section 4.4(a).  The Buyer has made available to the Company complete and accurate copies of all Buyer Stock Plans.

(c)           Except as set forth on Section 4.4(c) of the Buyer Disclosure Schedule (or elsewhere in this Section 4.4), (i) there are no options, warrants, equity securities, calls, rights, commitments or agreements to which the Buyer is a party or by which the Buyer is bound obligating the Buyer to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other Equity Interests of the Buyer or any security or rights convertible into or exchangeable or exercisable for any such shares or other Equity Interests, or obligating the Buyer to grant, extend, otherwise modify or amend or enter into any such option, warrant, Equity Interest, call, right, commitment or agreement, (ii) the Buyer has no obligation (contingent or otherwise) to issue any subscription, warrant, option, convertible security or other such right, or to issue or distribute to holders of any Equity Interests of the Buyer any assets of the Buyer, including evidences of Indebtedness, and (iii) the Buyer has no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any Equity Interests or to pay any dividend or to make any other distribution in respect thereof.

(d)           There is no agreement, written or oral, between the Buyer and any holder of its securities, or relating to the sale or transfer (including agreements relating to rights of first refusal, co-sale rights or “drag along” rights), registration under the Securities Act or the securities Laws of any other jurisdiction, or voting, of the capital stock of the Buyer.

4.5          Buyer Stock.  The shares of Buyer Common Stock subject to issuance pursuant to Article II of this Agreement (including in connection with the Closing and any Contingent Consideration), upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be duly authorized, validly issued, fully paid and non-assessable, free and clear of all Liens (other than restrictions on transfer imposed under applicable securities Laws or pursuant to this Agreement or any other agreement contemplated by this Agreement), and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of the DGCL or the organizational documents of the Buyer or any agreement to which Buyer is a party or is otherwise bound, and, subject to the accuracy of the certifications set forth in Annex B of the Support and Joinder Agreements and in Annex A of the Optionholder Agreements will be issued in compliance with all applicable federal and state securities Laws.

48

4.6          SEC Filings; Financial Statements.

(a)           The Buyer has filed all forms, reports, certifications and other documents required to be filed by Buyer with the SEC since January 1, 2016. All such registration statements, forms, reports and other documents (together with all exhibits, financial statements and schedules thereto and all information incorporated therein by reference) are referred to herein as the “Buyer SEC Reports.” All of the Buyer SEC Reports (i) were filed on a timely basis, (ii) at the time filed, or if amended, as of the date of the last such amendment, complied as to form in all material respects with the requirements of the Sarbanes-Oxley Act, the Securities Act and the Exchange Act applicable to such Buyer SEC Reports and (iii) did not at the time they were filed (or amended) contain any untrue statement of a material fact or omit to state a material fact required to be stated in such Buyer SEC Reports or necessary in order to make the statements in such Buyer SEC Reports, in the light of the circumstances under which they were made, not misleading, in any material respect.  Each of the financial statements (including, in each case, any related notes and schedules) contained in the Buyer SEC Reports at the time filed (i) complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, (ii) were prepared in accordance with GAAP applied on a consistent basis throughout the periods involved and at the dates involved (except as may be indicated in the notes to such financial statements or, in the case of unaudited interim financial statements, as permitted by the SEC on Form 10-Q under the Exchange Act) and (iii) fairly presented in accordance with GAAP the financial position of the Buyer as of the dates indicated and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal and recurring year-end adjustments.  To the knowledge of Buyer, there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case, regarding any accounting practices of Buyer.

(b)           The Buyer has established and maintains and has, since January 1, 2016, maintained, disclosure controls and procedures and a system of internal control over financial reporting (as such terms are defined in paragraphs (e) and (f), respectively, of Rule 13a-15 under the Exchange Act) in all material respects in compliance with the requirements of Rule 13a-15 under the Exchange Act. From the date of the filing of the Buyer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 to the date of this Agreement, the Buyer’s auditors and the Buyer’s board of directors have not been advised of (i) any significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Buyer’s ability to record, process, summarize and report financial information or (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Buyer’s internal control over financial reporting.

4.7          Compliance with Laws.  Each of the Buyer and its Subsidiaries has, for the past five (5) years, conducted, and is conducting, its business and operations in compliance in all material respects with all applicable Laws.  In the past five (5) years, neither the Buyer nor any Subsidiary has received any notice from any Governmental Entity alleging any noncompliance with any applicable Law.

4.8          Financial Advisor. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission based upon arrangements made by or on behalf of Buyer or any Merger Subsidiary in respect of any of the transactions contemplated hereby.

49

4.9          Litigation.  There is no Legal Proceeding pending or, to the knowledge of the Buyer, threatened with respect to, against or affecting the Buyer or any Subsidiary (including any Merger Subsidiary) or any current or former officer, director, employee, consultant, agent or stockholder of the Buyer or any Subsidiary in its, his or her capacity as such or with respect to the Buyer or any Subsidiary, seeking to prevent or delay the transactions contemplated hereby or that would reasonably be expected to result in a Buyer Material Adverse Effect, and no notice of any Legal Proceeding involving or relating to the Buyer or any Subsidiary, whether pending or threatened, has been received by the Buyer or any Subsidiary.

4.10        Permits and Regulatory Matters.

(a)           The Buyer is in compliance with the terms of each Permit; and, to the Knowledge of the Buyer, no suspension or cancellation of such Permit is threatened and there is no basis for believing that such Permit will not be renewable upon expiration.  Each such Permit will continue in full force and effect immediately following the Closing.

(b)           All manufacturing, processing, distribution, labeling, storage, testing, specifications and sampling of products performed by or on behalf of the Buyer are in material compliance with all applicable Laws administered or issued by the FDA, the EMA or any other Governmental Entity exercising comparable authority.  The Buyer has not received any written notices or correspondence from the FDA, the EMA or any other Governmental Entity exercising comparable authority, and there is no action or proceeding pending or threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in each case alleging that the Buyer is not currently in compliance with any and all applicable Laws implemented by the FDA, the EMA or any other Governmental Entity exercising comparable authority.

4.11        No Other Representations or Warranties.  Buyer is not relying and has not relied on any representations or warranties whatsoever regarding the Company, express or implied, except for the representations and warranties in Article III (including the related portions of the Company Disclosure Schedule).  Such representations and warranties by the Company constitute the sole and exclusive representations and warranties of the Company in connection with the Merger and Buyer understands, acknowledges and agrees that all other representations and warranties of any kind or nature as to the Company, whether express, implied or statutory, are specifically disclaimed by the Company.  In connection with the due diligence investigation of the Company by Buyer, Buyer and its Affiliates, directors, officers, employees, agents, representatives and advisors have received and may continue to receive after the date hereof from the Company and its Affiliates, directors, officers, employees, consultants, agents, representatives and advisors certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding the Company and its business and operations.  Buyer hereby acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and that Buyer will have no claim against the Company, or any of its Affiliates, directors, officers, employees, consultants, agents, representatives or advisors, or any other Person with respect thereto unless any such information is expressly addressed or included in a representation or warranty contained in this Agreement.  Accordingly, Buyer hereby acknowledges and agrees that neither the Company nor any of its Affiliates, directors, officers, employees, consultants, agents, representatives or advisors, nor any other Person, has

50

made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans unless any such information is expressly addressed or included in a representation or warranty made by the Company contained in this Agreement.

ARTICLE V

INDEMNIFICATION

5.1          Indemnification by the Company Equityholders.  The Company Equityholders shall, from and after the Effective Time, on a several and not joint basis in accordance with their respective Pro Rata Fraction, defend and indemnify the Buyer in respect of, and hold it harmless against and will compensate and reimburse the Buyer for, any and all Damages incurred or suffered by any Buyer Indemnified Party (regardless of whether such Damages relate to any Third Party Action) arising or resulting from, relating to or constituting:

(a)           any breach, as of the date of this Agreement (except to the extent expressly made as of an earlier date, in which case any inaccuracy of any representations and warranties as of such earlier date), of any representation or warranty of the Company contained in this Agreement (as such representations and warranties are modified by the Company Disclosure Schedule delivered contemporaneously with this Agreement) or the certificate furnished by the Company to the Buyer pursuant to Section 1.2(b)(H) of this Agreement;

(b)           any failure to perform any covenant or agreement of the Company to be performed prior to the Closing contained in this Agreement;

(c)           any Pre-Closing Taxes;

(d)           any Individual Contractor Amounts, any Closing Indebtedness, and any Company Transaction Expenses, in each case to the extent in excess of the amounts, if any, included in the calculation of the Aggregate Closing Consideration or the Final Closing Adjustment;

(e)           any claim by a stockholder or former stockholder of the Company, or any other Person seeking to assert, or based upon:  (i) the ownership or rights to ownership of any shares of stock of the Company; (ii) any rights of a stockholder (other than the right to receive the consideration pursuant to Article II), including any option, preemptive right or rights to notice or to vote; (iii) any rights under the Organizational Documents of the Company; (iv) any claim that his, her or its shares were wrongfully repurchased by the Company; or (v) any claim for appraisal or dissenters rights, including any payment in respect of Dissenting Shares in excess of the amount of payments otherwise payable to the stockholder seeking such rights under this Agreement;

(f)            any inaccuracy in the Allocation Schedule, as in effect from time to time; or

51

(g)           any fraud with respect to any representation or warranty of the Company contained in this Agreement (as such representations and warranties are modified by the Company Disclosure Modifications).

5.2          Indemnification by Buyer.  Subject to the terms and limitations set forth in this Article V, from and after the Effective Time, the Buyer shall, indemnify the Company Equityholders in respect of any and all Damages incurred or suffered by any Equityholder Indemnified Party (regardless of whether such Damages relate to any Third Party Action) resulting from, relating to or constituting:

(a)           any breach, as of the date of this Agreement (except to the extent expressly made as of an earlier date, in which case any inaccuracy of any representations and warranties as of such earlier date), of any representation or warranty of the Buyer or any Merger Subsidiary contained in this Agreement (as such representations and warranties are modified by the Buyer SEC Reports and/or the Buyer Disclosure Schedule delivered contemporaneously with this Agreement);

(b)           any failure to perform any covenant or agreement of Buyer or any Merger Subsidiary contained in this Agreement; or

(c)           any fraud with respect to any representation or warranty of the Buyer or any Merger Subsidiary contained in this Agreement (as such representations and warranties are modified by the Buyer Disclosure Modifications).

5.3          Indemnification Claims.

(a)           An Indemnified Party shall give written notification to the Indemnifying Party (which, in the case where the Company Equityholders are the Indemnifying Party, shall be given to the Company Equityholder Representative) of the commencement of any Third Party Action.  Such notification shall be given within twenty (20) calendar days after receipt by the Indemnified Party of the notice of such Third Party Action, and shall describe in reasonable detail (to the extent then known by the Indemnified Party) the facts constituting the basis for such Third Party Action and the amount of the claimed Damages and shall be accompanied by copies of any documentation submitted by the third party taking such Third Party Action.  No delay or failure on the part of an Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder except to the extent of any damage or liability caused by or arising out of such delay or failure.  Within twenty (20) calendar days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Action with counsel reasonably satisfactory to the Indemnified Party; provided, that (i) the Indemnifying Party may only assume control of such defense if (A) it acknowledges in writing to the Indemnified Party that, subject to the limitations of this Article V, the Indemnified Party shall be entitled to Damages incurred or suffered by it and resulting from or relating to such Third Party Action, (B) in the case where the Indemnified Party is the Buyer, an adverse resolution of the Third Party Action would not have a material adverse effect on the goodwill or reputation of the Buyer or the business, operations or future conduct of the Buyer and (ii) the Indemnifying Party may not assume control of the defense of any Third Party Action involving Taxes, any Governmental

52

Entity or criminal liability or in which equitable relief is sought against the Buyer or any of its Subsidiaries.  If the Indemnifying Party does not, or is not permitted under the terms hereof to, so assume control of the defense of a Third Party Action, the Indemnified Party shall control such defense.  The Non-controlling Party may participate in such defense at its own expense.  The Controlling Party shall keep the Non-controlling Party advised of the status of such Third Party Action and the defense thereof and shall consider in good faith recommendations made by the Non-controlling Party with respect thereto.  The Non-controlling Party shall furnish the Controlling Party with such information as it may have with respect to such Third Party Action (including copies of any summons, complaint or other pleading which may have been served on such party and any written claim, demand, invoice, billing or other document evidencing or asserting the same) and shall otherwise cooperate with and assist the Controlling Party in the defense of such Third Party Action.  The Controlling and Non-controlling Party shall cooperate in the defense or prosecution of such Third Party Action.  Such cooperation shall include the retention and (upon the Company Equityholder Representative’s request) the provision to the Company Equityholder Representative of records and information which are reasonably relevant to such Third Party Action, and making employees and other representatives and advisors available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.  The reasonable fees and expenses of counsel to the Indemnified Party with respect to a Third Party Action (x) may be considered Damages if the Indemnifying Party elects not to control the defense of such Third Party Action pursuant to the terms of this Section 5.3(a) and indemnification is thereafter determined to be appropriate and/or (y) shall be considered Damages for purposes of this Agreement if the Indemnifying Party assumes control of such defense and the Indemnified Party reasonably concludes that the Indemnifying Party and the Indemnified Party have conflicting interests or different defenses available with respect to such Third Party Action (provided, however, that in no event shall the Company Equityholder Representative be responsible for the fees and expenses of more than one counsel for all Buyer Indemnified Parties).  The Indemnifying Party shall not agree to any settlement of, or the entry of any judgment arising from, any Third Party Action without the prior written consent of the Indemnified Party which shall not be unreasonably withheld, conditioned or delayed; provided, that the consent of the Indemnified Party shall not be required if the Indemnifying Party, agrees in writing to pay any amounts payable pursuant to such settlement or judgment and such settlement or judgment includes a complete release of the Indemnified Party from further liability and has no other adverse effect on the Indemnified Party.  The Indemnified Party shall not agree to any settlement of, or the entry of any judgment arising from, any such Third Party Action without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything else herein to the contrary, to the extent there is any conflict between the provisions of this Section 5.3(a) and Section 6.2(d) with regard to any Third Party Action involving Taxes, Section 6.2(d) shall govern.  The existence of any Third Party Claim shall not create a presumption of any breach by a party to this Agreement of any of its representations, warranties or covenants set forth in this Agreement.

(b)           In order to seek indemnification under this Article V (other than pursuant to matters that are addressed by Section 2.6 which shall be governed thereby), the Indemnified Party shall deliver a Claim Notice to the Company Equityholder Representative (acting on behalf of the Company Equityholders in the case of indemnification sought against the Company Equityholders) and Buyer (in the case of indemnification sought against the Buyer).

53

(c)           Within twenty (20) calendar days after delivery of a Claim Notice by the Buyer or the Company Equityholder Representative, the applicable Indemnifying Party shall deliver to the Indemnified Party a Response, in which the Indemnifying Party, shall:  (i) agree that the Indemnified Party is entitled to receive all of the Claimed Amount, (ii) agree that the Indemnified Party is entitled to receive the Agreed Amount or (iii) dispute that the Indemnified Party is entitled to receive any of the Claimed Amount.  If no Response is delivered within such twenty (20)-day period, the Indemnifying Party shall be deemed to have agreed that all of the Claimed Amount is owed to the Indemnified Party.  The Indemnifying Party may not contest the payment of all or a portion of the Claimed Amount, except to the extent it believes in good faith that the Claimed Amount does not constitute Damages for which the Indemnified Party is entitled to indemnification under this Article V.  Acceptance by the Indemnified Party of partial payment of any Claimed Amount shall be without prejudice to the Indemnified Party’s right to claim the balance of any such Claimed Amount.

(d)           If the Company Equityholder Representative in such Response disputes payment of all or part of the Claimed Amount, the Company Equityholder Representative and Buyer shall use good faith efforts to resolve such Dispute.  If such Dispute is not resolved within sixty (60) calendar days following the delivery by the Company Equityholder Representative of such response any Dispute shall be resolved in accordance with Section 8.11.

(e)           Notwithstanding the other provisions of this Section 5.3, if a third party asserts (other than by means of a lawsuit) that any Buyer Indemnified Party is liable to such third party for a monetary or other obligation which may constitute or result in Damages for which a Buyer Indemnified Party may be entitled to indemnification pursuant to this Article V, and the Buyer reasonably determines that it has a valid business reason to fulfill such obligation, then (i) the Buyer shall be entitled to satisfy such obligation, without prior notice to or consent from the Company Equityholder Representative or the Company Equityholders, (ii) the Buyer may subsequently make a claim for indemnification in accordance with the provisions of this Article V, and (iii) the Buyer shall be reimbursed, in accordance with the provisions of this Article V, for any such Damages for which it is entitled to indemnification pursuant to this Article V (subject to the right of the Company Equityholder Representative, on behalf of the Company Equityholders, to dispute the applicable Buyer Indemnified Party’s entitlement to indemnification, or the amount for which it is entitled to indemnification, under the terms of this Article V).

(f)            Notwithstanding anything else in this Agreement, and subject to the limitations of Section 5.5, the Buyer shall have the right, but not the obligation, to set off, in whole or in part, against any Contingent Consideration that is or may become payable pursuant to this Agreement, amounts owed or claimed in good faith to be owed by such Company Equityholder to any Buyer Indemnified Party pursuant to this Agreement and set forth in a Claim Notice pursuant to this Article V.  If the final amount of Damages in respect of such Claim Notice is determined in accordance with this Article V to be less than the amount withheld from such Contingent Consideration pursuant to this Section 5.3(f), then no later than twenty (20) calendar days following such finalization the Buyer shall deliver to the Exchange and Paying Agent for the benefit of the Company Stockholders, and the Surviving Entity or the Exchange and Paying Agent, as applicable, for the benefit of holders of Company Options, either (A) a number of shares of Buyer Common Stock equal to the applicable amount divided by the Buyer Post-Closing Stock Price corresponding to the applicable Contingent Consideration, or (B) if the issuance of such shares of Buyer Common Stock pursuant to this Section 5.3(f), together with all other issuances of Buyer Common Stock pursuant to this Agreement prior to such date, would cause the Share Cap to be exceeded, pay such excess amount in cash to the Exchange and Paying Agent or the Surviving Entity, as applicable, for prompt distribution to the Company Equityholders in accordance with Section 2.7 and the applicable Post-Closing Disbursement Certificate; provided, that the “determination date” for purposes of determining the Buyer Post-Closing Stock Price under this Section 5.3(f) shall be the date the final amount of Damages in respect of the applicable Claim Notice is determined pursuant to this Article V.

54

(g)           Without limitation of Section 2.4, the Company Equityholder Representative shall have full power and authority on behalf of each Company Equityholder (as an Indemnifying Party and an Indemnified Party) to take any and all actions on behalf of, execute any and all instruments on behalf of, and execute or waive any and all rights of, the Company Equityholders under this Article V.  The Company Equityholder Representative shall have no liability to any Company Equityholders for any action taken or omitted on behalf of the Company Equityholders pursuant to this Article V.

5.4          Survival of Representations and Warranties.

(a)           Unless otherwise specified in this Section 5.4 or elsewhere in this Agreement, all provisions of this Agreement shall survive the Closing and the consummation of the transactions contemplated hereby and shall continue in full force and effect in accordance with their terms until the expiration of the applicable statute of limitations; provided, however, that, all representations and warranties that are covered by the indemnification obligations in Sections 5.1(a) and 5.2(a) shall expire on the date twelve (12) months following the Closing Date; provided further, however, that (i) the representations and warranties set forth in Sections 3.1, 3.2, 3.3, 3.4(a), 3.25, 3.27, 4.1, 4.2(a), 4.4, 4.8 and 4.11 shall survive until the date that is sixty (60) calendar days after the expiration of the longest statute of limitations applicable to the subject matter of the applicable representation or warranty (the representations and warranties described in this clause (i), the “Fundamental Representations”), (ii) the representations and warranties set forth in Sections 3.9, 3.17 (to the extent related to Taxes) and 3.23, shall survive until the date that is sixty (60) calendar days after the expiration of the longest statute of limitations applicable to the subject matter of the applicable representation or warranty (the representations and warranties described in this clause (ii), the “Specified Representations”), (iii) the representations and warranties set forth in Sections 3.12, 3.16, 3.20 and 4.10 shall survive until the date that is thirty (30) months following the Closing Date and (iv) with respect to claims made under Section 5.1(g) or Section 5.2(c), the relevant representations and warranties shall survive until the resolution of such claims.  The parties further acknowledge that the time periods set forth in this Article V for the assertion of claims under this Agreement are the result of arms’ length negotiation among the parties and that they intend for the time periods to be enforced as agreed by the parties.

(b)           If the Buyer delivers to the Company Equityholder Representative or the Company Equityholder Representative delivers to the Buyer, as applicable, before expiration of a representation, warranty, covenant or agreement, either a Claim Notice based upon a breach of such representation, warranty, covenant or agreement or an Expected Claim Notice based upon a

55

breach of such representation, warranty, covenant or agreement then the applicable representation, warranty, covenant or agreement shall survive until, but only for purposes of, the resolution of the matter covered by such notice.  If the legal proceeding or written claim with respect to which an Expected Claim Notice has been given is definitively withdrawn or resolved in favor of the Buyer or the Company Equityholder Representative, the Buyer or the Company Equityholder Representative, as applicable, shall promptly so notify the Company Equityholder Representative or the Buyer, as applicable.

5.5          Limitations.

(a)           With respect to claims for Damages arising under Section 5.1(a), the Company Equityholders shall not be liable for any such Damages until the aggregate amount of all such Damages exceeds $122,153 (the “Company Basket Amount”) (at which point the Company Equityholders shall become liable for all Damages under Section 5.1(a) in excess of the Company Basket Amount); provided, that the limitation set forth in this sentence shall not apply to (i) any claims pursuant to Section 5.1(g) or (ii) any claims pursuant to Section 5.1(a) relating to a breach of any of the Fundamental Representations.

(b)           With respect to claims for Damages arising under Section 5.2(a), the Buyer shall not be liable for any such Damages until the aggregate amount of all such Damages exceeds $122,153 (the “Buyer Basket Amount”) (at which point the Buyer shall become liable for all Damages under Section 5.2(a) in excess of the Buyer Basket Amount); provided, that the limitation set forth in this sentence shall not apply to (1) any claims pursuant to Section 5.2(c) or (2) any claims pursuant to Section 5.2(a) relating to a breach by Buyer or any Merger Subsidiary of any of the Fundamental Representations.

(c)           Except for claims pursuant to Section 5.1(g) and claims for breaches of Fundamental Representations, the aggregate liability of the Company Equityholders for Damages under Section 5.1(a) shall not exceed (i) in the case of the Specified Representations, the Specified Representation Cap or (ii) in the case of all other representations and warranties, the Non-Fundamental Cap; provided, that neither the Specified Representation Cap nor the Non-Fundamental Cap shall apply to any claims for breaches of any Specified Representations to the extent the Buyer Indemnified Parties seek or become entitled to recovery, set off, offset or withholding of Damages pursuant to Section 5.3(f) (but only with respect to such recovery, set off, offset or withholding of Damages pursuant to Section 5.3(f)).  Except for claims pursuant to Section 5.2(c) and claims for breaches of Fundamental Representations, the aggregate liability of the Buyer for Damages under Section 5.2(a) shall not exceed the Non-Fundamental Cap.

(d)           The aggregate liability of each Company Equityholder for Damages under this Article V shall not exceed the aggregate amount of Aggregate Consideration such Company Equityholder has received (or would have received but for the indemnification, set off, offset or holdback obligations set forth in this Article V) pursuant to this Agreement. The foregoing limitation on liability set forth in this Section 5.5(d) shall not apply to a Company Equityholder with respect to claims pursuant to Section 5.1(g) based on actions of such Company Equityholder.

56

(e)           Except for claims pursuant to Section 5.2(c), the aggregate liability of the Buyer for Damages under this Article V shall not exceed $12,215,346 in the aggregate; provided, that the Buyer’s maximum aggregate liability for any claim for a breach under Section 2.8 shall be as set forth in the last sentence of Section 2.8(d).

(f)            No Company Equityholder shall have any right of contribution against the Company or the Surviving Entity with respect to any breach by the Company of any of its representations, warranties, covenants or agreements.

(g)           The rights to indemnification set forth in this Article V shall not be affected by (i) any investigation conducted by or on behalf of any Buyer Indemnified Party or any knowledge acquired (or capable of being acquired) by any Buyer Indemnified Party, whether before or after the date of this Agreement or the Closing Date, with respect to the inaccuracy or noncompliance with any representation, warranty, covenant or obligation which is the subject of indemnification hereunder, or (ii) any waiver by the Buyer of any closing condition relating to the accuracy of representations and warranties or the performance of or compliance with agreements and covenants.

(h)           Notwithstanding anything to the contrary in this Agreement, for purposes of determining (i) whether there has been a breach of any representation or warranty set forth in Article III and (ii) the amount of Damages for which any Buyer Indemnified Party may be entitled to indemnification under this Article V, each such representation or warranty (other than the representations and warranties set forth in clause (b) of Section 3.5 and clause (a) of Section 3.6) shall be deemed to have been made without any qualifications or limitations as to materiality (including any qualifications or limitations made by reference to a Company Material Adverse Effect or Buyer Material Adverse Effect, as applicable).

(i)            Except (i) for specific performance and (ii) as set forth in Section 2.6 and Section 2.8, after the Closing, the rights of the parties under this Article V shall be the exclusive remedy of the parties with respect to claims resulting from or relating to any misrepresentation, breach of warranty or failure to perform any covenant or agreement of the other parties contained in this Agreement.

(j)            Any payments made to a party pursuant to this Article V shall be treated as an adjustment to the Aggregate Consideration for Tax purposes to the extent permitted by Law.

5.6          Recovery. Any Damages owed by a Company Equityholder pursuant to the terms and conditions of the Article V, shall be payable, at the election of each individual Company Equityholder by delivery (in book-entry form) of that number of shares of Buyer Common Stock then beneficially owned of record by such Company Equityholder, equal to such Company Equityholder’s Pro Rata Fraction of the applicable Damages divided by Buyer Post-Closing Stock Price.

5.7          No Duplication.

(a)           For purposes of this Agreement, Damages shall be calculated after giving effect to any amounts actually recovered from third parties, including amounts recovered under

57

insurance policies (for the avoidance of doubt, excluding any self-insurance program or similar arrangement) with respect to such Damages (net of any costs to recover such amounts); provided, however, that no Buyer Indemnified Party shall have any affirmative obligation to pursue any such claim against any third party or to pursue recovery under any policy of insurance.

(b)           Any Damages for indemnification under this Agreement shall be determined without duplication of recovery due to the facts giving rise to such Damages constituting a breach of more than one representation, warranty, covenant or agreement, including any recovery pursuant to Section 2.6.

ARTICLE VI

COVENANTS

6.1          Indemnification.  For a period of six (6) years after the Closing Date, the Surviving Entity shall not amend, repeal or otherwise modify any provisions of its limited liability company agreement concerning indemnification, exculpation or limitation of liability of directors, officers, fiduciaries or agents of the Company (the “D&O Indemnified Persons”) in any manner that would affect adversely the rights thereunder of persons who, prior to the Closing Date, were directors, officers, employees, fiduciaries or agents of the Company, except to the extent required by applicable Law and except for any such change that would not affect the application of such provisions to acts or omissions of such individuals prior to the Closing.  Notwithstanding anything to the contrary in the certificate of incorporation, bylaws or limited liability company agreement, as applicable, of the Company or the Surviving Entity or any provision in any indemnification or other agreement to which any of them is a party or by which any of them is bound, (a) no exculpation or other provision in the certificate of incorporation, bylaws or limited liability company agreement, as applicable, of the Company or the Surviving Entity or any such agreement shall be deemed to exculpate any such person from its obligations under this Agreement and (b) no person shall be entitled to indemnification or reimbursement or advancement of expenses under any provision of the certificate of incorporation, bylaws or limited liability company agreement, as applicable, of the Company or the Surviving Entity or any such agreement for any matter for which any Buyer Indemnified Party is entitled to indemnification pursuant to this Agreement.  Prior to the Closing Date, the Company shall have obtained a prepaid director and officer liability insurance coverage policy that will be in effect at the Effective Time (the “D&O Policy”) providing for six (6) years of “tail” coverage with respect to matters occurring prior to the Effective Time, for the benefit of the D&O Indemnified Persons with respect to their acts and omissions occurring prior to the Effective Time, and for all purposes of this Agreement the expense of which shall be paid by the Company. For the avoidance of doubt, any costs, expenses, liabilities or other amounts owed or payable with respect to such “tail policy” that remain unpaid as of the Closing shall be deemed to be “Company Transaction Expenses” for all purposes hereunder.  In the event the Company or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, the Buyer shall ensure that the successors and assigns of the

58

Company or the Surviving Entity, as the case may be, or at the Buyer’s option, Buyer, shall assume the obligations set forth in this Section 6.1.

6.2          Tax Matters.

(a)           Preparation and Filing of Tax Returns; Payment of Taxes.

(i)            The Buyer, at its expense, shall prepare and timely file or shall cause to be prepared and timely filed all Tax Returns for the Company for Pre-Closing Tax Periods that are due after the Closing Date (“Buyer Prepared Returns”), and subject to Buyer’s rights to indemnification for Pre-Closing Taxes, Buyer shall timely pay any Taxes shown on such Tax Returns.  Buyer Prepared Returns, including any Tax Return of the Company to be prepared and filed for taxable periods beginning on or before the Closing Date and ending after the Closing Date (a “Straddle Period”), shall be prepared on a basis consistent with the last previous similar Tax Return except as required by applicable Law. In the case of any Buyer Prepared Return that (1) is the final income Tax Return of the Company or (2) shows Taxes for which the Company Equityholders are required to indemnify the Buyer under Article V, the Buyer shall provide the Company Equityholder Representative with a copy of such proposed Tax Return (and such additional information regarding such Tax Return as may reasonably be requested by the Company Equityholder Representative) for review and comment at least forty-five (45) calendar days prior to the filing of such Tax Return (or in the case of non-income Tax Returns, such period of time prior to filing as is reasonably practicable).  The Buyer shall consider in good faith any comments reasonably requested by the Company Equityholder Representative in writing and received by the Buyer prior to the filing of such Tax Return.

(ii)           All transfer, sales, use, stamp, conveyance, real property transfer, recording, registration, documentary, filing and other non-income Taxes and administrative fees (including, without limitation, notary fees) arising in connection with the consummation of the transactions contemplated by this Agreement (“Transfer Taxes”) shall be borne fifty percent (50%) by the Company Equityholders and fifty percent (50%) by Buyer.  The party required by applicable Law to file any Tax Return relating to Transfer Taxes shall be responsible for filing such Tax Return and the other party shall cooperate with the filing party in the filing of any such Tax Returns with respect to Transfer Taxes, including promptly supplying any information in its possession that is reasonably necessary to complete such Tax Returns.

(b)           Allocation of Certain Taxes.

(i)            The Buyer and the Company Equityholders agree that if the Company is permitted but not required under applicable foreign, state or local Tax Laws to treat the Closing Date as the last day of a taxable period, the Buyer and the Company Equityholders shall treat such day as the last day of a taxable period.

(ii)           The amount of any Taxes for a Straddle Period allocable to a Pre-Closing Tax Period shall be deemed to equal (i) in the case of Taxes that (x) are based upon or related to income, receipts or payroll or (y) imposed in connection with any sale or other transfer or assignment of property (other than Transfer Taxes described in Section 6.2(a)), the amount which would be payable if the taxable year ended with the Closing Date, and (ii) in the case of

59

other Taxes imposed on a periodic basis (including property Taxes), the amount of such Taxes for the entire period multiplied by a fraction the numerator of which is the number of calendar days in the period ending with the Closing Date and the denominator of which is the number of calendar days in the entire period.  For purposes of computing the Taxes attributable to the two portions of a taxable period pursuant to this Section 6.2(b)(ii), the amount of any item that is taken into account only once for each taxable period (e.g., the benefit of graduated tax rates, exemption amounts, etc.) shall be allocated between the two portions of the period in proportion to the number of calendar days in each portion.

(c)           Post-Closing Restrictions. The Buyer, the Surviving Company, and its Subsidiaries will not (and will not permit their respective Affiliates to) (i) except for Tax Returns prepared and filed in accordance with Section 6.2(a), file or amend any Tax Returns of the Company or its Subsidiaries with respect to any Pre-Closing Tax Period, (ii) with respect to Tax Returns prepared and filed in accordance with Section 6.2(a) after the date such Tax Returns are filed, amend any such Tax Returns, (iii) make or change any Tax election or change any method of accounting that has retroactive effect to the Company for a Pre-Closing Tax Period (including any election pursuant to Section 338 of the Code), or (iv) agree to extend or waive the statute of limitations with respect to Taxes of the Company or any of its Subsidiaries for a Pre-Closing Tax Period, in each such case, if such action could reasonably be expected to form the basis for a claim of indemnification against the Company Equityholders pursuant to this Agreement, except, in each case, (A) with the prior written consent of the Company Equityholder Representative (which will not be unreasonably withheld delayed or conditioned), or (B) if required by Law (provided that the Buyer shall have consulted in good faith with the Company Equityholder Representative regarding the requirements of applicable Law before taking any action pursuant to this clause (B)).

(d)           Cooperation on Tax Matters; Tax Audits.

(i)            The Buyer, the Surviving Entity and the Company Equityholder Representative and their respective Affiliates shall cooperate in the preparation of all Tax Returns and the conduct of all Tax Contests relating to the determination of any Tax for any Tax periods for which one party could reasonably require the assistance of the other party in obtaining any necessary information.

(ii)           If Buyer, the Surviving Entity or any of their Affiliates receives notice of a Tax Contest with respect to (i) the qualification of the Merger as a reorganization within the meaning of Section 368(a) of the Code or (ii) any Taxes for which the Company Equityholders are required to indemnify the Buyer under Article V, then within ten (10) Business Days after receipt of such notice, the Buyer shall notify the Company Equityholder Representative of such notice. No delay or failure in so notifying the Company Equityholder Representative shall relieve the Company Equityholders of any liability or obligation hereunder except to the extent of any damage or liability caused by or arising out of such delay or failure.

(A)          The Company Equityholder Representative may elect to control the conduct and resolution of such Tax Contest solely to the extent that such Tax Contest relates to the qualification of the Merger as a reorganization within the meaning of Section 368(a) of the Code, provided that (i) the Company Equityholder Representative shall permit Buyer to

60

participate in such Tax Contest (using counsel of its own choosing), (ii) the Company Equityholder Representative shall keep Buyer reasonably informed of all material developments on a timely basis with respect to any such Tax Contest, and (iii) the Company Equityholder Representative shall not enter into any settlement of, otherwise compromise or abandon any Tax Contest without the prior written consent of Buyer, which consent shall not be unreasonably withheld, conditioned or delayed.

(B)          With respect to any Tax Contest (1) involving Tax matters or items that could reasonably be expected to form the basis for a claim of indemnification against the Company Equityholders pursuant to this Agreement and (2) that the Company Equityholder Representative does not or cannot elect to control pursuant to the preceding Section 6.2(d)(ii)(A), Buyer will control such Tax Contest, including the defense and settlement thereof; provided, that, (i) the Buyer shall permit the Company Equityholder Representative to participate in such Tax Contest (using counsel of its own choosing), (ii) Buyer shall keep the Company Equityholder Representative reasonably informed of all material developments on a timely basis with respect to any such Tax Contest, and (iii) Buyer shall not enter into any settlement of, otherwise compromise or abandon any such Tax Contest without the prior written consent of the Company Equityholder Representative, which consent shall not be unreasonably withheld, conditioned or delayed.

(e)           Termination of Tax Sharing Agreements.  All Tax sharing agreements or similar arrangements with respect to or involving the Company shall be terminated prior to the Closing Date.

(f)            Tax Treatment.

(i)            For U.S. federal income tax purposes, the First Merger and the Second Merger are intended to be treated as integrated steps in a single transaction that together qualify as a “reorganization” within the meaning of Section 368(a) of the Code.  The parties adopt this Agreement as a “plan of reorganization” for purposes of Sections 354 and 361 of the Code and within the meaning of Sections 1.368-2(g) and 1.368-3 of the Treasury Regulations. None of the parties shall (and each of the parties shall cause their respective Subsidiaries not to) take any action, or fail to take any action, other than as expressly contemplated by this Agreement, that could reasonably be expected to prevent or impede the Merger from qualifying as such a reorganization. Buyer, Merger Subsidiaries, and the Company agree to report the Merger for U.S. federal income tax purposes as a “reorganization” within the meaning of Section 368(a) of the Code unless otherwise required by a “determination” (within the meaning of Section 1313(a) of the Code) or otherwise determined in settlement of a Tax Contest in accordance with the procedures set forth in Section 6.2(d)(ii), including attaching the statement described in Treasury Regulations Section 1.368-3(a) on or with the Company’s return of the taxable year of the Merger.  Except for the covenants in this Section 6.2(f)(i), and the last sentence of Section 4.1, it is understood and agreed that neither Buyer nor Merger Subsidiaries makes any representations or warranties to the Company Equityholders regarding the Tax treatment of the Merger.

61

(ii)           For all applicable Tax purposes, the parties to this Agreement agree to, and no party shall take any action or filing position inconsistent with, the following Tax treatment of the items specified below:

(A)          The contingent rights of the Company Equityholders to their Pro Rata Share of the Contingent Consideration in respect of their Company Stock (i) shall be treated as deferred contingent purchase price potentially eligible for installment sale treatment under Section 453 of the Code and any corresponding provision of state, local or non-U.S. Law as appropriate, and (ii) if and to the extent any such amount is released or paid in respect of Company Stock, interest may be imputed on such amount to the extent required by Section 483 or 1274 of the Code.

(B)          Any payments made in respect of Company Options held by U.S. taxpayers pursuant to this Agreement shall be treated as compensation paid by the Company as and when received by the holder thereof to whom such payment is due.

(iii)          The entirety of the Aggregate Consideration payable by Buyer to the Company Equityholders in respect of Company Stock pursuant to this Agreement (including the any Future Payments) shall be allocated to Company Stock, and none shall be allocated to the noncompetition covenants made in connection with the Merger or otherwise treated as compensation; provided, however, that any such Aggregate Consideration payable in  in respect of a Company Restricted Stock Award for which an election under Section 83(b) of the Code was not properly or timely filed may be treated as compensation.

ARTICLE VII

DEFINITIONS

For purposes of this Agreement, each of the following terms has the meaning set forth below.

“Advisory Group” has the meaning set forth in Section 2.4(f).

“Affiliate” means, with respect to a Person, any other Person who is an “affiliate” of that Person within the meaning of Rule 405 promulgated under the Securities Act; provided, that, for the avoidance of doubt, Inception Sciences, Inc. and Inception Sciences Canada, Inc. shall be deemed to be Affiliates of the Company and of Versant Ventures for all purposes hereunder.

“Aggregate Closing Consideration” means a number of shares of Buyer Common Stock equal to (a) the Base Closing Shares less (b) the Holdback Shares less (c) the number of shares of Buyer Common Stock equal to (i) the sum of the Estimated Closing Adjustment plus the Company Equityholder Representative Expense Amount, divided by (ii) the Buyer Closing Stock Price.

“Aggregate Consideration” means the sum of (a) the Aggregate Closing Consideration, plus (b) any Future Payments that become payable in accordance with the terms of this Agreement.

62

“Aggregate Residual Closing Consideration” means a number of shares of Buyer Common Stock equal to (a) the Aggregate Closing Consideration less (b) a number of shares equal to (i) the Series A Preference Consideration multiplied by (ii) the aggregate number of shares of Company Preferred Stock outstanding as of immediately prior to the Effective Time; provided that the “Aggregate Residual Closing Consideration” shall be zero if the Aggregate Closing Consideration is less than the Series A Preference Consideration.

“Agreed Amount” means part, but not all, of the Claimed Amount.

“Agreement” has the meaning set forth in the first paragraph of this Agreement.

“Allocation Schedule” means the schedule attached hereto as Schedule AS (as such schedule may be updated, corrected, amended or modified in accordance with Section 2.7(a) from time to time after the Effective Time), setting forth (i) the Company’s calculations of the Aggregate Closing Consideration and Aggregate Residual Closing Consideration, and (ii) for each Company Equityholder: (a) the name and address for such Company Equityholder; (b) the number of shares of each class of Company Stock held as of the Closing Date by such Company Equityholder; (c) to the extent such Company Equityholder holds shares of Company Preferred Stock, the number of shares of Company Common Stock issuable upon conversion of the shares of each such series of Company Preferred Stock (assuming such conversion occurs as of immediately prior to the Effective Time) in accordance with the Company Certificate of Incorporation; (d) the number of shares of Company Common Stock subject to Company Equity Awards outstanding immediately prior to the Effective Time (after giving effect to the full acceleration of vesting in connection with the transactions contemplated by this Agreement or otherwise) held by such Company Equityholder (and, if applicable, the exercise price or measurement price thereof); (e) the amount to be paid to such Company Equityholder pursuant to Section 2.1(c) and pursuant to Section 2.5; (f) the portion of the Aggregate Closing Consideration attributable to such Company Equityholder’s Company Stock and Company Equity Awards; (g) whether such Company Equityholder executed a Support and Joinder Agreement certifying that such Company Equityholder is an “accredited investor” pursuant to Regulation D under the Securities Act and/or not a “U.S. Person” within the meaning of Rule 902 of Regulation S of the Securities Act; (h) the applicable Exchange and Paying Agent; and (i) such Company Equityholder’s Pro Rata Share and Pro Rata Fraction, expressed as a percentage.

“Anti-Bribery Laws” has the meaning set forth in Section 3.19.

“Applicable Bankruptcy Laws” shall have the meaning set forth in Section 3.4(a).

“Base Closing Shares” means 5,314,717 shares of Buyer Common Stock.

“Business Day” means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in San Diego, California, Wilmington, Delaware or New York, New York are permitted or required by Law, executive order or governmental decree to remain closed.

“Buyer” has the meaning set forth in the first paragraph of this Agreement.

63

“Buyer Basket Amount” has the meaning set forth in Section 5.5(b).

“Buyer Closing Stock Price” means $2.2984.

“Buyer Common Stock” means the common stock, $0.001 par value per share, of the Buyer.

“Buyer Disclosure Modifications” has the meaning set forth in the first paragraph of Article IV.

“Buyer Indemnified Parties” means the Buyer and its Affiliates (including, after the Closing, the Company and the Surviving Entity).

“Buyer Material Adverse Effect” means any Change that, individually or in the aggregate with all other Changes, has had or could reasonably be expected to have a material adverse effect on the ability of the Buyer or the Merger Subsidiaries to perform their respective obligations under (including, for the avoidance of doubt, payment of Contingent Consideration), or to consummate the transactions contemplated by this Agreement.

“Buyer Post-Closing Stock Price” means the volume-weighted average price, rounded to four decimal points, of shares of Buyer Common Stock on Nasdaq (as reported on Bloomberg L.P. under the function “VWAP”) over the five (5) consecutive trading day period ending three (3) full trading days prior to the applicable determination date.

“Buyer Preferred Stock” has the meaning set forth in Section 4.4(a).

“Buyer Prepared Returns” has the meaning set forth in Section 6.2(a)(i).

“Buyer RSU” means each restricted stock unit granted under the Buyer Stock Plan or otherwise that is outstanding immediately prior to the Effective Time.

“Buyer SEC Reports” has the meaning set forth in Section 4.6.

“Buyer Stock Plan” means any equity incentive plan of the Buyer, other than the Buyer’s Employee Stock Purchase Plan.

“CERCLA” means the federal Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended.

“Certificate” means a certificate which as of immediately prior to the Effective Time represented outstanding shares of Company Stock.

“Change” means any change, event, circumstance or development.

“Claim Notice” means written notification which contains (a) a description of the Damages incurred or reasonably expected to be incurred by the Indemnified Party and the Claimed Amount of such Damages, to the extent then known, (b) a statement that the Indemnified Party is entitled to indemnification under Article V for such Damages and a

64

reasonable explanation of the basis therefor, and (c) a demand for payment in the amount of such Damages.

“Claimed Amount” means the amount of any Damages incurred or reasonably expected to be incurred by the Indemnified Party and set forth in a Claim Notice.

“Closing” means the closing of the transactions contemplated by this Agreement.

“Closing Adjustment Items” means (a) the Company Transaction Expenses, and (b) any Individual Contractor Amounts and (c) if Closing Net Working Capital is less than the Working Capital Target, the amount of such shortfall.

“Closing Adjustment Statement” means the statement of the Closing Adjustment Items prepared in accordance with the provisions of Section 2.6.

“Closing Buyer Outstanding Shares” has the meaning set forth in Section 4.4(a).

“Closing Cash” means all cash and cash equivalents held by the Company (plus the amount of all un-cleared deposits of the Company outstanding, and less the amount of all un-cleared checks or withdrawals of the Company outstanding), measured as of the Effective Time and determined in accordance with GAAP applied on a basis consistent with the application thereof to the most recent audited financial statements included in the Company Financial Statements (to the extent consistent with GAAP).

“Closing Date” means the date of this Agreement.

“Closing Indebtedness” means all Indebtedness of the Company to the extent outstanding at the Effective Time.

“Closing Net Working Capital” means the Company’s current assets (including, for the avoidance of doubt, Closing Cash) less current liabilities (including all Closing Indebtedness whether long-term or current), calculated as of the end of the Closing Date, each determined in accordance with (a) GAAP applied on a basis consistent with the application thereof to the most recent audited financial statements included in the Company Financial Statements (to the extent consistent with GAAP) and (b) the example calculation included in the Estimated Closing Adjustment Statement.

“Code” means the Internal Revenue Code of 1986, as amended.

“Company” has the meaning set forth in the first paragraph of this Agreement.

“Company Basket Amount” has the meaning set forth in Section 5.5(a).

“Company Certificate of Incorporation” means the certificate of incorporation of the Company, as amended or restated from time to time and in effect immediately prior to the Effective Time.

65

“Company Common Stock” means the common stock, $0.001 par value per share, of the Company.

“Company Disclosure Modifications” has the meaning set forth in the first paragraph of Article III.

“Company Disclosure Schedule” means the Company Disclosure Schedule provided by the Company to the Buyer on the date hereof.

“Company Employee” means any employee (whether current or former) of the Company.

“Company Equity Award” means each Company Option and Company Restricted Stock Award outstanding as of immediately prior to the Effective Time.

“Company Equityholder” means any holder of Company Stock or Company Equity Awards as of immediately prior to the Effective Time.

“Company Equityholder Representative” has the meaning set forth in the first paragraph of this Agreement.

“Company Equityholder Representative Account Payment” has the meaning set forth in Section 2.4(c).

“Company Equityholder Representative Engagement Agreement” has the meaning set forth in Section 2.4(f).

“Company Equityholder Representative Expenses” has the meaning set forth in Section 2.4(d).

“Company Equityholder Representative Expense Amount” means $75,000.

“Company Equityholder Representative Group” has the meaning set forth in Section 2.4(f).

“Company Financial Statements” means:

(a)           the audited balance sheets and statements of income, changes in stockholders’ equity and cash flows of the Company as of the end of and for each of the fiscal years ended December 31, 2015, 2016 and 2017, as certified without qualification by BDO USA LLP, the Company’s independent public accountants; and

(b)           the unaudited balance sheet of the Company for the interim period after December 31, 2017 ended September 30, 2018, and the related unaudited statements of operations, changes in stockholders’ equity and cash flows for the period then ended.

“Company Intellectual Property” means the Company Owned Intellectual Property and the Company Licensed Intellectual Property.

66

“Company’s Knowledge,” “Knowledge of the Company” and words of similar effect means the knowledge of each of the individuals identified in Schedule K, in each case after due and reasonable inquiry.  Such individuals will be deemed to have knowledge of a particular fact, circumstance, event or other matter if (a) such individual has actual knowledge of such fact, circumstance, event or other matter, (b) such fact, circumstance, event or other matter is reflected in one or more documents (whether written or electronic, including electronic mails sent to or by such individual) in the possession of such individual, including his or her personal files, or (c) such fact, circumstance, event or other matter is reflected in one or more documents (whether written or electronic) contained in books and records of such individual that would reasonably be expected to be reviewed by such individual in the customary performance of his or her duties.  Company’s Knowledge, does not include the obligation to conduct or obtain any new freedom-to-operate opinions or similar opinions of counsel or any new Intellectual Property clearance searches, and no knowledge of any third-party Intellectual Property that would have been revealed by such new freedom-to-operate opinions or similar opinions of counsel or any new Intellectual Property clearance searches.

“Company Licensed Intellectual Property” means all Intellectual Property that is, or is purported to be, licensed to the Company by any third party.

“Company Material Adverse Effect” means any Change that, individually or in the aggregate with all other Changes, has had or could reasonably be expected to have a material adverse effect on the business, assets, liabilities, capitalization, condition (financial or other), results of operations, or prospects, of the Company, other than any Change to the extent arising after the date hereof and resulting from (i) Changes in the United States economy in general, so long as such changes do not disproportionately affect the business of the Company, and (ii) Changes in the industry in which the Company operates, so long as such Changes do not disproportionately affect the business of the Company.  For the avoidance of doubt, the parties agree that the terms “material,” “materially” and “materiality” as used in this Agreement with an initial lower case “m” shall have their respective customary and ordinary meanings, without regard to the meaning ascribed to Company Material Adverse Effect.

“Company Option” means an option to purchase Company Common Stock issued by the Company pursuant to the Company Stock Plan.

“Company Owned Intellectual Property” means all Intellectual Property owned or purported to be owned by the Company, in whole or in part.

“Company Plan” means any Employee Benefit Plan in respect of any employees, independent contractors, directors, officers or shareholders of the Company that are sponsored or maintained by the Company or with respect to which the Company has made or is required to make payments, transfers or contributions or has or may have any actual or potential liability.

“Company Preferred Stock” means the Series A convertible preferred stock, $0.001 par value per share, of the Company.

“Company Required Information” means (a) the Company Financial Statements and (b) such additional information, including other business information and reliance letters from

67

the Company’s independent accounting firm, as the Buyer may reasonably request, in order to comply with the requirements of the Securities Act and/or Exchange Act applicable to the Buyer.

“Company Registrations” means Intellectual Property Registrations that are registered or filed in the name of the Company, alone or jointly with others.

“Company Restricted Stock Award” means each award of restricted Company Common Stock that is unvested as of immediately prior to the Effective Time.

“Company Stock” means the Company Common Stock and the Company Preferred Stock.

“Company Stock Plan” means the 2013 Equity Incentive Plan.

“Company Stockholder” means each holder of Company Stock as of immediately prior to the Effective Time.

“Company Stockholder Approval” means the adoption of this Agreement and the approval of the Merger, by execution of Written Consents, by (a) a majority of the votes represented by the outstanding shares of Company Stock entitled to vote on this Agreement and the Merger (on a converted to Company Common Stock basis) and (b) more than 51% of the votes represented by the outstanding shares of Company Preferred Stock entitled to vote on this Agreement and the Merger.

“Company Transaction Expenses” means all costs and expenses of the Company incurred in connection with the negotiation, preparation and execution of this Agreement and the consummation of the transactions contemplated hereby, including any brokerage fees and commissions, finders’ fees or financial advisory fees and any fees and expenses of counsel or accountants payable by the Company.

“Confidentiality Agreement” means the Amended and Restated Confidential Disclosure Agreement, dated as of May 15, 2018, by and between the Company, certain Affiliates of the Company and the Buyer.

“Contract” has the meaning set forth in Section 3.13(a).

“Contingent Consideration” has the meaning set forth in Section 2.8.

“Controlling Party” means the party controlling the defense of any Third Party Action.

“Cooley” has the meaning set forth in Section 8.12.

“Covered Materials” means any communication between Cooley, on the one hand, and the Company or the Company Equityholders, on the other, to the extent that they are attorney-client privileged and solely relate to the negotiation, documentation and consummation of the transactions contemplated by this Agreement or, beginning on the date of this Agreement, any dispute arising under this Agreement.

68

“D&O Indemnified Persons” has the meaning set forth in Section 6.1

“D&O Policy” has the meaning set forth Section 6.1.

“Damages” means any and all debts, obligations and other liabilities, monetary damages, fines, fees, penalties, interest obligations, deficiencies, foreseeable consequential or incidental damages, losses and expenses (including amounts paid in settlement, interest, court costs, costs of investigators, reasonable out of pocket fees and expenses of attorneys, accountants, financial advisors and other experts, and other reasonable expenses of litigation, arbitration or other dispute resolution procedures) and, only to the extent paid or payable to a third party in connection with a Third Party Claim, any unforeseeable incidental or consequential damages and any punitive damages.

“DGCL” means the Delaware General Corporation Law.

“Dispute” means the dispute resulting if the Company Equityholder Representative in a Response disputes the liability of the Company Equityholders for all or part of a Claimed Amount.

“Dissenting Shares” means shares of Company Stock held as of the Effective Time by a Company Stockholder who has not voted such shares of Company Stock in favor of the adoption of this Agreement and with respect to which appraisal shall have been duly demanded and perfected in accordance with Section 262 of the DGCL and not effectively withdrawn or forfeited prior to the Effective Time.

“Documentation” means printed, visual or electronic materials, reports, white papers, documentation, specifications, designs, flow charts, code listings, instructions, user manuals, frequently asked questions, release notes, recall notices, error logs, diagnostic reports, marketing materials, packaging, labeling, service manuals and other information describing the use, operation, installation, configuration, features, functionality, pricing, marketing or correction of a product, whether or not provided to end users.

“Effective Time” has the meaning set forth in Section 1.1(b).

“EMA” means the European Medicines Agency or any successor agency thereto.

“Employee Benefit Plans” means all (a) “employee benefit plans,” as defined in Section 3(3) of ERISA, together with plans or arrangements that would be so defined if they were not (i) otherwise exempt from ERISA by Section 3(3) of ERISA or another Section of ERISA, (ii) maintained outside the United States or (iii) individually negotiated or applicable only to one individual and (b) any other written or oral benefit arrangement or obligation to provide benefits as compensation for services rendered, including employment or consulting agreements (except for agreements that provide termination at no cost to the Company), severance agreements, arrangements, plans or pay policies, stay or retention bonuses or compensation, incentive (including equity or equity-linked) plans, programs or arrangements, patent award programs, sick leave, vacation pay, plant closing benefits, salary continuation or insurance for disability, consulting, or other compensation arrangements, retirement, deferred compensation, bonus, stock option or purchase plans or programs, hospitalization, medical insurance, life insurance, tuition

69

reimbursement or scholarship programs, any plans subject to Section 125 of the Code and any plans providing benefits or payments in the event of a change of control, change in ownership or effective control, or sale of a substantial portion (including all or substantially all) of the assets of any business or portion thereof.

“Environmental Law” means any Law relating to the environment, occupational health and safety, or exposure of persons or property to Materials of Environmental Concern, including any statute, regulation, administrative decision or order pertaining to:  (a) the presence of or the treatment, storage, disposal, generation, transportation, handling, distribution, manufacture, processing, use, import, export, labeling, recycling, registration, investigation or remediation of Materials of Environmental Concern or documentation related to the foregoing; (b) air, water and noise pollution; (c) groundwater and soil contamination; (d) the release, threatened release, or accidental release into the environment, the workplace or other areas of Materials of Environmental Concern, including emissions, discharges, injections, spills, escapes or dumping of Materials of Environmental Concern; (e) transfer of interests in or control of real property which may be contaminated; (f) community or worker right-to-know disclosures with respect to Materials of Environmental Concern; (g) the protection of wild life, marine life and wetlands, and endangered and threatened species; (h) storage tanks, vessels, containers, abandoned or discarded barrels and other closed receptacles; and (i) health and safety of employees and other persons.  As used above, the term “release” shall have the meaning set forth in CERCLA.

“Equity Interest” means, with respect to any Person, (a) any share, partnership or membership interest, unit of participation or other similar interest (however designated) in such Person and (b) any warrant, purchase right, conversion right, exchange right or other agreement which would entitle any other Person to acquire any such interest in such Person (including share appreciation, phantom share, profit participation or other similar rights).

“Equityholder Indemnified Parties” means the Company Equityholders and their respective Affiliates.

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

“ERISA Affiliate” means any entity that is, or at any applicable time was, a member of (a) a controlled group of corporations (as defined in Section 414(b) of the Code), (b) a group of trades or businesses under common control (as defined in Section 414(c) of the Code), or (c) an affiliated service group (as defined under Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any of which includes or included the Company.  For purposes of this Agreement, “ERISA Affiliate” is deemed to include Versant Ventures, Inception Sciences, Inc., Inception Sciences Canada, Inc., and their respective Affiliates.

“Estimated Closing Adjustment” means the estimated amount of the Closing Adjustment Items as of the Closing Date delivered with the Estimated Closing Adjustment Statement in accordance with the provisions of Section 2.6(a).

“Estimated Closing Adjustment Statement” has the meaning set forth in Section 2.6(a).

“Exchange and Paying Agent” means Computershare Trust Company, N.A.

70

“Exchange and Paying Agent Agreement” means an agreement to be entered into at or prior to the Effective Time by the Exchange and Paying Agent and the Buyer, governing the disbursement of the Payment Fund and in a form reasonably acceptable to the Company.

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Expected Claim Notice” means a notice that, as a result of a legal proceeding instituted by or written claim made by a third party, the Buyer or the Company Equityholders reasonably expects to incur Damages for which it or they are entitled to indemnification under Article V.

“Exploit” means develop, design, test, modify, make, use, sell, have made, used and sold, import, reproduce, market, distribute, commercialize, support, maintain, correct and create derivative works of.

“FDA” means the United States Food and Drug Administration or any successor agency thereto.

“Final Closing Adjustment” has the meaning set forth in Section 2.6(f).

“Final Closing Adjustment Items” has the meaning set forth in Section 2.6.

“Final Closing Adjustment Statement” has the meaning set forth in Section 2.6.

“First Certificate of Merger” has the meaning set forth in Section 1.1(a)(i).

“First Merger” has the meaning set forth in Section 1.1(a)(i).

“First Merger Constituent Corporations” has the meaning set forth in Section 1.1(a)(i).

“First Step Surviving Entity” has the meaning set forth in Section 1.1(a)(ii).

“Forfeiture Agreements” means the executed forfeiture agreements, in each case in form and substance reasonably acceptable to the Buyer, delivered by certain holders of Company Options.

“fraud” means a statement or omission by a party with the knowledge or belief that such statement or omission was false or was made (or facts were omitted) with a “reckless indifference” to the truth with intent by such party to deceive the other party.

“Future Payments” means, collectively, (a) any Holdback Shares that become issuable to Company Equityholders pursuant to this Agreement, plus (b) any portion of any Contingent Consideration that may become distributable to Company Equityholders pursuant to this Agreement, plus (c) any Company Equityholder Representative Account Payment that may become distributable to Company Equityholders pursuant to this Agreement.

“Fundamental Representations” has the meaning set forth in Section 5.4(a).

“GAAP” means United States generally accepted accounting principles.

71

“Governmental Entity” means any federal, state, local or foreign government or any court, arbitrational tribunal, administrative agency or commission or government authority acting under the authority of the federal or any state, local or foreign government.

“Grant Date” has the meaning set forth in Section 3.2(d).

“Holdback Fund” means, as any time of determination, a number of shares of Buyer Common Stock equal to (a) the Holdback Shares less (b) if a positive number, the Final Closing Adjustment. “Holdback Shares” means 130,526 shares of Buyer Common Stock.

“Indebtedness” with respect to any Person means (a) any indebtedness or other obligation for borrowed money or under bonds, notes, debentures or similar instruments; (b) any obligation incurred for all or any part of the purchase price of property or other assets (including earnout, milestone, royalty and similar obligations) in each case to the extent due and payable, other than accounts payable and accrued expenses included in current liabilities and incurred in respect of property purchased or services rendered in the Ordinary Course of Business; (c) the amounts owed on all letters of credit issued for the account of such Person; (d) obligations (whether or not such Person has assumed or become liable for the payment of such obligation) secured by Liens; (e) capitalized lease obligations; (f) all guarantees and similar obligations of such Person; (g) all accrued interest, fees and charges in respect of any indebtedness; (h) all bankers acceptances and overdrafts; and (h) all interest, premiums and penalties (whether or not related to prepayment), and any other fees, expenses, indemnities and other amounts payable in respect of any of the foregoing.

“Indemnified Party” or “Indemnified Parties” means the Buyer Indemnified Parties or the Equityholder Indemnified Parties, as applicable.

“Indemnifying Party” or “Indemnifying Parties” means the Buyer or the Company Equityholders, as applicable.

“Individual Contractor Amount” means all amounts, if any, payable pursuant to (a) any bonus plan implemented by the Company in connection with the transactions contemplated by this Agreement or (b) any other change in control bonus plan, severance plan, change of control, retention or similar arrangement of the Company, in each case of this clause (b) payable in connection with the Merger or any of the other transactions contemplated by this Agreement or upon related, concurrent or subsequent termination of services, or in combination with any other event.

“Intellectual Property” means the following subsisting throughout the world:

(a)           Patent Rights;

(b)           Trademarks and all goodwill in the Trademarks;

(c)           copyrights, designs, data and database rights and registrations and applications for registration thereof, including moral rights of authors;

72

(d)           mask works and registrations and applications for registration thereof and any other rights in semiconductor topologies under the Laws of any jurisdiction;

(e)           inventions, invention disclosures, statutory invention registrations, trade secrets and confidential business information, know-how, scientific and technical information, data and technology, including medical, preclinical and clinical, toxicological and other scientific data, manufacturing and product processes, algorithms, techniques and analytical methodology, research and development information, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, whether patentable or nonpatentable, whether copyrightable or noncopyrightable and whether or not reduced to practice; and

(f)            other proprietary rights relating to any of the foregoing (including remedies against past, present and future infringement thereof and rights of protection of interest therein under the Laws of all jurisdictions).

“Intellectual Property Registrations” means Patent Rights, Trademarks (other than unregistered trademarks, service marks and trade dress), registered copyrights and designs, mask work registrations and applications for each of the foregoing.

“Internal Systems” means the Software and Documentation and the computer, communications and network systems (both desktop and enterprise-wide), laboratory equipment, reagents, materials and test, calibration and measurement apparatus used by the Company in its business or operations or to develop, manufacture, fabricate, assemble, provide, distribute, support, maintain or test the Product Offerings, whether located on the premises of the Company or hosted at a third party site.

“IRS” has means the United States Internal Revenue Service.

“Law” means any United States federal, state or local or foreign law, common law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any decree, order, injunction, rule, judgment, consent of or by any Governmental Entity, or any Permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law.

“Lease” means any lease, sublease, license, or occupancy agreement pursuant to which the Company leases or subleases from or to another party any real property, or otherwise occupies any real property.

“Legal Proceeding” means any action, suit, proceeding (including administrative proceeding), claim, complaint, hearing, information request, notice of violation, arbitration, inquiry or investigation of or before any Governmental Entity or before any arbitrator.

“Letter of Transmittal” means a letter of transmittal in the form attached hereto as Exhibit C.

“Lien” means any mortgage, pledge, security interest, encumbrance, charge or other lien (whether arising by contract or by operation of Law), other than (a) mechanic’s, material men’s

73

and similar liens, (b) liens arising under worker’s compensation, unemployment insurance, social security, retirement and similar legislation, (c) liens on goods in transit incurred pursuant to documentary letters of credit, in each case arising in the Ordinary Course of Business of the Company and not material to the Company, (d) Liens for Taxes and other governmental charges and assessments which are not yet due and payable or are being contested in good faith by appropriate proceedings and for which appropriate reserves have been accrued in accordance with GAAP; and (e) purchase money or equipment Liens incurred in the Ordinary Course of Business.

“Materials of Environmental Concern” means any:  pollutants, contaminants or hazardous substances (as such terms are defined under CERCLA), pesticides (as such term is defined under the Federal Insecticide, Fungicide and Rodenticide Act), solid wastes and hazardous wastes (as such terms are defined under the Resource Conservation and Recovery Act), chemicals, other hazardous, radioactive or toxic materials, oil, petroleum and petroleum products (and fractions thereof), or any other material (or article containing such material) listed or subject to regulation under any Law due to its potential, directly or indirectly, to harm the environment or the health of humans or other living beings.

“Merger” has the meaning set forth in the Recitals.

“Merger Subsidiary I” has the meaning set forth in the first paragraph of this Agreement.

“Merger Subsidiary II” has the meaning set forth in the first paragraph of this Agreement.

“Merger Subsidiaries” has the meaning set forth in the first paragraph of this Agreement.

“Milestone Achievement Date” has the meaning set forth in Section 2.8(b)(i).

“Milestone Event” has the meaning set forth in Section 2.8.

“Most Recent Balance Sheet” means the unaudited balance sheet of the Company as of the Most Recent Balance Sheet Date.

“Most Recent Balance Sheet Date” means September 30, 2018.

“Neutral Accountant” means PricewaterhouseCoopers LLP; provided, that, if such firm is not available for any reason, the Neutral Accountant shall be an independent nationally recognized accounting firm selected in accordance with the rules of the New York, New York office of the American Arbitration Association.

“Non-controlling Party” means the party not controlling the defense of any Third Party Action.

“Non-Fundamental Cap” means an amount equal to $1,526,918.

“Objection Notice” has the meaning set forth in Section 2.6(c).

74

“Optionholder Agreement” means the Optionholder Agreement in the form attached hereto as Exhibit E.

“Ordinary Course of Business” means the ordinary course of business consistent with past custom and practice (including with respect to frequency and amount).

“Organizational Documents” means, with respect to any Person (other than an individual), (a) the certificate or articles of incorporation or organization and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all by-laws, stockholder agreements, voting agreements and similar documents, instruments or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.

“Patent Rights” means all patents, patent applications (including provisional patent applications), utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues, reexaminations and extensions).

“Payment Certificate” means a certificate, signed by an executive officer of the Company on behalf of the Company, which (a) sets forth (i) a calculation of the Series A Preference Consideration, (ii) a calculation of the payments to be made by the Buyer in accordance with Section 2.1(d)(ii), (iii) the identity of each Person entitled to a payment pursuant to Section 2.1(d)(ii), (iv) the amount due to each such Person and (v) the Pro Rata Share and Pro Rata Fraction and (b) attaches the Allocation Schedule as a schedule thereto.

“Payment Fund” means shares of Buyer Common Stock constituting the Aggregate Closing Consideration issued or issuable to Company Equityholders (including shares of Buyer Common Stock in any Buyer reserve account with the Exchange and Paying Agent) through the Exchange and Paying Agent pursuant to Article II.

“Permits” means all permits, licenses, registrations, certificates, orders, exemptions, approvals, franchises, variances, clearances and similar rights issued by or obtained from any Governmental Entity (including those issued or required under Environmental Laws and those relating to the occupancy or use of owned or leased real property).

“Person” means any natural person, firm, limited liability company, general or limited partnership, association, corporation, unincorporated organization, company, joint venture, trust, Governmental Entity or other entity.

“Post-Closing Disbursement Certificate” means a certificate, provided by the Company Equityholder Representative, which (a) sets forth (i) a calculation of any disbursements to be made for the benefit of Company Equityholders pursuant to Section 2.1(e), Section 2.4(c), Section 2.7(c), and/or Section 2.8, as applicable, (ii) the identity of each Person entitled to such disbursement or payment, (iii) the amount due to each such Person pursuant to Section 2.1(e), Section 2.4(c), Section 2.7(c), and/or Section 2.8, as applicable, and (iv) the applicable wire instructions for the account or accounts of such Person, and (b) attaches a schedule, prepared by the Company Equityholder Representative in the format of the Allocation Schedule (but with

75

respect to any such certificate relating to a Future Payment also including the portion of the applicable Future Payments attributable to each Company Equityholder’s Company Stock and Company Equity Awards), setting forth, for each Company Equityholder:  (a) such Company Equityholder’s name and address; (b) the number of shares of each class of Company Stock held as of the Closing Date by such Company Equityholder or underlying Company Options held by such Company Equityholder; (c) the amount to be paid to such Company Equityholder pursuant to Section 2.1(e), Section 2.4(c), Section 2.7(c), and/or Section 2.8, as applicable; and (d) an updated calculation of each Company Equityholders’ Pro Rata Share and Pro Rata Fraction.

“Pre-Closing Tax Period” means (i) any Tax period ending on or before the Closing Date and (ii) with respect to any Straddle Period, the portion of such period ending on the Closing Date.

“Pre-Closing Taxes” means (i) any Taxes of the Company due and payable for, or allocated in accordance with Section 6.2 to, any taxable period (or portion thereof) ending on or before the Closing Date; (ii) any Taxes for which the Company has any liability under Treasury Regulation Section 1.1502-6 or under any comparable or similar provision of state, local or foreign Laws as a result of being a member of an affiliated, consolidated, combined, unitary or similar group on or prior to the Closing Date; (iii) any Taxes for which the Company has any liability as a transferee or successor, pursuant to any contractual obligation or otherwise, which Tax is attributable to the operations of the Company on or prior to the Closing Date or an event or transaction occurring before the Closing; (iv) the Company Equityholders’ share of any Transfer Taxes pursuant to Section 6.2(a)(ii) and (v) any withholding or payroll Taxes due on payments of the Aggregate Consideration payable to holders of Company Options; provided, however, that “Pre-Closing Taxes” shall not include (a) any Taxes attributable to any election under Section 338 of the Code (or any comparable applicable provision of state, local or non-U.S. Tax Law) with respect to the transactions contemplated by this Agreement, (b) any Taxes resulting from any transactions occurring on the Closing Date after the Closing outside the Ordinary Course of Business (other than as explicitly contemplated by this Agreement), (c) any Transfer Taxes to the extent to be borne by Buyer as pursuant to Section 6.2(a)(ii), or (d) any Taxes taken into account in the calculation of Closing Adjustment Items.

“Product Offerings” means the Lead Compounds that the Company currently develops or manufactures.

“Pro Rata Fraction” means, with respect to each Company Equityholder, a fraction equal to the quotient of: (a) the amount of Aggregate Consideration and other amounts previously paid by the Buyer pursuant to this Agreement and actually received by such Company Equityholder (inclusive of amounts withheld pursuant to Section 2.9, if any), divided by (b) the Aggregate Consideration and other amounts previously paid by the Buyer pursuant to this Agreement and actually received by all Company Equityholders (inclusive of amounts withheld pursuant to Section 2.9, if any), to all Company Equityholders pursuant to this Agreement, in each case as set forth in the Allocation Schedule and/or the most recent Post-Closing Disbursement Certificate, as applicable; provided, that any Aggregate Consideration in respect of any shares of Company Stock, any Company Option or other Company Equity Awards shall be disregarded for purposes of determining clause (b) of the applicable Pro Rata Fraction for purposes of Article V to the extent any such holders of such shares of Company Stock, Company Options or other

76

Company Equity Awards has failed to execute and deliver a Support and Joinder Agreement and/or Optionholder Agreement, as applicable.

“Pro Rata Share” means, with respect to any shares of Company Stock or, if applicable, any Company Equity Award, with respect to the Aggregate Residual Closing Consideration, the portion of the Aggregate Closing Consideration payable with respect to such share of Company Stock or, if applicable, any Company Equity Award, and, with respect to each Future Payment, the portion of the Future Payment payable with respect to such Company Stock or, if applicable, any Company Equity Award, in accordance with the Company Certificate of Incorporation, applicable Law and the terms of this Agreement (and, if applicable, the Company Stock Plan and/or the terms of the applicable Company Equity Award), in each case as set forth in the Allocation Schedule and/or the most recent Post-Closing Disbursement Certificate, as applicable.  Any calculation of Pro Rata Share for a Future Payment that involves a payment to holders of Company Options shall take into account (i) the aggregate exercise price for the purposes of such calculation and (ii) the amount the holders of such Company Options contributed to the Company Equityholder Representative Expense Amount.

“Regulatory Authorities” means the FDA, EMA or any other Governmental Entity in another country or jurisdiction that is a counterpart to the FDA and holds responsibility for granting regulatory approval for a product, or otherwise regulating the research, development or commercialization of a product, in such country, and any successor(s) thereto.

“Representatives” means, with respect to any Person, such Person’s officers and directors (or persons holding comparable positions), employees, consultants, independent contractors, subcontractors, leased employees, volunteers, temporary workers, equityholders, accountants, legal and other representatives, agents, executors, heirs, successors and permitted assigns.

“Response” means a written response containing the information provided for in Section 5.3(c).

“SEC” means the United States Securities and Exchange Commission.

“Second Certificate of Merger” has the meaning set forth in Section 1.1(a)(iii).

“Second Effective Time” has the meaning set forth in Section 1.1(b)(i).

“Second Merger” has the meaning set forth in the Recitals.

“Second Merger Constituent Corporations” has the meaning set forth in Section 1.1(a)(iii).

“Securities Act” means the Securities Act of 1933, as amended.

“Series A Preference Consideration” means, with respect to each share of Company Preferred Stock outstanding immediately prior to the Effective Time, a number of shares of Buyer Common Stock equal to (a) $1.00 plus any accrued but unpaid dividends (whether or not declared) thereon, as set forth on the Payment Certificate, divided by (b) the Buyer Closing

77

Stock Price (taking into account the marketability discount as provided for in the Company’s Organizational Documents).

“Share Cap” means such number of shares of Buyer Common Stock equal to 19.9% of the Closing Buyer Outstanding Shares.

“Specified Representation Cap” means an amount equal to $6,107,673; provided, that the Specified Representation Cap shall be deemed reduced by the amount of any Claimed Amounts actually disbursed to Buyer Indemnified Parties in respect of any claim for Damages under Section 5.1(a), other than claims for breaches of any Fundamental Representations or Specified Representations (provided, that, for the avoidance of doubt, any Damages for breaches of any Specified Representations will be included in the “aggregate liability of the Company Equityholders” for purposes of Section 5.5(c)).

“Software” means computer software code, applications, utilities, development tools, diagnostics, databases and embedded systems, whether in source code, interpreted code or object code form.

“Stockholder Agreement” means the Stockholder Agreement in the form attached as Exhibit G.

“Straddle Period” has the meaning set forth in Section 6.2(a)(i).

“Subsidiary” means, with respect to any Person, any corporation, partnership, trust, limited liability company or other non-corporate business enterprise in which such Person (or another Subsidiary of such Person) holds stock or other ownership interests representing (a) more than 50% of the voting power of all outstanding stock or ownership interests of such entity or (b) the right to receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such entity.

“Support and Joinder Agreement” means the Support and Joinder Agreement attached hereto as Exhibit D.

“Surviving Entity” has the meaning set forth in Section 1.1(a)(iv).

“Tax Returns” means any and all reports, returns (including information returns), declarations, or statements relating to Taxes, including any schedule or attachment thereto and any amendment thereof, filed with or submitted to, or required to be filed with or submitted to, any Governmental Entity in connection with the determination, assessment, collection or payment of Taxes or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.

“Tax Contest” means any audit, other administrative proceeding or inquiry or judicial proceeding involving Taxes.

“Taxes” means any and all taxes, charges, fees, duties, contributions, levies or other similar assessments or liabilities, including income, gross receipts, corporation, ad valorem,

78

premium, value-added, net worth, capital stock, capital gains, documentary, recapture, alternative or add-on minimum, disability, registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment, insurance, social security (or similar), former Code Section 59A, workers compensation, payroll, profits, severance, stamp, occupation, escheat, windfall profits, customs duties, franchise, estimated and other taxes of any kind whatsoever imposed by the United States of America or any state, local or foreign government, or any agency or political subdivision thereof, and any interest, fines, penalties, assessments or additions to tax imposed with respect to or related to such items.

“Third Party Action” means any Legal Proceeding by a Person other than a party for which indemnification may be sought by the Buyer under Article V.

“Trademarks” means all registered trademarks and service marks, logos, Internet domain names, corporate names and doing business designations and all registrations and applications for registration of the foregoing, common law trademarks and service marks and trade dress.

“Transfer Taxes” has the meaning set forth in Section 6.2(a)(ii).

“Versant Ventures” means Versant Venture Capital IV, L.P.

“Working Capital Target” means $6,400,000.

“Written Consent” shall mean a written consent of the stockholders of the Company in the form attached hereto as Exhibit F.

ARTICLE VIII

MISCELLANEOUS

8.1          Notices.  All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) four (4) Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable nationwide overnight courier service, in each case to the intended recipient as set forth below; provided, that with respect to notices delivered to the Company Equityholder Representative, such notices must be delivered solely via facsimile or via email (and shall be deemed duly delivered on the day such facsimile or email notice is transmitted):

(a)                                 if to the Buyer or the Merger Subsidiaries or (after the Effective Time) the Company, to:

Ophthotech Corporation

One Penn Plaza, 35th Floor

New York, NY 10119

Attention: Todd Anderman, Vice President, General Counsel & Secretary

Email copy: todd.anderman@ophthotech.com

79

with a copy (which shall not constitute notice) to:

Wilmer Cutler Pickering Hale and Dorr LLP
7 World Trade Center
New York, New York 10007
Attention:                                         Jay Bothwick, Esq.

Brian A. Johnson, Esq.

Email copy:                              jay.bothwick@wilmerhale.com

brian.johnson@wilmerhale.com

(b)                                 if (prior to the Effective Time) to the Company, to:

Inception 4, Inc.

5871 Oberlin Drive, Suite 100

San Diego, CA 92121

Attention: Petpiboon Prasit, Ph.D., President & Chief Executive Officer

Email copy: PPrasit@inceptionsci.com

with a copy (which shall not constitute notice) to:

(c)                                  Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
Attention: Tom Coll; Rama Padmanabhan
Email copy: tcoll@cooley.com; rama@cooley.com

(d)                                 if to any Company Equityholder or the Company Equityholder Representative, to:

Fortis Advisors LLC

Attention: Notice Department

Telecopy:  (858) 408-1843
Email copy: notices@fortisrep.com

(e)                                  with a copy (which shall not constitute notice) to:

Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
Attention: Tom Coll; Rama Padmanabhan
Email copy: tcoll@cooley.com; rama@cooley.com

Any party to this Agreement may give any notice or other communication hereunder using any other means (including personal delivery, messenger service, ordinary mail or electronic mail), but no such notice or other communication shall be deemed to have been duly

80

given unless and until it actually is received by the party for whom it is intended.  Any party to this Agreement may change the address to which notices and other communications hereunder are to be delivered by giving the other parties to this Agreement notice in the manner herein set forth.

8.2          Entire Agreement.  This Agreement (including the schedules and exhibits hereto and the documents and instruments referred to in this Agreement that are to be delivered at the Closing) constitutes the entire agreement among the parties to this Agreement and supersedes any prior understandings, agreements or representations by or among the parties hereto, or any of them, written or oral, with respect to the subject matter hereof; provided, that the Confidentiality Agreement shall remain in effect in accordance with its terms.

8.3          Third-Party Beneficiaries.  This Agreement is not intended to, and shall not, confer upon any other Person any rights or remedies hereunder, except that the (a) Buyer Indemnified Parties shall be third-party beneficiaries of Article V and (b) the D&O Indemnified Parties are entitled to the rights and remedies of third party beneficiaries with respect to Section 6.1, in addition to any remedy at law or in equity.

8.4          Assignment.  None of this Agreement nor any of the rights, interests or obligations under this Agreement may be transferred, assigned or delegated, in whole or in part, by operation of Law or otherwise by any of the parties hereto without the prior written consent of the other parties, and any such transfer, assignment or delegation without such prior written consent shall be null and void, except that the Buyer or the Merger Subsidiaries may, without the consent of the other parties hereto, transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, (a) to one (1) or more of their Affiliates (provided, that such transfer or assignment shall not relieve the Buyer or the Merger Subsidiaries of its primary liability for its obligations hereunder or enlarge, alter or change any obligation of any other party hereto or due to the Buyer or the Merger Subsidiaries) or (b) to any Successor Entity in accordance with Section 2.8(f), in which case, if such Successor Entity expressly agrees in writing to assume and perform the Buyer’s obligations under Section 2.8 of this Agreement and the other obligations pursuant to Section 2.8, the Buyer shall cease to have any further obligations under Section 2.8 of this Agreement.  Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns.  During the Payment Term, the Buyer and/or its Subsidiaries or any of their respective Affiliates shall not sell, transfer or otherwise convey to any Person (other than to an Affiliate pursuant to the first sentence of this Section 8.4) all or substantially all of its or their assets related to the Lead Compounds and Milestone Products except to the extent permitted under Section 2.8(f) of this Agreement. For the avoidance of doubt, nothing in Section 2.8(f) or this Section 8.4 shall limit the ability of the Buyer and/or its Subsidiaries or any of their respective Affiliates from selling, transferring or otherwise conveying less than substantially all of its or their assets related to the Lead Compounds and Milestone Products, other than pursuant to any of the events set forth in clause (1) or (2) of Section 2.8(h)(ix).

8.5          Severability.  Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term

81

or provision in any other situation or in any other jurisdiction.  If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.  In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

8.6          Counterparts and Signature.  This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which together shall be considered one (1) and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart.  This Agreement may be executed and delivered by an electronic scan delivered by electronic transmission.

8.7          Interpretation.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) “either” and “or” are not exclusive and “include,” “includes” and “including” are not limiting; (b) “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (c) “date of this Agreement” refers to the date set forth in the initial caption of this Agreement; (d) “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if”; (e) the descriptive headings and table of contents included herein are included for convenience only and shall not affect in any way the meaning or interpretation of this Agreement or any provision hereof; (f) definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (g) references to a contract or agreement mean such contract or agreement as amended or otherwise supplemented or modified from time to time; (h) references to a Person are also to its permitted successors and assigns; (i) references to an “Article,” “Section,” “Exhibit” or “Schedule” refer to an Article or Section of, or an Exhibit or Schedule to, this Agreement; (j) references to “$” or otherwise to dollar amounts refer to the lawful currency of the United States; and (k) references to a federal, state, local or foreign Law include any rules, regulations and delegated legislation issued thereunder; and (l) references to accounting terms used and not otherwise defined herein have the meaning assigned to them under GAAP.  When reference is made in this Agreement to information that has been “made available” to the Buyer, that shall consist of only the information that was (i) contained in the Company’s electronic data room no later than 5:00 p.m., Eastern time, on the second (2nd) Business Day prior to the date of this Agreement or (ii) delivered to the Buyer or its counsel prior to the date of this Agreement.  The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party hereto.  No summary of this Agreement prepared by any party shall affect the meaning or interpretation of this Agreement.  If any date on which a party is required to make a payment or a delivery pursuant to the terms hereof is not a Business Day, then such party shall make such payment or delivery on the next succeeding Business Day.

82

8.8          Governing Law.  This Agreement (and any claims or disputes arising out of or related hereto or the transactions contemplated hereby or to the inducement of any party to enter herein, whether for breach of contract, tortious conduct or otherwise and whether predicated on common law, statute or otherwise) shall be governed in all respects, including validity, interpretation, and effect, by and construed in accordance with the internal Laws of the State of Delaware (including in respect of the statute of limitations or other limitations period applicable to any claim, controversy or dispute) without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdictions other than those of the State of Delaware.

8.9          Remedies.  The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.  It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions of this Agreement, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at Law or in equity.  Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (i) the party seeking such remedy has an adequate remedy at Law or (ii) an award of specific performance is not an appropriate remedy for any reason at Law or equity.

8.10        Confidentiality.  The parties acknowledge that the Buyer, the Company and Affiliates of the Company have previously executed the Confidentiality Agreement, which Confidentiality Agreement shall continue in full force and effect in accordance with its terms, except as expressly modified herein or in the other agreements delivered in connection with this Agreement.  The parties acknowledge and agree that the Buyer: (i) may issue a press release with respect to this Agreement and the matters contemplated hereby; (ii) intends to publicly file this Agreement with the SEC; (iii) intends to seek confidential treatment under applicable SEC rules with respect to certain matters and terms contained in this Agreement; and (iv) may make any public disclosure it believes in good faith is required by applicable Law or stock market rule, or, following the Closing, for any other reason.

8.11        Submission to Jurisdiction.  Each of the parties to this Agreement (a) consents to submit itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, (b) agrees that all claims in respect of such action or proceeding may be heard and determined in any such court, (c) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (d) agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court, and (e) waives any right it may have to a trial by jury with respect to any action or proceeding arising out of or relating to this Agreement.  Each of the parties hereto waives any defense of improper venue or inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto.  Any party hereto may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of

83

notices in Section 8.1.  Nothing in this Section 8.11, however, shall affect the right of any party to serve legal process in any other manner permitted by Law.  Nothing in this Section 8.11 shall limit the right of a party to seek injunctive relief under Section 8.9(b) in any applicable jurisdiction.

8.12        Conflict of Interest.  If the Company Equityholder Representative so desires, acting on behalf of the Company Equityholders and without the need for any consent or waiver by the Company or Buyer, Cooley LLP (“Cooley”) shall be permitted to represent the Company Equityholders after the Closing solely in connection with the transactions contemplated by this Agreement, any other agreements referenced herein or any disagreement or dispute relating thereto.  Without limiting the generality of the foregoing, after the Closing, Cooley shall be permitted to represent the Company Equityholders, any of their agents and Affiliates, or any one or more of them, solely in connection with any negotiation, transaction or dispute (including any litigation, arbitration or other adversary proceeding) with the Buyer, the Company or any of their agents or Affiliates under or relating to this Agreement, any transaction contemplated by this Agreement, such as claims or disputes arising under other agreements entered into in connection with this Agreement, including with respect to any indemnification claims.

8.13        Attorney-Client Privilege.  The Buyer and the Company agree that any Covered Materials, shall belong to and be controlled by the Company Equityholder Representative, and not by the Surviving Entity, following the Closing, and may be waived only by the Company Equityholder Representative, and not the Surviving Entity, and shall not pass to or be claimed or used by the Buyer or the Surviving Entity. Absent the consent of the Company Equityholder Representative, neither the Buyer nor the Surviving Entity shall have a right to access the Covered Materials following the Closing and, in the event the Buyer or the Surviving Entity accesses Covered Materials in violation of this sentence, such access will not waive or otherwise affect the rights of the Company Equityholder Representative with respect to the related privilege or protection. Notwithstanding the foregoing, if a dispute arises between the Buyer or the Surviving Entity, on the one hand, and a third party other than (and unaffiliated with) the Company Equityholders and the Company Equityholder Representative, on the other hand, after the Closing, then the Surviving Entity may assert such attorney-client privilege to prevent disclosure of such Covered Materials; provided, further, that the Buyer and the Surviving Entity may not waive such privilege without the prior written consent of the Company Equityholder Representative (such consent not to be unreasonably withheld, conditioned or delayed).  The parties acknowledge and agree that this Section 8.13 shall not limit or otherwise prohibit the Buyer’s ability to (a) compel discovery of information that is not subject to an attorney-client privilege in the event that such information is relevant to a dispute that arises after the Closing, (ii) in the event that the Buyer or the Surviving Entity receives a subpoena or other discovery request pursuant to Law that calls for the search for, or of, documents that may include Covered Materials, comply with its legal obligations, and (iii) in the event that a dispute arises between the Buyer or the Surviving Entity and a third party other than a party to this Agreement following the Closing, the Buyer and/or the Surviving Entity may assert the attorney-client privilege to prevent disclosure of confidential communications by Cooley.

8.14        Amendment.  This Agreement may not be amended except by an instrument in writing making specific reference to this Agreement and signed on behalf of each of the parties hereto (including the Company Equityholder Representative following the Closing).

[Remainder of the Page Intentionally Left Blank]

84

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

Exhibit A-1

Form of First Merger Certificate of Merger

EXHIBIT A-1

CERTIFICATE OF MERGER

MERGING

ORION OPHTHALMOLOGY MERGER SUB, INC.

A DELAWARE CORPORATION
(merging corporation)

WITH AND INTO

INCEPTION 4, INC.
A DELAWARE CORPORATION
(surviving corporation)

Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law (“DGCL”), the undersigned corporation, duly organized and existing under and by virtue of the DGCL, does hereby certify as follows:

FIRST:  The name and state of incorporation of each of the constituent corporations to the Merger (as defined below) (each, a “Constituent Corporation”) is as follows:

SECOND:  An Agreement and Plan of Merger entered into as of October 30, 2018 (the “Merger Agreement”), by and among Ophthotech Corporation, a Delaware corporation (“Buyer”), Orion Ophthalmology Merger Sub, Inc. (“Merger Sub”), Orion Ophthalmology LLC, a Delaware limited liability company, Inception 4, Inc. (the “Company”) and solely in such Person’s capacity as the representative, agent and attorney-in-fact of the Company Equityholders, Fortis Advisors LLC, a Delaware limited liability company, setting forth the terms and conditions of the merger of Merger Sub with and into the Company (the “Merger”), has been approved, adopted, certified, executed and acknowledged by each of Buyer, Merger Sub and the Company in accordance with Section 251 of the DGCL.

THIRD:  The surviving corporation of the Merger shall be the Company, whose name shall remain Inception 4, Inc. after the Merger (the “Surviving Entity”).

FOURTH:  The Certificate of Incorporation of the Surviving Entity shall be amended and restated in full to be and to read as set forth in EXHIBIT A to this Certificate of Merger.

FIFTH:  The Merger shall become effective upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

SIXTH:  An executed copy of the Merger Agreement is on file at the principal place of business of the Surviving Entity at the following address: One Penn Plaza, 35th Floor, New York, NY 10119.

SEVENTH:  A copy of the Merger Agreement will be furnished by the Surviving Entity, on request and without cost, to any stockholder of a Constituent Corporation.

IN WITNESS WHEREOF, the Surviving Entity has caused this CERTIFICATE OF MERGER to be executed by its duly authorized officer as of this 30th day of October, 2018.

EXHIBIT A

CERTIFICATE OF INCORPORATION

[See Form of Certificate of Incorporation of First Step Surviving Entity attached as Exhibit B-1]

Exhibit A-2

Form of Second Merger Certificate of Merger

EXHIBIT A-2

CERTIFICATE OF MERGER

MERGING

INCEPTION 4, INC.

(a Delaware Corporation)

WITH AND INTO

ORION OPHTHALMOLOGY LLC

(a Delaware Limited Liability Company)

Pursuant to Title 8, Section 264 of the General Corporation Law of the State of Delaware

Orion Ophthalmology LLC, a Delaware limited liability company (the “Company”), does hereby certify as follows:

FIRST:                                            Inception 4, Inc., a Delaware corporation (“Merger Sub”), is a corporation duly organized and existing under the laws of the State of Delaware.

SECOND:                             The Company is a limited liability company duly organized and existing under the laws of the State of Delaware.

THIRD:                                       An Agreement and Plan of Merger entered into as of October 30, 2018 (the “Merger Agreement”), by and among Ophthotech Corporation, a Delaware corporation (“Buyer”), Orion Ophthalmology Merger Sub, Inc., a Delaware corporation, the Company, Merger Sub and solely in such Person’s capacity as the representative, agent and attorney-in-fact of the Company Equityholders, Fortis Advisors LLC, a Delaware limited liability company, setting forth the terms and conditions of the merger of Merger Sub with and into the Company (the “Merger”), has been approved, adopted, certified, executed and acknowledged by each of Buyer, the Company and Merger Sub in accordance with Section 264 of the Delaware General Corporation Law.

FOURTH:                            The Company shall be the surviving entity in the Merger (the “Surviving Entity”), whose name shall remain Orion Ophthalmology LLC.

FIFTH:                                           The Certificate of Formation of the Company, as in effect immediately prior to the Merger, shall remain in effect and shall be the Certificate of Formation of the Surviving Entity.

SIXTH:                                         An executed copy of the Merger Agreement is on file at the principal place of business of the Surviving Entity at the following address: One Penn Plaza, 35th Floor, New York, NY 10119.

SEVENTH:                     A copy of the Merger Agreement will be furnished by the Surviving Entity, on request and without cost, to any member of the Company or stockholder of Merger Sub.

EIGHTH:                              The Merger shall become effective upon filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

[Signature Page Follows]

IN WITNESS WHEREOF, Company has caused this Certificate of Merger to be executed in its limited liability company name as of October 30, 2018.

Exhibit B-1

Form of Certificate of Incorporation of the First Step Surviving Entity

EXHIBIT B-1

CERTIFICATE OF INCORPORATION

OF

INCEPTION 4, INC.

FIRST:  The name of the Corporation is: Inception 4, Inc.

SECOND:  The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801.  The name of its registered agent at such address is The Corporation Trust Company.

THIRD:  The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporate Law (“DGCL”).

FOURTH:  The total number of shares of stock which the Corporation shall have authority to issue is 1,000 shares of Common Stock, $0.001 par value per share.

The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.

FIFTH:  In furtherance of and not in limitation of powers conferred by statute, it is further provided:

1.                                      The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.

2.                                      Election of directors need not be by written ballot.

3.                                      The Board of Directors is expressly authorized to adopt, amend, alter or repeal the By-Laws of the Corporation.

SIXTH:  Except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director of the Corporation, notwithstanding any provision of law imposing such liability.  No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment.  If the DGCL is amended after the Filing Date to authorize corporate action further eliminating or limiting the personal liability of directors of the Corporation, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.

SEVENTH:

(a)                                 To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) such directors and officers (and any other persons to which the DGCL or other applicable state law permits the Corporation to provide indemnification) who are made or threatened to be made a party to an action or proceeding whether criminal, civil, administrative or investigative, by reason of the fact that he/she, his/her testator or intestate is or was a director, officer, employee or agent of the Corporation or any predecessor of the Corporation or serves or served at any other enterprise as a director, officer, employee or agent at the request of the Corporation or any predecessor to the Corporation to the same extent as permitted by law, through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL or other applicable state law, subject only to limits created by the DGCL or other applicable state law (statutory or non-statutory), with respect to actions for breach of duty to a company, its stockholders, and others.

(b)                                 Neither any amendment nor repeal of this Article SEVENTH, nor the adoption of any provision of the Corporation’s Certificate of Incorporation inconsistent with this Article SEVENTH, shall (i) eliminate or reduce the effect of this Article SEVENTH in respect of any matter occurring or any action or proceeding accruing or arising or that, but for this Article SEVENTH, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision, or (ii) increase the liability of any director of the Corporation with respect to any acts or omissions of such director, officer or other agent occurring prior to, such amendment, repeal or modification.

(c)                                  The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.

EIGHTH:  The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation.

Exhibit B-2

Form of Limited Liability Company Agreement of the Surviving Entity

EXHIBIT B-2

LIMITED LIABILITY COMPANY AGREEMENT

OF

ORION OPHTHALMOLOGY LLC

This Limited Liability Company Agreement (this “Agreement”) of Orion Ophthalmology LLC (the “Company”) is dated as of October    , 2018 and entered into by Ophthotech Corporation, a Delaware corporation, the sole member of the Company as of the date hereof (the “Member”).

The Member has formed or caused to be formed a limited liability company pursuant to and in accordance with the Delaware Limited Liability Company Act (6 Del.C. 18-101, et seq.), as amended from time to time (the “Act”), and hereby agrees as follows:

1.                                      Name.  The name of the limited liability company is Orion Ophthalmology LLC.

2.                                      Certificates. Todd Anderman, as an authorized person within the meaning of the Act, has executed, delivered and caused to be filed the Certificate of Formation of the Company with the Secretary of State of the State of Delaware.  Upon the filing of the Certificate of Formation with the Secretary of State of the State of Delaware, such individual’s powers as an authorized person ceased and the Member is thereafter designated as an authorized person within the meaning of the Act.  The Member shall execute, deliver and cause to be filed any other certificates and documents (and any amendments and/or restatements thereof) as may be necessary or appropriate to comply with the Act and any other applicable requirements for the operation of a limited liability company in accordance with the laws of any jurisdiction in which the Company shall conduct business, and shall continue to do so for so long as the Company conducts business therein.

3.                                      Office of the Limited Liability Company; Agent for Service of Process.  The address of the registered office of the Company in the State of Delaware, and the name and address of the resident agent for service of process on the Company in the State of Delaware, are as set forth in the Certificate of Formation of the Company.  The Member may establish places of business of the Company within and without the State of Delaware, as and when required by the Company’s business, and may appoint agents for service of process in all jurisdictions in which the Company shall conduct business.  The Member may cause the Company to change from time to time its resident agent for service of process, or the location of its registered office in the State of Delaware.

4.                                      Purpose.  The Company is formed for the object and purpose of, and the nature of the business to be conducted and promoted by the Company is to engage in any lawful act or activity for which limited liability companies may be formed under the Act.

5.                                      Powers.  The Company shall have and exercise all of the powers and rights conferred upon limited liability companies formed pursuant to the Act, including, without limitation, the power and right to:

(a)                                 Enter into, execute, modify, amend, supplement, acknowledge, deliver, perform and carry out contracts of any kind in accordance with applicable law;

(b)                                 Borrow money and issue evidences of indebtedness or to guarantee loans or other indebtedness of any other person or entity, and to secure the same by mortgages, pledges or other liens on the property of the Company;

(c)                                  To the extent that funds of the Company are available therefor, pay all expenses, debts and obligations of the Company;

(d)                                 Enter into or engage in any kind of activity, so long as said activities may be lawfully carried on or performed by a limited liability company under the laws of the State of Delaware and other applicable law; and

(e)                                  Take any other action not prohibited under the Act or other applicable law.

6.                                      Member.  The name and the mailing address of the Member are set forth on Schedule A attached hereto.

7.                                      Limited Liability.  Except as otherwise provided by the Act, the debts, obligations and liabilities of the Company, whether arising in contract, tort or otherwise, shall be solely the debts, obligations and liabilities of the Company, and the Member shall not be obligated personally for any such debt, obligation or liability of the Company solely by reason of being a member of the Company.

8.                                      Initial Capital Contributions.   The Member shall initially contribute to the Company the assets specified on Schedule A attached hereto.

9.                                      Additional Contributions.  The Member is not required to make any additional capital contribution to the Company.  However, the Member may make additional capital contributions to the Company in such amounts and at such times as the Member shall determine.

10.                               Distributions.  Distributions shall be made to the Member at the times and in the aggregate amounts determined by the Member, to the extent not prohibited by the Act or other applicable law.

11.                               Management.

(a)                                 In accordance with Section 18-402 of the Act, management of the Company shall, subject to subsection (b) below, be fully vested in and reserved to the Member, and the Company shall not have “managers” as such term is used in the Act.  The

2

powers of the Company shall be exercised by or under authority of, and the business and affairs of the Company shall be managed under the direction and authority of, the Member, which shall have all powers, statutory or otherwise, possessed by members of a limited liability company without managers under the laws of the State of Delaware.  The Member has full authority to bind the Company.

(b)                                 Notwithstanding anything to the contrary herein, the Member may, and hereby does, delegate any or all of his rights, powers, authority, duties and responsibilities with respect to the management of the Company to such officers with such titles as the Member may determine (the “Officers”); provided that, unless the Member determines otherwise, any officer position with a title customarily or statutorily used in corporations organized and existing under the Delaware General Corporation Law shall have the rights, powers, authority, duties and responsibilities customarily or statutorily associated with such officer position in such corporations.

12.                               Other Business.  The Member may engage in or possess an interest in other business ventures (unconnected with the Company) of every kind and description, independently or with others.  The Company shall not have any rights in or to such independent ventures or the income or profits therefrom by virtue of this Agreement.

13.                               Tax Status.  The Company shall be treated as a “disregarded entity” for U.S. federal income tax purposes. The Member shall take all steps necessary or advisable to maintain the status of the Company as a “disregarded entity” for U.S. federal income tax purposes.

14.                               Assignments.  The Member may assign in whole or in part its limited liability company interest.  If the Member transfers all of its interest in the Company pursuant to this Section, the admission of the transferee as a member of the Company shall be deemed effective immediately after the transfer, and, immediately following such admission, the Member shall cease to be a member of the Company.

15.                               Admission of Additional Members.  One or more additional members of the Company may be admitted to the Company with the written consent of the Member.

16.                               Dissolution.

(a)                                 The Company shall dissolve, and its affairs shall be wound up upon the first to occur of the following:  (i) the written consent of the Member, (ii) at any time there are no members of the Company, unless the business of the Company is continued in a manner permitted by the Act, or (iii) the entry of a decree of judicial dissolution under Section 18-802 of the Act.

(b)                                 The bankruptcy of the Member shall not cause the Member to cease to be a member of the Company and upon the occurrence of such an event, the business of the Company shall continue without dissolution.

3

(c)                                  In the event of dissolution, the Company shall conduct only such activities as are necessary to wind up its affairs (including the sale of the assets of the Company in an orderly manner), and the assets of the Company shall be applied in the manner, and in the order of priority, set forth in Section 18-804 of the Act.

17.                               Separability of Provisions.  Each provision of this Agreement shall be considered separable and if for any reason any provision or provisions herein are determined to be invalid, unenforceable or illegal under any existing or future law, such invalidity, unenforceability or illegality shall not impair the operation of or affect those portions of this Agreement which are valid, enforceable and legal.

18.                               Facsimile Signature Page.  This Agreement may be executed and delivered by the Member by an executed signature page transmitted by facsimile, and any failure to deliver the originally executed signature page shall not affect the validity, legality or enforceability of this Agreement.